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Abstract
This thesis describes structural and functional analysis of members of the 
XPF/Mus81 family of junction-specific endonucleases. These enzymes recognise 
and nick double-stranded DNA within a variety of flaps, bubbles and branched DNA 
substrates. Genetic and biochemical evidence indicates that these endonucleases 
have important functions in nucleotide excision repair, DNA interstrand crosslink 
repair, recombination and replication fork repair, and thereby help maintain genomic 
integrity.
Eukaryotic XPF orthologues are large multidomain proteins that are not suitable for 
structural studies at present. For this reason, an XPF orthologue from the 
crenarchaeote Aeropyrum pemix has been used to shed light on the mechanism of 
XPF action. The crystal structure of the core nuclease domain of A. pemix XPF has 
been solved to 2 .1 A resolution. This together with other structures detailed in the 
literature has provided insight into enzyme architecture and possible mechanisms of 
substrate binding and cleavage. Attempts to co-crystallise A. pem ix  XPF with short 
oligonucleotides akin to repair substrates are detailed. Other evidence in the 
literature has implicated the processivity factor PCNA in stimulating crenarchaeal 
XPF activity. With this in mind, recombinant heterotrimeric A. pemix PCNA has 
been expressed and been complexed with various A. pemix XPF constructs. The 
repair helicase XPB has also been added to form a ternary repair complex. 
Structural studies of these complexes by crystallography and electron microscopy 
have been initiated and some crystals have been produced.
Bioinformatic analysis of eukaryotic Mus81 orthologues has identified a region of 
conserved sequence of previously unknown structure or function. This putative 
domain appears to be conserved in most eukaryotic Mus8,l orthologues. The human 
domain was overexpressed for biochemical and structural analyses. Deletion of this 
domain from within Mus81 appears to affect endonuclease activity against splayed 
arm substrates in vitro, suggesting it has a role in protein-DNA interaction. Crystals 
of the human domain have been produced, although diffraction data sufficient for 
structure determination has not been obtained.
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Chapter 1: Introduction
1 Introduction
1.1 DNA damage
Since deoxyribonucleic acid (DNA) was identified in 1944 as Avery’s “transforming 
principle” (Avery et al., 1944), it has occupied a central position in biochemistry and 
genetics. As the source of genetic information in virtually all living organisms and 
the blueprint for cellular operations, maintaining the integrity of DNA is essential. 
This is underlined by the fact that DNA is the only biomolecule that is specifically 
repaired, all the others being replaced. If the repair mechanisms fail then this can lead 
to genomic instability, which can contribute to the development of cancer and other 
human diseases.
Some types of DNA damage are listed below. Some damage occurs spontaneously (a 
& b), whilst other damage is caused by radiation or chemical stresses (c, d, e, f; 
Friedberg et al., 2006)
a) Base loss
A consequence of the presence of 2-deoxyribose in DNA (as opposed to ribose) is 
that the N-glycosyl bond between sugar and base becomes more labile. Loss of a 
purine or pyrimidine base produces either an apurinic or apyrimidinic (AP) site 
(figure 1.1a).
b) Deamination
Apart from thymine, the bases found in DNA contain exocyclic amino groups. The 
loss of these primary amino groups (deamination) could lead to mutation, since these 
amino groups are important in the specific base-pairing described by Watson and 
Crick. The conversions of cytosine to uracil (figure 1.1b), adenine to hypoxanthine, 
guanine to xanthine and 5-methylcytosine to thymine have all been observed.
c) Oxidative damage
The bases are susceptible to numerous different modifications by a wide variety of 
chemical agents. Reactive oxygen species generated during oxidative metabolism and 
by ionizing radiation can modify bases. The most common is the modification of
18
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thymine to thymine glycol (figure 1.1c). However oxidative degradation of the sugar 
backbone can lead to single strand breaks.
©
©
AP SITE
CYTOSINE URACIL
©
©
THYMINE
ADENINE
THYMINE GLYCOL
3-METHYLADENINE
Figure 1.1 -  Types of DNA damage. [A] Base loss. [B] Deamination. [C] Chemical 
modification: oxidation. [D] Chemical modification: methylation. Carbon atoms are in 
green; nitrogen, blue; oxygen, red and hydrogen, grey. All figures o f this type in this thesis 
were produced using the program PyMol (DeLano, 2002)
In addition other metabolites may accidentally react with bases. S- 
adenosylmethionine, the normal biological methyl group donor reacts with DNA to
19
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produce alkylated bases like 3-methyladenine (figure l.ld ). These bases must be 
repaired in order to prevent mutation. Mutations may lead transitions and 
transversions.
d) Photodamage
Ultraviolet (UV) light is absorbed by bases and frequently induces chemical changes 
leading to so-called photoproducts. The most frequent photoproducts involve 
covalent linkages being formed between adjacent pyrimidines within the same strand. 
In turn the most common of these photoproducts are cyclobutane pyrimidine dimers 
(CPDs), where two bonds are formed between the adjacent bases (figure 1.2 a, b).
Figure 1.2 -  Types of DNA damage caused by UV-light. [A] A CPD in the context of 
duplex DNA (PDB accession code 1PIB (Lee et al., 2004). [B] Close-up of the CPD.
[C] A (6-4) PP in the context of duplex DNA (PDB accession code 1CFL (Lee et al., 1999)).
[D] Close-ups of the 6-4 PP
20
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Dimers can also be produced by formation of a single covalent bond between the C6 
of one pyrimidine and the C4 of the adjacent downstream pyrimidine. This type of 
photoproduct is called a pyrimidine (6-4) pyrimidone photoproduct (6-4 PP) (figure
1.2 c, d).
As figure 1.2 shows both type of photoproduct create extensive distortion within the 
DNA structure. This distortion is an important consequence of forming 
photoproducts, as this is often the primary recognition signal for the repair apparatus.
e) Inter-strand crosslinks
Inter-strand crosslinks (ICLs) are formed by a covalent connection of two DNA bases 
on opposite strands of DNA. ICLs are particularly problematic because they block all 
unwinding of the double helix for DNA replication and transcription. The model ICL 
is generally one that has been generated using the bifunctional aromatic molecule 
psoralen (figure 1.3 a, b, c). A large number of antitumour drugs such as mitomycins 
and cisplatin form ICLs, and although these adducts are not the major products, they 
are thought to be clinically relevant and they often trigger apoptosis as they are 
difficult to resolve.
f) Double strand breaks
Ionizing radiation and radiomimetic drugs can cause multiple damaged sites in close 
proximity in DNA and induce double strand breaks (DSB) in DNA. DSBs are also 
formed during replication, typically during the collapse of a replication fork. DSBs 
are a potentially lethal type of DNA damage, as they may lead to major chromosomal 
aberrations.
21
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Figure 1.3 -  Interstrand crosslinking by psoralen. [A] The structure of psoralen. [B] An 
psoralen-mediated interstrand crosslink in the context of duplex DNA (PDB accession code 
1FHY (Eichman et al., 2001)). [C] Close-up of the interstrand crosslink. Psoralen is shown 
in maroon.
1.2 Repair of DNA damage
Although a direct reversal of DNA damage is attractive for many reasons, not least 
simplicity, in most cases the reverse reaction is not possible for kinetic and/or 
thermodynamic reasons. However, in a few cases, the reaction is reversible, and in 
some of these cases mechanisms have been developed to take advantage of this.
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Examples include the photoreversal of CPDs and 6-4 PPs by CPD/ 6-4 PP DNA 
photolyases (Garinis et al., 2006), the repair of 0 6-alkyl guanine by 0 6-alkylguanine 
DNA alkyltransferase (Pegg and Byers, 1992) and the repair of l-methyladenine/3- 
methylcytosine by AlkB (Begley and Samson, 2003).
Mismatches in DNA are where one of the bases within a given base pair is unsuitable 
for forming appropriate hydrogen bond donor and acceptors within the base pair. 
Most mismatches are due to replication errors. Other mismatches are caused by 
damage such as deamination. The mismatch repair pathway of E.coli is probably the 
best understood and key players within it include MutS and MutL, the endonuclease 
Mut H, the helicase UvrD, DNA polymerase III and DNA ligase (Friedberg et al., 
2006). A key feature of mismatch repair is the utilisation of methyl groups present on 
the older (and assumed correct) strand of DNA to guide the correction of the 
mismatch. There are eukaryotic orthologues for most of these proteins, which implies 
that the mechanism is conserved throughout evolution. Bacteria are thus a good 
model system for studying mismatch repair.
Another mechanism of DNA repair is base excision repair (BER). BER pathways are 
employed to remove incorrect bases (e.g. uracil) or damaged bases (e.g. 3- 
methyladenine) with each pathway specific for each types of incorrect base. 
However, all BER pathways have a common general mechanism.
1) Removal of the incorrect base by an appropriate DNA N-glycosylase to create 
an apurinic/apyrimidinic (AP) site.
2) Nicking of the damaged DNA strand by AP endonuclease upstream of the AP 
site, thus creating a 3’-OH terminus adjacent to the AP site
3) Extension of the 3’-OH terminus by a DNA polymerase in concert with 
excision of the AP site.
Structures of several of the DNA N-glycosylases involved in step 1 have been solved. 
It is the specificity of the DNA N-glycosylase for the inappropriate nucleobase that 
determines whether and how BER proceeds (Friedberg et al., 2006).
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1.3 Nucleotide excision repair (NER)
The repair mechanisms above can deal with DNA damage so long as there is an 
appropriate enzyme capable of recognising that specific damage. However, the wide 
range of DNA-reactive chemicals in our environment leads to a huge range of lesions 
that cannot be covered by specific DNA glycosylases. Evolution cannot be expected 
to keep developing focussed pathways for each new environmental mutagen and 
chemotherapy drug. To compensate for this, a more flexible, but more complex 
damage repair mechanism has evolved. This is called nucleotide excision repair 
(NER).
There are 6 major steps in eukaryotic NER involving 15-18 different polypeptides 
(figure 1.4; unless otherwise noted human protein names are given; (Araujo and 
Wood, 1999; Park and Choi, 2006)
1) Damage recognition. In NER this occurs by recognising an abnormal 
structure in the DNA such as that caused by CPDs and 6-4 PPs. Damage 
recognition is thought to involve the XPC-HR23B complex, as well as XPA 
and the single-stranded DNA binding protein RPA.
2) Binding of a multi-protein complex at the damage site and unwinding of the 
double helix around the damage. The 3’ -> 5’ helicase XPB and the 5’ -*> 3’ 
helicase XPD are part of the TFIIH complex involved in this step.
3) Double incision of the damaged strand several nucleotides away from the 
damage site on both the 5’ and 3’ sides, followed by excision of this 18-25 
nucleotide stretch of the damaged strand. The incisions are performed by the 
endonucleases XPG, which is a member of the FEN-1 family of 
endonucleases and ERCC1-XPF, a heterodimeric enzyme which will be 
discussed in more depth in section 1.5 and onwards.
4) De novo DNA synthesis filling in the gap by a repair DNA polymerase, 
followed by ligation.
The overall process of NER in bacteria resembles that in eukaryotes but the proteins 
involved are generally not homologous. The UvrABC complex performs the incision 
events in bacterial NER. Thus bacteria are not good model organisms for the study of
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eukaryotic NER. However, yeast and Archaea provide appropriate model organisms 
for the study of NER.
wmMimmw
i [A] Damage recognition.
[B] DNA unwinding.
[ XPG
I [C] Excision of dam aged DNA.
mum:
[D] De novo DNA synthesis 
and ligation
POL 6/e
Figure 1.4 -  A general scheme for eukaryotic nucleotide excision repair
How NER proceeds is dependent on how the damage is recognised. It has been 
observed that damage within heavily transcribed regions of the genome is usually 
repaired more rapidly than damage in the non-transcribed regions. Thus it is 
generally accepted that there are two types of NER, global genome repair (GGR) and 
transcription-coupled repair (TCR). It is thought that GGR is initiated by the XPC- 
HR23B complex “finding” damage, where as TCR is initiated by the stalling of RNA 
polymerase at sites of damage (van Hoffen et al., 2003). Apart from these differences
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in damage recognition and initiation, the general mechanism of NER is common to 
both processes.
There are three human diseases associated with defects in NER; Xeroderma 
pigmentosum (XP), Cockayne’s syndrome (CS) and Trichothiodystrophy (TTD) 
(Lehmann, 2003). Indeed the XPA -> XPG genes encoding many of the human NER 
proteins mentioned above were first identified in genetic complementation studies of 
XP. Although all three diseases are associated with defective NER, they have 
different clinical symptoms. XP patients are noted for their light sensitivities, an early 
onset of skin cancer at high incidence, elevated frequency of other forms of cancer 
and neurological defects. CS and TTD have similar symptoms of premature aging of 
some tissues, facial and limb abnormalities and in some cases light sensitivity and 
dwarfism.
Gene Gene product function Phenotype
XP-A binds damaged DNA in preincision complex neurological
XP-B (ERCC3) no TCR, CS
3’ to 5’ helicase
XP-C binds damaged DNA in complex with no GGR
HHR23B
XP-D (ERCC5) no TCR, CS
5’ to 3’ helicase
XP-E subunit of UV-DDB mild defects
XP-F (ERCC4) mild defects
3’-flap endonuclease
XP-G 5’-flap endonuclease severe XP, CS
XP-V (variant DNA polymerase) mild defects
Table 1.1 -  Xeroderma pigmentosum genes. XP genes, the roles of their protein products in 
NER and in disease.
1.4 NER in Archaea -  model organisms for eukaryotic NER.
The basic repair processes discussed thus far are common to bacteria and eukaryotes, 
but the proteins involved are not always conserved between these two domains of life 
and this is particularly true for NER and double strand break repair. However, in 
Archaea, the third domain of life, there are marked similarities between eukaryotic 
and archaeal DNA replication and transcription proteins, as well DNA compaction 
proteins such as histones (White and Bell, 2002). Thus it is not surprising that many
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archaeal organisms contain homologues of eukaryotic NER components rather than 
homologues of bacterial proteins such as UvrABC (White, 2003). (A small sub-group 
of Archaea do have UvrABC orthologues although this is thought to have occurred by 
a lateral gene transfer from bacteria). Table 1.2 summarises the distribution of NER 
proteins in sequenced archaeal genomes (adapted from White, 2003 and Kelman and 
White, 2005). It is therefore evident that that Archaeal DNA repair provides a model 
system to study eukaryotic DNA repair.
Species
Aeropyrum pernix
Pyrobaculum
aerophilum
Sulfolobus
solfataricus
Sulfolobus tokodaii
Thermoplasma
acidophilum
Thermoplasma
volcanium
Methanopyrus
kandleri
Pyrococcus juriosus 
Pyrococcus horikoshii 
Pyrococcus abyssi 
Methanococcus 
jannaschii
Archeoglobus fulgidus
Methanothermobacter
thermautotrophicus
Methanosarcina
acetivorans
Methanosarcina
mazei
Halobacterium
Short XPF Long XPB XPD PCNA RPA SSB UvrABC 
XPF
Optimal
temperature
(°C)
95
95
80
80
60
60
100
100
100
100
85
85
70
<40
<40
<40
Table 1.2 -  Distribution o f selected DNA repair proteins in sequenced archaeal genomes. 
Crenarchaea are shown in bold, euryarchaea in normal text. Adapted from Kelman and White, 2005; 
White, 2003.
1.5 The XPF/Mus81 family of endonucleases
XPF-ERCC1 and Mus81-Emel are heterodimeric endonucleases (Boddy et al., 2001; 
Sijbers et al., 1996). Each endonuclease has at least a single metal-dependent 
catalytic site located within the XPF or Mus81 subunit, whilst their respective 
partners ERCC1 and Emel lack a catalytic function. XPF-ERCC1 and Mus81-Emel 
are structurally related but functionally distinct and have been found in eukaryotes 
from yeast to humans. There is evidence for a third related endonuclease in higher 
mammals (Meetei et al., 2005). XPF/Mus81 homologues have also been identified in
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Archaea (White, 2003). Collectively these endonucleases and their non-catalytic 
endonuclease-like partners form a family of evolutionarily related proteins.
Members of this family have not been named systematically but have had names 
assigned from radiation-sensitive mutational screens or by their ability to complement 
certain repair-deficient cell lines. The first XPF-like endonuclease described was the 
S.cerevisiae orthologue of XPF-ERCC1, the Radi-Rad 10 complex (Tomkinson et al., 
1993). Both Radi and RadlO were identified by screening genomic libraries for the 
complementation of UV-radiation sensitive mutants. A similar screen in S.pombe 
identified another XPF orthologue Radi6 (Carr et al., 1994); whilst the ERCC1 
orthologue, SwilO, was found by characterising mutants with a reduced frequency of 
mating-type switching (Schmidt et al., 1989).
ERCC1, the mammalian counterpart to SwilO and RadlO, was found by its ability to 
complement a nucleotide excision repair (NER) repair defect in a mutant Chinese 
hamster ovary (CHO) cell line and was named excision repair cross-complementing 
gene 1 (or ERCC1) (Westerveld et al., 1984). XPF is the human orthologue of Radi 
and Rad 16 and was found by degenerate PCR based on sequence similarity with the 
yeast orthologues (Sijbers et al., 1996). It was also independently found to 
complement a mutant CHO cell line and named ERCC4. The XPF gene product 
complements the NER defect in patients with Xeroderma pigmentosum 
complemenation group F (Yagi et al., 1998).
The XPF paralogue, Mus81 (methyl methansulfonate, UV sensitive clone 81), was 
identified independently by several groups using two-hybrid screens with Rad54 from 
S.cerevisiae and with Cdsl from S.pombe (Interthal and Heyer, 2000). Mus81 was 
also found in a synthetic lethal screen for genes that are essential in the absence of the 
RecQ helicase Sgsl (Mullen et al., 2001). The non-catalytic partner of Mus81, 
analogous to the ERCC1 subunit of XPF-ERCC1, is called Mms4 (methyl 
methanesulfonate-sensitive 4) in S.cerevisiae (Xiao et al., 1998), and Emel (essential 
meiotic endonuclease 1) in S.pombe, where it was identified as a Mus81-associated 
protein (we refer to the S.pombe convention throughout) (Boddy et al., 2001).
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A third human XPF/Mus81 endonuclease has recently been characterised as the 
product of the FANCM gene involved in the disease Fanconi anemia. Fanconi 
anemia patients are characterised by their genomic instability and predisposition to 
cancer. It has been proposed that the FANCM protein may have an active helicase 
domain enabling it to act as a translocase for other FANC proteins. A second ERCC1- 
like gene, MGC32020, is also found in the human genome and together with FANCM 
gene products could reconstitute an active nuclease, although this remains to be 
shown (Meetei et al., 2005). In a similar manner, analysis of archaeal genomes 
revealed XPF homologues in both the major divisions of Archaea, the Euryarchaea 
and the Crenarchaea (White, 2003). Many are uncharacterized open reading frames 
with the exception of the XPF homologue from Pyrococcus furiosus designated Hef 
(Helicase-associated endonuclease for fork-structured DNA) (Komori et al., 2002), 
and the smaller XPFs from Aeropyrum pemix (Lally et al., 2004) and Sulfolobus 
solfataricus (Roberts et al., 2003). Hef has an ATP-dependent helicase activity in 
addition to its endonuclease activity and was identified from a screen for factors that 
enhanced Holliday junction resolvase activity (Komori et al., 2002).
1.6 Domain organisation of XPF/Mus81 family members
There are five subgroups within the XPF/Mus81 family; four of which provide good 
evidence for a common evolutionary origin. The characteristic feature of most family 
members is the presence of an endonuclease or endonuclease-like domain and two 
helix-hairpin-helix (HhH) motifs (figure 1.5). There are three branches with catalytic 
endonuclease subunits and two that are non-catalytic but associate with their cognate 
active subunit. The ERCC1 and Emel proteins probably originated from a gene 
duplication of an active XPF subunit that subsequently diverged to produce a single 
catalytic centre heterodimeric endonuclease from a two catalytic centre homodimeric 
endonuclease. Evidence from the homodimeric A.pemix XPF (Newman et al., 2005) 
indicates that only a single catalytic centre is active at one time and could explain why 
eukaryotic XPF-ERCC1 or Mus81-Emel complexes retain only one catalytic motif 
within the endonuclease.
The long XPF nucleases range in size from 892 to 2048 amino acids and have an SF2 
superfamily helicase domain or helicase-like domain fused to the amino-terminus of 
the core nuclease and tandem helix-hairpin-helix ((HhH)2) domains. XPF subunits
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with known or predicted helicase activity are found in Euryarchaea, for example the 
Hef endonuclease of P.furiosus (Komori et al., 2004) and the FANCM gene product 
in the human and mouse genomes (Meetei et al., 2005). However the conserved 
eukaryotic XPF subunit has a degenerate helicase domain that has accumulated 
mutations and not retained helicase activity.
The small XPFs have the simplest structure comprising just the conserved core 
nuclease and (HhH)2 domains and are restricted to crenarchaea and a gene encoded 
within the African swine fever virus (ASFV) genome (Yanez et al., 1995). The small 
XPFs in crenarchaea have evolved a further elaboration through a carboxy-terminal 
motif that binds to a heterotrimeric PCNA processivity factor (Roberts et al., 2003). 
Archaeal genomes typically encode only one XPF/Mus81 gene except A.fulgidus that 
appears to have a short and a long XPF gene (White, 2003).
The Mus81 sub-group has a variant domain organization where the carboxy-terminal 
(HhH)2 domain is replaced by single HhH motifs at each sequence extremity. The 
different arrangement of HhH motifs between XPF and Mus81 subunits is reminiscent 
of circularly permuted protein folds and it is possible that folding of Mus81 may 
permit contacts that reconstitute the (HhH)2 domain. Mus81 proteins have two other 
characteristics; an insert within their nuclease domain and a small functional domain 
between the amino-terminal HhH domain and nuclease domain (to be discussed in 
Chapter 5).
The last two subgroups in the family are the ERCC1 and Emel proteins unique to 
eukaryotes. Both ERCC1 and Emel are structurally related to their cognate active 
XPF or Mus81 subunits. Both probably evolved by gene duplication of an active 
nuclease subunit and retained their HhH motifs but lost the catalytic function of their 
nuclease-like domain. ERCC1 is extremely well conserved within known orthologues 
suggesting a critical function that is still not well understood. The nuclease-like 
domain of Emel is poorly conserved and known orthologues cannot be reliably 
aligned either with ERCC1 or other XPF/Mus81 members. However secondary 
structure predictions support the presence of a nuclease-like domain and justify the 
inclusion of these proteins in the XPF/Mus81 family. Moreover the carboxy-terminal 
portion of Emel has an HhH motif that is closely related to Mus81.
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Figure 1.5 -  Domain organisation of the XPF/Mus81 family o f endonucleases. 
Helicase/helicase-like domains are in yellow, nuclease/nuclease-like domains are in blue and 
helix-hairpin-helix domains are in green.
1.7 Characteristic structural features
At the beginning of this thesis there were no crystal structures published from the 
XPF/Mus81 family. However, in recent years, several have shed light on the 
structures of the various domains within this family (figure 1.6).
1.7.1 Nuclease domain
The nuclease domain common to all XPF/Mus81 family members encompasses both 
a type II restriction endonuclease fold with a central six stranded p-sheet flanked by 
several a-helices and a a-helix-P-strand-a-helix dimerisation motif (Newman et al., 
2005; Nishino et al., 2003)(representive structures shown in figure 1.6). The nuclease­
like domain of ERCC1 has the same structural elements as the active subunits and the 
same interface used for dimerisation in Hef may also be used by heterodimeric XPF- 
ERCC1 complexes, though there is some controversy over this issue. Active subunits 
such as XPF and Mus81 have a conserved GDXnERKX3 D motif within their nuclease 
fold indicative of a metal-dependent nuclease activity. Mutagenesis and biochemical 
evidence indicates that this motif and other residues within this region are required for 
nuclease activity but not for DNA junction binding (Enzlin and Scharer, 2002; 
Nishino et al., 2003). There is a good correspondence between the active site 
GDXnERKJGD motif of Hef and the PDXn(E/D)XK motif of type II restriction 
endonucleases (Pingoud et al., 2005). These acidic residues in the Hef active site
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motif coordinate a divalent metal ion together with several main chain carbonyl 
groups.
The nuclease domain is required but is not sufficient for endonuclease activity. It is 
likely that the major DNA-binding affinity resides within the (HhH)2 domain and this 
is required to recruit substrate to the catalytic domain. The XPF from A.pemix has its 
nuclease and (HhH)2 domains connected together via a flexible linker (Newman et al., 
2005). This separation of DNA-binding and catalytic functions is also found in 
certain modular prokaryotic restriction endonucleases such as Fokl (Wah et al., 
1997).
1.7.2 Helix-hairpin-helix (HhH)2 domain
A distinguishing feature of the XPF/Mus81 family is their ability to recognise DNA 
junctions with a defined polarity and to do this they employ sequence-independent 
HhH DNA-binding motifs (Doherty et al., 1996)(representive structures shown in 
figure 1.6). The HhH motif is a ubiquitous DNA-binding motif that was first found 
by Thayer et al. (1995). In a more specialised variant, two HhH motifs, designated as 
an (HhH)2 domain, form a globular domain with a fifth connecting helix (Shao and 
Grishin, 2000). Such domains are found in prokaryotic RuvA Holliday junction 
resolvases and UvrC nucleases and often have glycine residues at the first and third 
positions of the hairpin portion of the HhH motif (Rafferty et al., 1998; Singh et al.,
2002). More reliable predictors of the motif are core hydrophobic residues typically 
found in the five-helix bundle and in this context the (HhH)2 domain recognises the 
minor groove of duplex DNA (Newman et al., 2005).
As well as the nuclease-domain dimerisation motif, both Hef and A.pemix XPF also 
dimerise through their (HhH)2 domains. Consequently simultaneous disruption of 
both interfaces is required to produce a monomeric form with a greatly diminished 
endonuclease activity. Association of these (HhH)2 domains into distinct quaternary 
structures is most likely the key to understanding the XPF/Mus81 substrate 
specificity. For example, the (HhH)2 dimer observed for A.pemix XPF suggests it can 
distort a nicked DNA duplex or 3’-flap by independently engaging both the upstream 
and downstream duplex regions. Recently structures of the C-terminal regions of
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Figure 1.6 -  Representative structures of domains from XPF/Mus81 family members 
published during this period of this thesis. [A] Crystal structures o f domains from the 
Pyrococcus furiosus XPF homologue, Hef. The helicase domain (yellow; PDB accession 
code 1WP9 (Nishino et al., 2005a)), the nuclease (blue; PDB accession code 1J25 (Nishino 
et al., 2003)) and the (HhH)2 domain (green; PDB accession code 1X21 (Nishino et al., 
2005b)). [B] Crystal structure of the XPF homologue from Aeropyrum pernix with DNA- 
bound (PDB accession code 2BGW (Newman et al., 2005)) [C] Crystal structures o f 
domains from human ERCC1-XPF. The helicase-like domain from human ERCC1 (blue; 
PDB accession code 2A1I (Tsodikov et al., 2005)) and the (HhH)2 domain dimer from 
ERCC1-XPF (green/dark green; PDB accession code 2A1J (Tsodikov et al., 2005))
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XPF and ERCC1 (Tripsianes et al., 2005; Tsodikov et al., 2005) have shown that 
human XPF-ERCC1 possesses a similar (HhH)2 domain heterodimer.
1.7.3 Helicase domains
The long XPF proteins found in euryarchaeal and eukaryotic XPFs have a SF2 
superfamily helicase/helicase-like domain (Caruthers and McKay, 2002; Soultanas 
and Wigley, 2001). The Hef helicase domain has three sub-domains. The first and 
third sub-domains share the RecA-like fold and contain motifs I-III and IV-VI 
respectively. The second sub-domain is entirely helical and is found in a limited sub­
group of helicases including Hef, FANCM, Mphl and Dicer helicases (representive 
structure shown in figure 1.7 (Nishino et al., 2005a)). SF2 helicases typically have a 
3’ 5* polarity consistent with the double-stranded/single-stranded DNA junction
polarity recognised by the XPF/Mus81 family.
Eukaryotic XPF subunits have no ATP-dependent helicase activity and only the first 
sub-domain of Hef can be reliably aligned. Even from this analysis it is clear that their 
degenerate helicase domains have lost key residues involved in ATP binding and 
hydrolysis, a catalytic function required for helicase action. For example, the acidic 
residues of the DEAD/DExH motif III that coordinate Mg2+ are lacking from eukaryl 
XPF proteins. The function of the helicase-like domain of eukaryotic XPFs is unclear. 
Evidence from Hef implicates the helicase domain in binding and recognition of DNA 
junctions but this remains to be proven for other XPFs (Komori et al., 2004).
1.8 Mechanism and substrate specificity
Biochemical studies on S.cerevisiae Radi-Rad 10 and human XPF-ERCC1 indicate 
that both complexes preferentially nick duplex DNA adjacent to a 3’ single-stranded 
stretch in simple Y and stem-loop structures (Bastin-Shanower et al., 2003; de Laat et 
al., 1998). In contrast Mus81-Mms4 from S.cerevisiae nicks 3’-flaps and other model 
replication fork substrates, which contain 5’ DNA ends not further than 3 bases 
downstream of the branchpoint (Bastin-Shanower et al., 2003; Fricke et al., 2005; 
Whitby et al., 2003)(figure 1.7). The crenarchaeal XPF from Sulfolobus solfataricus 
exhibits similar substrate preferences to Mus81-Emel despite their different HhH 
motif arrangements (Roberts and White, 2005). This has lead to the suggestion that 
the archaeal XPFs represent an ancestral form of XPF/Mus81 before the enzyme
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diverged to select different substrates by the co-evolution of XPF-ERCC1 and 
Mus81-Emel complexes (White, 2003). These subtle differences in substrate 
specificity observed in vitro help ensure each endonuclease plays a distinct role in the 
repair and preservation of the genome.
Mus81-Eme1
Nicked
Holliday
junction
3'-flap
Replication ForkD-loop
XPF-ERCC1
bubble
loop^stem-l
splayed arm
Figure 1.7 -  Preferred substrates cleaved by XPF-ERCC1 and Mus81-Emel in vitro. 
Archaeal XPF homologues prefer Mus81-Emel-type substrates rather than XPF-ERCC1- 
type substrates.
XPF-ERCC1 cleaves a single phosphodiester bond in one strand of the junction 
duplex. This activity requires Mg2+ (or other suitable divalent cations such as Mn2+) 
and the active site residues coordinating this metal ion have been identified (Enzlin 
and Scharer, 2002). Beyond this, the catalytic mechanism of XPF/Mus81 
endonucleases is not well understood though there are several general mechanistic 
features shared with the type II restriction enzymes. What is unique to the 
XPF/Mus81 family is how they recognize DNA junctions. Insights into how this is 
achieved have come from studies on archaeal XPFs implicating both XPF subunits in 
substrate recognition through a large distortion of the DNA junction (Newman et al., 
2005; Nishino et al., 2005b). It remains unclear whether the duplex part of the DNA 
junction is bent as it enters the XPF active site as observed for EcoRV (Horton and 
Perona, 1998), or whether the individual strands close to the junction are locally 
unwound permitting only one strand to enter the XPF-ERCC1 catalytic centre.
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1.9 Other cellular functions of the XPF-ERCC1 endonuclease
Although the primary cellular function of XPF-ERCC1 is in the NER-dependent 
repair of DNA lesions, there are other repair processes it has been implicated in. The 
extreme sensitivity of XPF and ERCC1 mutants to cross-linking agents as well as the 
severe phenotypes observed for XPF-null and ERCCl-null mice, such as growth 
retardation, early death and abnormalities in many organs, provides good evidence 
that XPF-ERCC1 and its orthologues have NER-independent functions (McWhir et 
al., 1993; Tian et al., 2004). XPF-ERCC1 is known to function in a recombination 
repair sub-pathway called single-strand annealing (Motycka et al., 2004). XPF- 
ERCC1 is also essential for targeted homologous recombination of exogenous DNA 
into mice (Niedemhofer et al., 2001). XPF-ERCC1 is also able to process blocked 3’ 
termini that prevent priming of DNA synthesis (Guzder et al., 2004) and XPF/ERCC1 
has also been shown to remove the 3' overhang from uncapped telomeres (Zhu et al.,
2003).
It is well documented that XPF-ERCC1 activity is required for the repair of ICLs, 
independently of other NER components (De Silva et al., 2000). Evidence suggests 
XPF-ERCC1 is required for unhooking the ICL and resectioning the substrate for 
processing by homologous recombination (McHugh et al., 2001). It is not clear how 
XPF-ERCC1 targets ICLs or how it cooperates with recombination proteins that are 
also required for ICL repair.
These questions have potential medical implications since compounds such as 
melphalan and cisplatin introduce highly cytotoxic ICLs into DNA and are often part 
of chemotherapy regimens to treat cancer. Genetic and RNAi knockdown data have 
validated XPF-ERCC1 as an anti-cancer target and small molecular inhibitors could 
have important therapeutic uses. Compounds that block XPF-ERCC1 activity in the 
short term and thereby impede DNA repair capacity could enhance the toxicity of 
ICL-generating compounds. Indeed it been found that testis tumour cell lines are 
defective in NER and it is thought that this is a major reason why cisplatin-based 
chemotherapy is so effective against testicular cancer. Thus inhibition of NER by 
inhibition of XPF-ERCC1 could sensitize a wider range of tumours to such treatments 
and reduce acquired drug resistance.
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1.10 Cellular function(s) of Mus81-Emel
In keeping with its preferred substrates in vitro, the major cellular role of Mus81- 
Emel is though to be in the repair of replication forks and double-strand breaks by a 
mechanism distinct from that of classical bacterial homologous recombination. A 
model has been suggested where by Mus81-Emel is involved in double-strand break 
repair without the formation of a double HJ intermediate (figure 1.8, (Whitby, 2005)). 
In this model Mus81-Emel cleaves a D-loop on one side of the DSB and a half­
junction formed by second strand capture on the other side of the break. This 
cleavage would leave gaps and/or 5’-flaps of ~ 5 nucleotides. Such flaps could 
isomerise and be cut by Mus81-Emel or could be dealt with by a Rad2/XPG/Fen-1 
type endonuclease. DNA synthesis and ligation of the cleaved strands results in a 
repaired molecule, which has been crossed-over without formation of a double HJ. 
This model for Mus81-Emel action is attractive as it ties together biochemical and 
genetic evidence nicely (Hollingsworth and Brill, 2004).
Mus81-null mice, unlike XPF-ERCCl-null mice, are viable but are highly 
predisposed to lymphomas and other cancers, pointing to a role in maintaining 
genomic stability. Both Mus81-null and Emel-null mice are hypersensitive to 
mitomycin C and cisplatin, both agents which cause ICLs. (Abraham et al., 2003; 
McPherson et al., 2004). These mice are however, not sensitive to other DNA 
damaging agents such as infrared, UV or hydroxyurea. However double strand break 
formation in these mice is normal, which suggests that if Mus81-Emel is involved in 
ICL repair, it is at a late stage (Dendouga et al., 2005). This is consistent with the 
model of action in figure 1.8.
The cellular function of archaeal XPF/Mus81 homlogues is not yet understood. In 
vitro data for the Pyrococcus furiosus XPF homologue, Hef, demonstrating it can 
cleave nicked, flapped and fork-structures, is consistent with a role in resolving 
stalled replication forks similar to Mus81-Emel (Komori et al., 2002).
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Figure 1.8 -  A scheme for double-strand break repair involving Mus81.
1.11 Thesis outline
The aim of this thesis was to understand how XPF/Mus81 endonucleases recognise 
their substrates and the catalytic mechanism underlying the cleavage reaction.
XPF and Mus81 endonucleases are large, multi-domain proteins that pose challenging 
problems for X-ray crystallography analysis. To develop a tractable crystallographic 
project, a reductionist approach was taken to study individual domains from XPF and 
Mus81 and thereby remove conformational flexibility. In this way the nuclease 
domain of A.pernix XPF (Chapter 3) and the ACE domain of Mus81 (Chapter 5) were
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prepared and crystallised. In parallel, longer XPF/Mus81 complexes were prepared 
that included DNA substrate mimetics (Chapter 3) or activating PCNA subunits 
(Chapter 4) to explore the effect of these components had on the crystallisation of 
resulting complexes. The hypothesis was that such complexes evidently better reflect 
the physiologically relevant XPF complexes found in cells and could reduce 
flexibility and potential aggregation problems.
The main objective of the thesis was to pursue all aspects of a structure determination 
by X-ray crystallography from construct design, optimisation and expression through 
to data collection, phasing and structure refinement. A successful structure 
determination was carried out for the A. pemix XPF nuclease domain (Chapter 3) and 
a near successful outcome for the Mus81 ACE domain (Chapter 5). The nuclease 
domain provides a high-resolution structure of the catalytic centre of an XPF and may 
allow complexes with inhibitors, single-stranded DNA and various metal ions to be 
prepared. The Mus81 ACE domain was successfully biosynthetically labelled with 
nitrogen-15 to facilitate an ongoing structure determination by NMR. An 
overexpression system was developed for producing the heterotrimeric PCNA 
complex from A. pemix (Chapter 4). Problems arising from toxicity of individual 
PCNA subunits to the host cells were overcome by more stringent transcriptional 
control. A reconstituted PCNA complex with XPF enabled crystal screens to be setup 
leading to small needles being produced. Higher order complexes with the XPB 
helicase were also assembled for ongoing electron microscopy experiments.
Structure-function analysis on XPF-ERCC1 required a functional assay for catalytic 
activity to allow selected point mutations to be prepared and characterised. Efforts to 
increase yields of human XPF-ERCC1 by optimisation of expression constructs and 
an improved purification protocol had a major impact on the human XPF-ERCC1 
project (Chapter 2). Benefits included allowed establishment of activity assay, 
permitting screening of a large chemical library for XPF-ERCC1 inhibitors and 
allowing selected point mutations of XPF-ERCC1 to be prepared and assayed. 
Functional assays were also established for A.pemix XPF and for Mus81-Emel 
complexes.
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2 Preparation and characterisation of the human XPF- 
ERCC1 endonuclease
The role of XPF-ERCC1 as a structure-dependent endonuclease belonging to the 
XPF/Mus81 family of endonuclease is outlined in chapter 1. This chapter describes 
experiments relating to structural studies of the human XPF-ERCC1 complex, as well 
as functional assays and efforts to enhance yields of XPF-ERCC1 A flowchart 
describing these experiments can be found below (Figure 2.1).
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Figure 2.1 -  Flowchart o f the experiments described in chapter 2
2.1 General considerations
The human XPF-ERCC1 endonuclease is a large protein complex with a predicted 
molecular mass of 136 kDa. Given its role in nucleotide excision repair and its status 
as a validated drug target, a structure-function analysis of this enzyme may yield 
valuable information. Flowever, large protein complexes from mammalian sources,
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such as XPF-ERCC1, are rarely amenable to structural studies. XPF-ERCC1 is too 
large for three-dimensional structure determination by nuclear magnetic resonance 
measurements but too small for study by electron microscopy. Crystallography is 
thus the only avenue to pursue. However, limited protein expression and 
conformational flexibility are often hurdles in structure determination by this method.
Earlier studies have shown that it is possible to produce active XPF-ERCC1 in E.coli 
(Gaillard and Wood, 2001). Subsequent studies have shown that it is possible to 
produce active XPF-ERCC1 recombinantly in baculovirus-infected insect cells 
(Enzlin and Scharer, 2002). Expression levels in this study allowed for mutagenesis 
experiments that identified key residues for activity within the XPF nuclease domain. 
The yields were not however suitable for crystallography. Comparisons of proteins 
from both expression hosts suggest that XPF-ERCC1 overexpressed in E.coli is 
aggregated, whilst XPF-ERCC1 overexpressed in insect cells is monodisperse (Enzlin 
and Scharer, 2002). Previous studies detailing recombinant expression in E.coli have 
suggested overexpression is possible but leads to aggregated protein (Enzlin and 
Scharer, 2002). Therefore it was implied that insect cells were the preferred host for 
XPF-ERCC1 overexpression.
2.2 Bacterial expression of the XPF-ERCC1 complex and associated degradation
Using a pET30b dicistronic bacterial expression plasmid provided by members of 
Prof. Rick Wood’s laboratory (ex-imperial Cancer Research Fund, Clare Hall 
Laboratories), a former postdoctoral fellow, Matthew Newman and a scientific officer 
John Lally (Structural Biology Laboratory) were able to express and purify 
recombinant XPF-ERCC1 complexes. The dicistronic plasmid coded for an N- 
terminally His6-tagged XPF and a C-terminally His6-tagged ERCC1. The E.coli 
strain used was FB810 (BL21(DE3) recA ) and affinity chromatography on nickel- 
NTA was used. In addition, non-aggregated XPF-ERCC1 has been produced. The 
key to this success appears to be use of the non-denaturing zwitterionic detergent 3- 
[(3-cholamidopropyl)dimethylammonio]-l-propanesulfonate (CHAPS). CHAPS was 
added to all extraction, purification and storage buffers. The success of this 
expression was tempered by a significant proportion of the XPF subunit being 
proteolytically degraded. This occurred at two major sites within the XPF enzyme. 
The first yielded a 70 kDa XPF fragment and the second a 40 kDa XPF fragment.
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Mass spectrometry revealed that the 70 kDa fragment was caused by an amino- 
terminal degradation and the first peptide identified after tryptic digest started at 
residue 361. The 40 kDa fragment was shown to compose of residues 629-905 of 
XPF. There did not appear to be any degradation of ERCC1.
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Figure 2.2 -  Bacterial overexpression of the XPF-ERCC1 complex using a dicistronic 
expression plasmid. The SDS-PAGE gel shows protein extracted and purified by Ni2+-NTA 
chromatography before loading onto a single-stranded DNA-agarose affinity column and 
elution with NaCl. The full-length XPF-ERCC1 complex is eluted from the column at high 
NaCl concentrations. A complex o f ERCC1 and a 40 kDa XPF fragment is eluted from the 
column at low NaCl concentration. A significant 70 kDa XPF fragment does not bind to the 
DNA-agarose column. The sites o f proteolysis of the XPF polypeptide with respect to its 
known domain organisation are shown in the schematic.
2.3 Expression, purification and characterisation of an ERCC1-XPF (629-905) 
complex.
As the schematic in figure 2.2 suggests, the fragment of XPF consisting of residues 
(629-905) encodes a little more than the core nuclease and (HhFI) 2  domains. 
However, since the proteolysis in the XPF-ERCC1 preparation highlighted this
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sequence as a potentially stable polypeptide, Matthew Newman (Structural Biology 
Laboratory) created a pET3b XPF (629-905). Using a pET30b ERCC1 construct (a 
gift from Prof. Rick Wood), Matthew Newman also created a dicistronic pET30b 
ERCC1-XPF (629-905) construct. This plasmid encodes a carboxy-terminally 
hexahistidine-tagged ERCC1 protein and an untagged XPF fragment.
I attempted the expression of the ERCC1-XPF (629-905) complex using this construct 
and Rosetta pLysS cells. Cells were grown, induced at 25 °C for 3 hours and 
harvested as described in Appendix A. Proteins were extracted from the cell pellets in 
50 mM Tris (8), 300 mM NaCl, 2 mM 2-mercaptoethanol, with protease inhibitors. 
Sonication was used to lyse cells and the cell debris was removed by centrifugation. 
(General protocols for protein preparations can be found in Appendix A). Soluble 
proteins were bound to nickel-NTA, the affinity matrix washed extensively and then 
eluted with imidazole. Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) was used to elucidate the composition of the eluate.
Figure 2.3 clearly shows that two major proteins co-eluted from the nickel-NTA. The 
theoretical molecular masses for ERCC1 and XPF (629-905) are 34.2 kDa and 30.6 
kDa. In this case it appears that both proteins are migrating through the gel a little 
slower than might be expected, although hexahistidine tags are known to exert such 
an effect on proteins during SDS-PAGE analysis. The conclusion was that the correct 
complex had been formed, with a respectable expression level of 1-2 mg per litre of 
bacterial culture. The purity of the complex after this purification step was good. The 
eluate was dialysed to remove the imidazole, and concentrated to 10 mg ml"1 for 
crystallisation trials.
Hanging drop vapour diffusion and microbatch experiments were set up using 
commercial sparse matrix screens. However, no crystallisation hits were produced 
and many drops had precipitate in them. Parallel crystallisation trials with simple 
synthetic duplex DNA (11, 13, 15, 17 base-pairs in length) were also unsuccessful.
At this stage further biochemical characterisation of the protein was attempted. Gel 
filtration of ERCC1-XPF (629-905) protein was attempted in order to identify 
whether a homogeneous, monodisperse sample was being used for crystallisation.
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After running the sample on both Sephacryl-100 and Superose-12 columns the sample 
did not elute as a single peak, indeed there was a lot of complex lost on the columns 
(data not shown). This indicated that perhaps the protein had a sticky patch that was 
interacting with the column. Detergents (CHAPS) and glycerol were added to 
alleviate these problems but with little effect.
ERCC1
XPF (629-905)
Figure 2.3 -  Expression of ERCC1-XPF (629-905). SDS-PAGE gel showing fractions
taken during protein extraction and purification on Ni2+-NTA.
Such sticky hydrophobic patches on protein surfaces are not uncommon. In this case 
one might base this conclusion on the fact that the XPF (629-905) is engineered and 
in vivo would be part of a larger polypeptide. Thus a formerly buried surface could 
be accessible due to an inappropriate truncation. However, as we know that the full 
length XPF polypeptide is degraded options are limited in this direction. Another 
possibility lies in the fact that the XPF-ERCC1 endonuclease is part of the NER 
machinery and is specifically recruited to the site of damage by protein-protein 
interactions. A well-documented interaction is that with XPA. XPA is a 36 kDa zinc 
metalloprotein that is known for its interactions with RPA, TFIIH and ERCC1, as 
well as binding single-stranded DNA (figure 2.4). A linear epitope has been 
identified within the XPA amino acid sequence that defines the ERCC1 binding site. 
It was hoped that the addition of XPA as a binding partner might improve the stability 
of the ERCC1-XPF (629-905) complex.
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Figure 2.4 -Domain structure of the human xeroderma pigmentosum A (XPA) protein and 
solution structure of the XPA minimal DNA-binding domain (XPA-MBD) (IPDB accession 
code 1XPA (Ikegami et al., 1998)). Adapted from Park and Choi, 2006.
2.4 Preparation of an ERCC1-XPF (629-905) -  XPA complex
The Peptide Synthesis Laboratory at Cancer Research UK synthesised the appropriate 
XPA peptide. The peptide sequence is GGKI1DTGGGFILEEEEEEE. This peptide is 
based on studies of the XPA-ERCC1 interaction that identify these residues as the 
minimal XPA fragment required for interaction with ERCC1 (Li et al., 1994; Li et al., 
1995). The run of seven glutamic acid residues at the end gives this peptide an acidic 
nature (pi 3.88). This acidity caused solubility problems when trying to dissolve it in 
similar buffers to that of the ERCC1-XPF (629-905) protein. Adding a five-fold 
molar excess of this peptide to the purified ERCC1-XPF (629-905) protein did not 
improve its monodispersity on gel filtration columns. Crystallisation trials with a 2- 
fold molar excess of peptide resulted in the limited solubility of the peptide being 
explored.
However, with the ERCC1-XPA interaction possibly being of crucial importance, a 
study involving full length XPA was undertaken. His6-tagged XPA had been 
produced in modest amounts by Annabel Borg (Protein Isolation Laboratory, Cancer 
Research UK). However, as the ERCC1-XPF (629-905) complex is also His6-tagged, 
this precluded a simple pull-down experiment. To circumvent this problem, a new 
GST-tagged XPA construct was made. The original pET15b-XPA expression
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construct (a gift from Annabel Borg) was digested with the restriction enzymes Ncol 
and Sail to release an XPA reading frame. This was ligated into a pET41a-3C vector 
cut with the same enzymes (see Appendix A for pET41a-3C vector details). 
Expression trials with the new construct were conducted in FB810 cells with a 25 °C, 
3hr, 25 pM IPTG, 10 mM ZnSC>4 induction. Proteins were extracted in buffer 
containing 150 mM NaCl and purified by affinity chromatography on glutathione- 
sepharose. Figure 2.5 shows that GST-XPA was expressed and eluted with excess 
glutathione. The yield of GST-XPA was around 2 mg per litre of bacterial culture, a 
significant improvement on the yields of His6-XPA.
kDa
GST-XPA
Figure 2.5 -  Expression o f GST-tagged XPA. SDS-PAGE gel showing fractions taken 
during protein extraction and purification on glutathione sepharose
The eluted GST-XPA was dialysed free of glutathione and rebound to a fresh batch of 
glutathione-sepharose. Purified ERCC1-XPF (629-905) was then passed over these 
beads in the hope of XPA-ERCC1-XPF (629-905) ternary complex formation. Two 
salt concentrations were used for these experiments 100 mM and 500 mM NaCl. As 
figure 2.6 shows ternary complex formation occurred and the GST-XPA pulled down 
the ERCC1-XPF (629-905). This complex was then eluted from the affinity column 
by cleavage with 3C protease. The complex formation was not efficient and some 
ERCC1-XPF (629-905) was not pulled down by the XPA.
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Figure 2.6 -  Preparation o f an ERCC1-XPF (629-905) -  XPA ternary complex. SDS-PAGE 
gel of fractions taken during the pull-down experiment in 500 mM NaCl. [1] GST-XPA 
bound to glutathione-sepharose. [2] GST-XPA and ERCC1-XPF D3 bound to glutathione- 
sepharose. [3] Wash step. [4] Glutathione-sepharose after wash. [5] Glutathione-sepharose 
after 3C protease cleavage. [6] Ternary complex eluted by 3C protease.
This initial experiment did not provide enough material for crystallisation trials. 
Large scale purifications of this ternary complex were attempted both by mixing cell 
pellets of GST-XPA and ERCC1-XPF (629-905), as well as mixing lysates after 
sonication but in both cases no significant amounts of ternary complex were formed. 
Whilst confirmation of the XPA-ERCC1-XPF complex was useful, the inability to 
“scale-up” preparations of the complex meant it was not possible to exploit this 
interaction to aid our structural goals. A recent study investigating the recognition of 
helical kinks by XPA also suggests that XPA binds ERCC1-XPF more readily when 
associated with a distorted DNA substrate (Camenisch et al., 2006). It may be 
possible to exploit this enhanced interaction in future experiments.
2.5 Activity of the ERCC1-XPF (629-905) complex
As has been mentioned, ERCCl-XPF’s critical role in NER makes it an attractive 
drug target. Inhibition of XPF activity would stop NER. NER is responsive to 
chemotherapy agents such as cis-platin that mediate DNA damage and subsequent 
apoptosis. Therefore, inhibiting NER could enhance and render many tumour types 
sensitive to cis-platin based drugs. If this inhibition could be targeted to specific cells 
such as tumour cells, then such an inhibitor drug could be very desirable. XPF-
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ERCC1 and XPG are particularly good targets because, as endonucleases, they have 
activities that can be assayed and thus there is a reporter system for inhibition.
Previous studies by de Laat et al., 1998 and Enzlin and Scharer, 2002, established an 
activity assay for XPF-ERCC1 activity. A 32P 5’-labelled stem-loop substrate (Figure
<2 i
2.8) was used as a synthetic NER substrate. Manganese ions (Mn ) were identified 
as the preferred cation and reactions were incubated at 28 °C. The reactions were 
stopped by addition of formamide, denatured at 95 °C and run out on polyacrylamide 
sequencing gels. The products of the endonuclease reaction were visualised on a 
Phosphoimager. Whilst these experiments established an assay for XPF-ERCC1 
activity and showed that the recombinant enzyme is active; this type of gel-based 
assay is not suitable for high-throughput inhibitor screening. The number of gels that 
would have to be run would be prohibitive and the use of radiolabelled phosphorus on 
a large scale is not desirable. Also, despite the fact that XPF-ERCC1 can be 
expressed in bacteria, the yields are certainly not great enough to provide enough 
protein for a comprehensive high-throughput inhibitor screen.
The ERCC1-XPF (629-905) protein described earlier contains a whole nuclease 
domain and thus may be expected to contain all the residues required for 
endonuclease activity. An attempt to develop a high-throughput assay centred around 
the ERCC1-XPF (629-905) protein was initiated in collaboration with Tim 
Hammonds’ group at Cancer Research Technology. The basic principle behind the 
high-throughput assay proposed is depicted in figure 2.7. A stem-loop substrate is 
retained with a 5’ fluorophore (carboxyfluorescein, FAM) and a quencher (dabcyl) at 
the 3’ end. When the cleavage occurs the stem becomes unstable and the labelled 5’ 
strand is lost. The delocalisation of the fluorophore from the quencher results in an 
increase in fluorescence at the specific emission wavelength.
In order to verify that any perceived activity was due to the enzyme and not a 
contaminant in the preparation, I engineered a catalytically dead form of ERCC1-XPF 
(629-905). Amino acid residue 720 of XPF was mutated from aspartic acid to 
asparagine using the Stratagene QuikChange protocol. This mutation was based on 
the previous mutagenesis study on human XPF (Enzlin and Scharer, 2002) that 
targetted this aspartic acid residue. Its role was postulated to be as a general base in
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activating a water molecule as a nucleophile required for phosphodiester bond 
hydrolysis. Hence, this D720N mutation was predicted to eliminate activity but not to 
affect the intrinsic protein fold.
l l l l l l l l l l l
XPF-ERCC1
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Figure 2.7 -  Schematic diagram of the high-throughput assay for XPF-ERCC1 activity. [A] 
Structure of carboxyfluorescein. [B] Structure of dabecyl. [C] The stem-loop substrate has a 
5’-fluorophore (yellow) and a 3’-quencher (grey). Upon cleavage of the substrate by 
ERCC1-XPF, the stem of the substrate is no long stable and the 5’-strand dissociates from 
the rest of the substrate. The delocalisation of the fluorophore from the quencher leads to an 
increase in fluorescence at 517 nm when excited with light at 492 nm.
Although some nuclease activity was present in the ERCC1-XPF (629-905) 
preparations, the D720N mutant proved that this was due to a contaminating E.coli 
nuclease (data not shown). This E.coli nuclease preferred Mg2+ to Mn2+ (the study of
0-4—de Laat et al. showed XPF-ERCC1 prefers Mn in vitro). Using radiolabelled 
stem/loop substrates and a gel-based assay (akin to those of de Laat et al., 1998) and 
the ERCC1-XPF (629-905) proteins, a scientific officer, Maureen Biggerstaff 
(Structural Biology Laboratory) showed that the substrate was not being cut cleanly 
near the double-strand/single-strand junction but rather indiscriminately along its 
length.
Extra purification steps were undertaken in order to remove the contaminating E.coli 
nuclease. As well as the initial purification step on nickel-NTA, John Lally 
(Structural Biology Laboratory) used affinity chromatography on Hi-Trap heparin-
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sepharose columns and gel filtration on a Superose 12 column to improve the purity 
of the ERCC1-XPF (629-905) complex. By assaying various fractions from the 
Superose 12 columns and using the gel-based assay, Maureen Biggerstaff was able to 
show that fractions containing ERCC1-XPF (629-905) were inactive (both “wild- 
type” and D720N), whilst fractions with a greater elution volume (and thus smaller 
molecular masses) contained the contaminant nuclease. Therefore, despite the 
advantage of high yields of ERCC1-XPF (629-905), the fact it is inactive makes it 
unsuitable for any sort of high-throughput activity-based functional assay.
2.6 Activity of the full-length XPF-ERCC1 complex
This result posed the question of whether any bacterially expressed XPF-ERCC1 
complex is active. John Lally produced the full-length XPF-ERCC1 complex as 
described before and used the same three-step purification procedure (nickel-NTA, 
heparin-sepharose, Superose 12) to eradicate the contaminant bacterial nuclease. In 
this case fractions containing the XPF-ERCC1 complex as judged by SDS-PAGE 
were active and cleaved specifically near the double-strand/single-strand junction, 
whilst later fractions contained the contaminant nuclease. In order to confirm that the 
observed structure-specific activity was due to XPF-ERCC1, I used the QuikChange 
mutagenesis strategy to make the D720N mutation in the full-length XPF-ERCC1 
construct. As expected the D720N mutant showed no activity and was catalytically 
dead (figure 2 .8).
With the evidence of real structure-specific activity, Maureen Biggerstaff successfully 
transferred the principles behind the radioactive gel-based assay to a fluorescence- 
based high-throughput assay. A stem-loop substrate was again used, with a 
fluorophore and a quencher. Mn2+ ions were used in the reaction buffer. A key 
consideration in this assay is the length of the substrate’s stem. The stem is ideally 
short to increase the oligonucleotide yield. However, the stem has to be long enough 
to be recognised by the enzyme. On top of this, the stem has to be long enough to be 
annealed at the assay temperature; yet short enough to be destabilised after XPF- 
ERCC1 has cleaved it. The salt concentration of the reaction is critical in these 
considerations. In the end, a stem 10/loop 22 substrate was chosen with a reaction 
temperature of 25 °C in a buffer containing 20 mM NaCl.
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Figure 2.8 -  XPF-ERCC1 activity. An autoradiogram showing the activity o f increasing 
amounts of XPF-ERCC1 against a stem 10 -  loop 22 substrate. Note the significant 
depletion of the stem-loop substrate at higher wild-type XPF-ERCC1 concentrations. Also 
note that the D720N mutant complex shows no significant activity.
Another key element in this assay is of course the XPF-ERCC1 enzyme. In order to 
screen tens of thousands of compounds for inhibition, it was necessary to produce 
milligrams of XPF-ERCC1. Clearly this was a problem, as the existing yields of the
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recombinant enzyme from E.coli were typically of the order of 50 p,g for 12 litres of 
bacterial culture. Three molecular biology approaches were employed to boost yields.
2.7 Expression of GST-XPF -  ERCC1 complex
Tagging protein at the amino-terminus with a GST tag has two major benefits. The 
first is that soluble protein may be purified by affinity chromatography on 
glutathione-sepharose. This is frequently an excellent purification step. The second 
is that yields and solubility of recombinant GST-fusion proteins are often found to be 
greatly increased compared to the overexpression of native or hexahistidine tagged 
proteins. On top of this, it was thought that the 60 kDa and 30 kDa fragments 
generated in previous preparations of XPF would be eliminated, as these fragments 
would also be lacking the amino-terminal GST tag. Due to these factors, an 
expression of GST-XPF was considered an avenue worth pursuing.
Using an existing human XPF construct (originally provided by Rick Wood, Imperial 
Cancer Research Fund), a GST-XPF construct was designed and made. An coding 
sequence for human XPF was excised from a pET30b-XPF plasmid using Ncol and 
Sail restriction sites. This was ligated into a pET41a-3C vector cut with the same 
restriction enzymes (see Appendix A for pET41a-3C vector details). The resultant 
plasmid coded for a GST-XPF fusion protein under the control of a T7 promoter.
Since ERCC1 is considered an obligate partner of XPF and is required for activity, a 
strategy for co-expression of GST-XPF and ERCC1 was devised. As pET41a-3C is a 
kanamycin-resistant plasmid, it was decided that a plasmid coding for ERCC1 could 
be co-transformed so long as it was ampicillin resistant. An untagged pET3a ERCC1 
expression plasmid was constructed using the Ndel restriction site (the ERCC1 
reading frame was taken from pET3/4b ERCC1, a plasmid generated by Matthew 
Newman). The orientation of the ERCC1 reading frame within the Ndel site was 
checked by DNA sequencing. Both pET41a-3C XPF and pET3a ERCC1 were co­
transformed in FB810 cells, selected for with both kanamycin and ampicillin, and 
expression trials were conducted.
Bacteria were grown at 37 °C and induced at 18 °C. Protein was extracted as for the 
previous XPF-ERCC1 complex preparations. Protein was purified by affinity
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chromatography on glutathione-sepharose. Proteins were eluted with buffer 
containing 20 mM reduced glutathione (pH 8). SDS-PAGE analysis of the 
preparations (figure 2.9) showed that the majority of GST-XPF protein is not eluted 
from the glutathione sepharose but rather is stuck to the affinity matrix. In addition, 
little ERCC1 appears to be made at all. Since ERCC1 is an obligate partner to XPF, 
and is required for activity, this method was not considered a viable route to enhanced 
XPF yields.
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Figure 2.9 -  Expression o f GST-XPF -  ERCC1. SDS-PAGE gel showing fractions taken 
during protein extraction and purification on glutathione sepharose
2.8 Expression using a redesigned ERCC1-XPF dicistronic vector
The respectable yield of the ERCC1-XPF (629-905) construct is interesting for many 
reasons. The enhanced yield of the XPF (629-905) fragment relative to that of full- 
length XPF is not surprising as it is a shorter and probably structurally more compact 
polypeptide. The enhanced expression of ERCC1 when co-expressed with XPF (629- 
905) compared to when expressed with full-length XPF is slightly puzzling, as both 
ERCC1 coding sequences are identical. One possible explanation for this observation 
is that for the ERCC1-XPF (629-905) construct, the ERCC1 is transcribed first from 
within the dicistronic plasmid. In the full-length XPF-ERCC1 construct the ERCC1
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is transcribed after the XPF. It was felt that the order in which the ERCC1 and XPF 
coding sequences were placed within the dicistronic plasmid could be significant and 
was worth investigating.
N del BamHI
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Xbal
N del Sail
X bal J
Blpl
pET30b
hXPF
N del Sail
-  1 my j  1—
N del
Xbal
N del
Sail
pET30b 
hERCC! -hXPF B lpl/B  Ip1
Figure 2.10 -  Construction of a new ERCC1-XPF dicistronic vector. This strategy relies on 
the presence of a unique Xbal site before the ribosome binding site in pET vectors and the 
fact that Xbal and Spel sites have identical cohesive overhangs after cleavage. Orange 
circles indicate ribosome-binding sites.
To this end, a new ERCC1-XPF dicistronic plasmid was created. The method of 
creation of the dicistronic plasmid is shown in figure 2.10. The method exploits the
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fact that pET vectors have a unique Xbal site upstream of the ribosome-binding site, 
and a unique Blpl site downstream of the multiple cloning site. Thus by cutting a 
pET30b XPF construct (a gift from Prof. Rick Wood) with Xbal and Blpl, the coding 
sequence for XPF complete with its own ribosome-binding site was excised. The 
recipient vector pET30b ERCC1 was linearised by digestion with Spel and Blpl. 
Since Spel (A jCTAGT) and Xbal (TjCTAGA) leave identical cohesive ends, the 
XPF (with its own ribosome-binding site) sequence can be ligated easily into 
linearised pET30b ERCC1. This results in a functional ERCC1-XPF dicistronic 
plasmid with each gene possessing its own ribosome-binding site.
Expression from this dicistronic vector was trialled by John Lally using identical 
bacterial growth and induction conditions, as well as protein extraction and 
purification conditions. In general, a 200 % increase in the yield of useful ERCC1- 
XPF complex has been found. This has allowed, albeit slowly, 2 milligrams of 
recombinant ERCC1-XPF required for the high-throughput inhibition assay to be 
stockpiled. In collaboration with Cancer Research Technology, the high-throughput 
inhibitor screen has been performed and potential specific inhibitors are currently 
being evaluated using material produced with this expression vector.
2.9 Deletion of putative protease sensitive loops within XPF
A major hindrance in producing milligram quantities of the XPF-ERCC1 enzyme has 
been the proteolytic degradation of XPF. Up to 50 % of expressed protein is 
degraded to the 70 kDa and 40kDa (629-905) fragments discussed in section 2.2. 
There are stretches of basic residues within the amino acid sequence of XPF. One of 
these sequences flanks the site of proteolysis causing the 40 kDa (629-905) fragment. 
Examination of the amino acid sequence also points to a particular basic stretch (339- 
360) that could conceivably flank the site of proteolysis causing the 70 kDa fragments 
(figure 2.11). Since the polar nature of these stretches make them unlikely to be 
contained in the core fold of the protein, it was hypothesised that these stretches of 
basic residues form flexible loops that make the XPF polypeptide sensitive to 
degradation.
With this in mind, a strategy was devised to delete the basic stretches from within the 
XPF polypeptide (figure 2.12). Overlap PCR was employed (Ho et al., 1989).
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Figure 2.11 -  Sequence alignment of selected XPF orthologues. Sequence numbers for 
each alignment panel are indicated. Magenta boxes indicate the positions of the basic 
stretches referred to in the text that were deleted. The orange line demarcates the helicase 
domain; the blue line, the nuclease domain; and the green line, the (HhH)2 domain. The 
positions of human XPF residues 629 and 720 are shown by red stars.
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Complementary primers and PCR are used to generate primary PCR products having 
overlapping ends. These primary products are combined in a subsequent reaction in 
which the overlapping ends anneal, allowing the 3’-overlap of each strand to serve as 
a primer for the 3’-extension of the complementary strand. Flanking primers can be 
used to amplify this product by standard PCR. This process can be repeated 
depending on the strategy and number of changes desired. In this case, the primers 
anneal near the site of the desired loop deletions.
The basic stretches in XPF that were targeted were as follows (and figure 2.11). The 
sequence coding for amino acid residues 339 to 360 was changed from 
KMSKKEKISEKMEIKEGEETKK to TGS. A short replacement linker was used in 
this case, as this putative loop is entirely absent in many other eukaryotic XPF 
homologues (figure 2.11). The sequence coding for residues 475 to 480 was changed 
from KKKKRK to TGSTGS. Finally the sequence coding for residues 613 to 626 
was changed from RKEKEAFEKLIREK to TGSSEAFEKLISES. It was felt 
necessary to introduce some residues to replace these putative loops. The sequence 
TGSQ has been used previously as a flexible linker to couple two weakly interacting 
proteins into a single polypeptide (Pellegrini et al., 2002).
The overlap PCR strategy worked and a coding sequence for the XPFAloops was 
produced. This sequence was cloned into pET14b-3C using Ncol and Ndel 
restriction sites. After this, an ERCC1- XPFAloops dicistronic plasmid was 
constructed in the manner explained previously in section 2.8 and figure 2.10. (An 
Xbal-Blpl fragment from pET14b-3C XPFAloops was ligated into pET30b-ERCCl 
linearised with Spel and Blpl).
Expression trials from this dicistronic plasmid were conducted. Bacteria were grown 
at 37 °C and then induced at 18 °C. Proteins were extracted as for the wild-type 
ERCC1-XPF complex in the presence of CHAPS. The protein was purified by 
affinity chromatography on Ni2+-NTA. However, SDS-PAGE analysis (figure 2.13) 
after this step revealed no significant ERCC1-XPFAloops expression. Subsequent 
trials with other induction conditions yielded similarly disappointing results.
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Figure 2.12 -  Strategy for generating XPFAloops coding sequence. The red lines represent 
the deletion of residues 339 to 360. The orange lines represent the mutation of residues 475 
to 480. The green lines represent the mutation of residues 613 to 626.
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Figure 2.13 -  Expression of ERCC1-XPFAloops. SDS-PAGE gel showing fractions taken 
during protein extraction and purification on Ni2+-NTA.
2.10 Summary
Structural characterisation of the full-length XPF-ERCC1 complex proved to be 
unfeasible at this time. Its size prevents study by structural techniques other than X-
58
Chapter 2: Preparation and characterisation of the human XPF-ERCC1 endonuclease
ray crystallography, whilst the poor expression and susceptibility to proteolysis make 
it a difficult crystallisation target.
The proteolysis of the XPF polypeptide did generate stable fragments that were 
exploited. The robust expression of the ERCC1-XPF (629-905) complex provided 
hope that a structural study could be initiated using a “divide and conquer” approach. 
However this complex, whilst apparently devoid of proteolytic degradation, could not 
be produced in a monodisperse, homogenous state necessary for crystallisation. A 
new construct and method for expressing the repair protein XPA was formulated and 
although it was possible to form the XPA-ERCC1-XPF (629-905) ternary complex; 
quantities of such a complex necessary for crystallography were not obtainable.
The lack of success in these initial efforts to obtain structural information for the 
XPF-ERCC1 complex was disappointing. However, given XPF-ERCCl’s status as a 
drug target, pursuing and establishing a high-throughput functional assay was of equal 
importance. Experiments showed that the ERCC1-XPF (629-905) was inactive, 
despite early experiments suggesting structure-specific activity. However, the 
expression of a dead D720N mutant of XPF showed that this activity was actually due 
to a contaminating bacterial nuclease. The full-length XPF-ERCC1 complex 
expressed in E.coli was shown to exhibit structure-specific activity in assays using 
both P-radiolabelled and fluorescent stem-loop type substrates.
A protocol for a high-throughput fluorescence assay of XPF was devised. However, 
to obtain suitable amounts of protein for a large-scale inhibitor screen, the expression 
levels of XPF-ERCC1 needed to be increased. Three approaches were employed. 
The first was to create a GST-tagged version of XPF that would hopefully eliminate 
the 70 and 40 kDa proteolysis fragments from the enzyme preparations as well as 
increasing the yield of the enzymes. Although expression of GST-XPF was observed, 
there appeared to be no ERCC1 co-purified and the GST-XPF was not eluted from a 
glutathione-sepharose affinity matrix. Another approach was to delete putative 
protease sensitive loops from the XPF sequence. An overlap PCR approach was 
employed to achieve this and a dicistronic plasmid of ERCC1-XPFAloops was 
constructed. However, protein expression experiments using this construct proved
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fruitless. The most successful approach to enhance XPF-ERCC1 yields involved 
creating a new dicistronic plasmid where the respective positions of XPF and ERCC1 
were changed. In the redesigned vector, the coding sequence for ERCC1 is 
transcribed first, followed by that of XPF. Such a rearrangement of coding sequences 
has enhanced the yield of XPF-ERCC1 by 200 %. This has allowed the successful 
screening of 55,000 compound library for potential inhibitors of XPF-ERCC1 
activity.
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3 Structural analysis of Aeropyrum pernix XPF domains and 
complexes with DNA substrates.
The presence of archaeal homologues of XPF has been discussed in Chapter 1. This 
chapter describes the structure determination of the nuclease domain of the XPF 
homologue from Aeropyrum pernix and attempts to crystallise this enzyme with 
different DNA substrates. A description of the experiments carried out is illustrated in 
the flowchart in Figure 3.1.
Unexpected proteolysis
Data collection 
and processing
M odel b u ild in g  w ith  
C o o t a n d  re f in e m e n t 
w ith  R efm ac
R efined  crysta l s t ru c tu re  
o f  ApeXPF n u c le a se  
d o m a in
C rystallisa tion  o f 
A peX PFA N A Cw ith 
n e w  DNA su b s tra te s
Crystals of SeMet 
ApeXPF nuclease 
(18-150)
Refined crystal structure 
of ApeXPFANAC with and 
without DNA
F o rm u la tio n  o f  m o d e ls  
fo r s u b s tra te  b in d in g  
b y  ApeXPF
D esign , c re a tio n  a n d  
e x p ress io n  o f  ApeXPFANAC 
d isu lp h id e  c o n s tru c t  to  p ro m o te  
DNA b in d in g  c o n fo rm a tio n
Structure solution by molecular 
replacement using 
ApeXPFANAC structure and anomalous 
data from selenium atoms
Figure 3.1 -  Flowchart of the experiments described in chapter 3. Experiments in grey were 
largely performed by others.
3.1 Expression, purification, crystallisation and structure solution of the XPF 
homologue from Aeropyrum pernix
The use of model organisms in the study of DNA replication, recombination and 
repair is well documented. Virtually every aspect of DNA biology was first studied in 
E.coli and yeast before analogies were drawn to mammalian pathways.
Although there are XPF homologues in lower eukaryotes such as S. cerevisiae and S. 
pombe, they remain large proteins that are difficult to express recombinantly and thus
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Figure 3.2 -Sequence alignment of selected archaeal and eukaryotic XPF homologues. 
Sequence numbers for each alignment panel are indicated. Ape = Aeropyrum pernix, Pfu = 
Pyrococcus furiosus, Sso = Sulfolobus solfataricus, Hsa = Homo sapiens, Spo = 
Schizosaccharomyces pombe and See = Saccharomyces cerevisiae. The blue line 
demarcates the nuclease domain; the green line, the (HhH)2 domain.
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to study structurally. Nucleotide excision repair in bacteria is achieved by different 
proteins and so bacterial equivalents are not relevant to understand eukaryotic XPFs. 
However, XPF homologues in the Archaea are an attractive option for structural 
studies for many reasons. Firstly, a great many archaeal proteins are thermostable. 
Secondly, archaeal enzymes on the whole tend to be more compact with fewer 
disordered loop regions. This often makes these proteins more amenable to 
crystallisation. And thirdly, these proteins tend to have a simpler quaternary structure 
as they are often found to be homooligomers, rather than heterooligomers. These last 
two points are presumably as a consequence trying to retain a comparatively small 
genome.
With this in mind, Matthew Newman (Structural Biology Laboratory, Cancer 
Research UK) cloned XPF homologues from two archaeal genomes; Archaeoglobus 
fulgidus and Aeropyrum pernix. Work by John Lally and Matthew Newman showed 
that the A.fulgidus XPF did not express well, but a pET14b-3C construct encoding 
residues 18-231 of Aeropyrum pernix XPF expressed well (figure 3.3 a). This 
construct is referred to as ApeXPFANAC. This hexahistidine-tagged protein construct 
was purified by affinity chromatography on nickel-NTA and was crystallised as 
described in Lally et al. (Lally et al., 2004), both in the presence and absence of a 
synthetic 15-mer duplex DNA. Diffraction data for these two crystal forms were 
collected but obtaining experimental phases by either extensive screening for heavy 
atom derivatives or biosynthetically labelling with selenomethionine proved 
problematic.
To circumvent this problem, Matthew Newman made a shorter XPF pET14b-3C 
construct, which corresponded to the ApeXPF nuclease domain only (residues 18- 
150, figure 3.3 b). Expression of this protein construct was again good, although 0.5 
% CHAPS was required in all buffers to maintain protein solubility. 
Selenomethionine derivatised protein was produced and crystallised. These triclinic 
crystals diffracted to 2.5 A, and a dataset was collected at ESRF ID29 (figure 3.4 and 
table 3.1).
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18-231
AlwNI
Figure 3.3
This dataset was processed and scaled, and the structure of this ApeXPF nuclease 
domain was solved by Judith Murray-Rust (Structural Biology Laboratory). This was 
achieved by molecular replacement using the structure of the Pyrococcus furiosus Hef 
nuclease domain that had been recently published at the time (Nishino et al., 
2003)PDB code 1J23). An anomalous difference Fourier map confirmed the 
molecular replacement solution by indicating the position of the selenium sites. 
Judith Murray-Rust used a partially refined (Rfact =35.2 %; Rfree = 41.5 %) ApeXPF 
nuclease model to solve the larger ApeXPF (18-231) structure and the ApeXPF-DNA 
complex as mentioned in (Newman et al., 2005). This structure has already been 
addressed briefly in Chapter 1.
Blpl C lal Hindlll 
I  I/  EcoRI
/ .A p o l
pET14b-3C
ApeXPF
18-150
AlwNI
Ncol ^  Ndel BamHI
CCATGGGCAGCAGC I T x  R B  TCTGAGGTGCTATTCCAGGGACCCGGATCTC ATAT(, g g t c j j f e t g c g t g t t ......................................... t C C a C ta g jM fl tj l lGGATCcI
3C pro tease site ApeXPF 18-150
-  Schematic diagram of ApeXPF expression plasmids used in chapter 3.
64
Chapter 3: Structural analysis of Aeropyrum pernix XPF domains and complexes with
DNA substrates.
Figure 3.4 -  Crystals and diffraction for ApeXPF nuclease domain. [A] Single ApeXPF 
nuclease crystal grown in 10 % PEG 400, 50 mM sodium acetate (pH 5). [B] Diffraction 
data image from ESRF BM14. Circles are at 2.1, 2.8, 4.2 and 8.4 A.
3.2 Building, refinement and validation of ApeXPF nuclease domain model.
The structure of the ApeXPF nuclease on its own remained unrefined. Since the data 
collected extended to a higher resolution than observed for the ApeXPF (18-231) 
DNA complex, it was thought that full refinement would yield interesting information 
on the active site and the water structure around the nuclease domain. Towards this 
end, the structure of the ApeXPF nuclease domain was re-solved by Judith Murray- 
Rust by molecular replacement. Molrep was implemented in CCP4 (Collaborative 
Computational Project, 1994) with a validated refined ApeXPF nuclease structure 
from the ApeXPFANAC-DNA complex. This yielded better electron density maps 
than the initial molecular replacement with the Hef nuclease domain.
Data collection site ESRF ID29
Space group PI
Celia, b, c (A) 33.65,38.68, 55.33
C elia , p, Y(°) 89.04, 102.90, 115.66
Number of protomers in a.u. 2
Resolution range (A) 34.731-2.10(2.21-2.10)
Wavelength (A) 0.979127
Total number o f reflections 50529
Unique Reflections 13094
<l/al> 8.6 (5.2)
Completeness (%) 91.4 (91.8)
Rsym 0.071 (0.105)
Table 3.1 -  Data processing statistics for ApeXPF nuclease domain crystals. Figures in
parentheses refer to the highest resolution shell. Information provided by Judith-Murray
Rust.
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Using the program Coot (Emsley and Cowtan, 2004)., I built the model of ApeXPF 
nuclease domain into the electron density. Refmac 5 ((Murshudov et al., 1997); 
Colloborative Computational Project, 1994) was used to refine the model. The 
structure was refined to 2.1 A and a representative view of the final electron density 
can be seen in figure 3.5.
The final structure of the ApeXPF nuclease domain contains the amino acids 18-148 
with the remaining two amino acids at the carboxy-termini of the polypeptides 
disordered and not visible in the electron density. The refinement of the structure was 
concluded when the Rfact and Rfree converged at 20.4 % and 25.9 % respectively. The 
final model has acceptable stereochemistry. Root mean square deviation (RMSD) 
values from target bond lengths and target bond angles are reasonable at 0.015 A and 
1.498 ° respectively (table 3.2). The two protomers present in the asymmetric unit are 
very similar: least squares superposition of the two molecules gave a RMSD of 0.288
During refinement if became clear that the side chains for several residues were 
disordered and thus there was insufficient electron density to be modelled into. 
Details of these residues are given in table 3.3.
Figure 3.5 -  Final weighted electron density map (2Fo-Fc) contoured at l a  with superposed 
ApeXPF nuclease domain model. Screenshot from Coot (Emsley and Cowtan, 2004).
A.
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Using the program PROCHECK (Laskowski et al., 1993), it is possible to generate 
Ramachandran plots to evaluate how the main chain dihedral angles <j> and cp compare 
to theoretically allowed limits. Figure 3.6 shows the Ramachandran plot. Excluding 
glycine and proline residues, 97.3 % of residues fall within the most favoured regions 
of the plot and 2.7 % in additionally allowed regions. There are no residues that fall 
within disallowed regions of the plot.
Model
Protein atoms in final model 2060
Solvent atoms 24
Protein atoms missing from the structure 138
Diffraction Agreement
Resolution limits (A) 34.731-2.100
Total reflections (test for R free) 12381 (649)
Rfact (% ) 20.5
Rfree (% ) 25.9
Stereochemistry
RMSD bond lengths (A) 0.015
RMSD bond angles (°) 1.498
Table 3.2 -  Statistics for final ApeXPF nuclease model from REFMAC 5.0.
Residue Chain A Chain B
Arg 20 Cy-C6-Ne-C^-Nri 1 and Nrj2 Cy-C6-Ne-C£-Nti1 and Nt]2
Arg 26 C6-Ne-C^-Nti1 and Nrj2 Cy-C6-Ne-C^-Nti1 and Nr]2
GlU 27 Cj3- Cy-CS-Oel and Oe2 -
Glu 28 Oel andOe2 C6-Oe 1 and Oe2
Arg 29 CP-Cy-Cb-Ne-C^-Nri 1 and Nr\2 -
Glu 37 CP-Cy-Cb-Oel andOs2 Cy-C5-Oe 1 and Oe2
Lys46 Ce-NC C6-Ce-N^
Gin 47 Cy-C5-Oe and N e Cy-C6-Oe and N e
Asp 57 061 and 062 062
Glu 62 Cy-C6-Oe1 andOE2
Lys 71 Cy-C6-Ce-N£ C5-Ce-N£
Arg 77 Cy-C6-Ne-C^-Nti 1 and Nt]2 C6-Ne-C^-Nti1 andNri2
Arg 84 Ne-C^-Nt)1 and Nri2 C6-Ne-CC-Nti1 andNri2
Glu 87 Cy-C6-Oe1 and Oe2 Cy-C6-Oe1 and Oe2
Glu 90 CP-Cy-C5-Oe1 and Oe2
Arg 103 - Cy-C6-Ne-C^-Nti 1 and Nr]2
Arg 104 Cy-C6-Ne-C^-Nti1 and Nri2 Cy-C6-Ne-C^-Nti 1 and Nr]2
Arg 106 Cy-C6-Ne-C^-Nti1 and Nrj2 -
L y s134 Ce-N£ Cy-C6-Ce-N^
Table 33  -  Table listing omitted and truncated amino acids.
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Figure 3.6 -  Ramachandran plot for the ApeXPF nuclease domain model. The plot was 
calculated using the program PROCHECK (Laskowski et al., 1993) using the final refined 
co-ordinates o f the ApeXPF nuclease structure. Glycine residues are represented as black 
triangles.
3.3 Discussion of the structure of ApeXPF nuclease domain.
The structure of the ApeXPF nuclease domain consists of an a /p  fold with a six- 
stranded p-sheet flanked on both sides by a-helices. Five of the six P-strands run 
parallel to one another. A topology diagram is shown in figure 3.7.
The structure of the ApeXPF nuclease domain is closely related to the Pyrococcus 
furiosus Fief nuclease domain. Like Fief, the nuclease domain of ApeXPF adopts the 
type II restriction endonuclease fold found in the majority of restriction enzymes, as 
well as Hjc, an archaeal Holliday junction resolvase from Pyrococcus furiosus 
(Nishino et al., 2003).
.. r
V i-
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Figure 3.7 -  Fold and topology diagram o f an ApeXPFANAC protomer. Alpha helices are 
shown in red, beta strands in yellow, loops in green. The |3-sheet is flanked in both sides by 
a-helices.
The active site of ApeXPF nuclease domain lies in a cleft bounded by a-helices a  1 ’ 
(a l  from the other protomer), a2  and a3  and the loop linking strands |32 and p3. This 
cleft is lined with many residues conserved in XPF homologues, including those 
involved in metal binding and catalysis (figure 3.8). Residues within this cleft include 
those from the GDXnERKX3 D motif discussed in Chapter 1. The first aspartic acid 
residue in this motif, Asp52, lies on a loop connecting p2 and P3. Glu62, Arg63, and 
Lys64 all lie on strand P4. Asp68 is not directly around the Mg2+ ion identified but 
is involved in co-ordination of a water molecule. Gln81 reaches into the active site 
from a-helix a4. The active site is shown in figure 3.9.
Although the active site contains only one Mg2+ ion, this does not necessarily mean 
that catalysis is achieved with a one metal ion mechanism. It is often the case that an 
enzyme’s full complement of divalent ions is only observed when substrate is bound. 
The majority of DNA processing enzymes use two metal ion mechanisms, but it is 
possible in this case that the presence of Arg63 in the active site stabilises an activated 
nucleophilic water, thus negating the need for a second metal ion. Future studies with 
substrate-bound would aid analysis of the catalytic mechanism.
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G lu62
Figure 3.8 -  The active site of ApeXPF. Side chains are coloured by element; green- 
carbon, blue-nitrogen, red-oxygen. Mg2+ is shown as magenta sphere. Residues Glu62, Arg 
63 and Lys64 are part of the signature E-R-K motif o f XPF homologues.
The crystal structure, as expected, shows that the nuclease domain of ApeXPF forms 
a homodimer. The dimer interface of the nuclease domain of the ApeXPF nuclease 
domain is again similar to that of the Fief nuclease domain. The dimer interface 
consists mainly of C-terminal residues contributed by two a-helices (a6  and a l)  and 
a (3-sheet (|36). Many residues involved in the dimer interfaces are hydrophobic in 
nature (Y113, A117, L121, M128, M131, L138, L146) but there are residues involved 
in polar interactions as well (Q120, R126, N129, D132, K134, E141, S142, R145). 
Figure 3.9 (a and b) shows the extent of the ApeXPF nuclease dimer interface.
There is however, a notable difference between the dimer interfaces of ApeXPF and 
Hef. The difference is at the position occupied by R126 in ApeXPF. Sequence 
alignments of ApeXPF and other XPF homologues (figure 3.9 c) show that Hef does 
not have a conserved arginine at this site but has a proline residue instead. The 
arginine is notable as sequence alignments predict this residue to be equivalent to 
R788 in human XPF. A patient with a mild case of XP with late onset carcinomas 
and neurological disease was shown to be homozygous for a point mutation that 
changed R788 to tryptophan (Sijbers et al., 1998). The substitution of arginine for a 
bulky tryptophan residue in the XPF-ERCC1 dimer interface may explain the 
phenotype of this patient.
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Figure 3.9 - The ApeXPF (18-150) nuclease dimer interface. [A] Surface and cartoon 
representation of the ApeXPF nuclease domain dimer. Residues contributing to the dimer 
interface are coloured magenta. [B] The dimer interface. Protomers have been rotated 
through 90 °. Again residues contributing to the dimer interface are coloured magenta. 
These residues are found in a “S”-shape made by a6-(36-a7. Residue R126 in each protomer 
is circled [C] Alignment of XPF homologues in the region o f the ApeXPF dimer interface. 
Note that ApeXPF and the eukaryotic XPF homologues share the same conserved arginine 
residue discussed in the text.
This observation has a bearing on current opinion as to how XPF/Mus81 
endonucleases engage their substrates. Tom Ellenberger’s group at Harvard 
University have proposed a model for human XPF action where the nuclease and
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nuclease-like domains of hXPF and hERCCl do not dimerise (figure 3.10), but 
instead cleave and bind opposing single-strands of a bubble substrate (Tsodikov et al., 
2005). The (HhH) 2  domains bind opposing single-strands of the substrate, contrary to 
the structure of ApeXPF with DNA-bound which shows an (HhH)2 domain binding 
duplex DNA. The model is supported by DNA-binding studies which show that 
ERCCl’s nuclease-like domain binds DNA of the suggested 3’ to 5’ polarity and 
putative single-stranded binding surfaces on the hXPF and hERCCl (HhH)2 domains 
have also been identified.
Flowever, as figure 3.9C shows, the conservation at the region predicted to be the 
XPF nuclease dimer interface is good, with key residues such as R788 present. Thus 
XPF might indeed be predicted to form a dimer with ERCC1 through its nuclease 
domain, as well as through its (HhH)2 domain. It is difficult to explain the phenotype 
of the R788W mutation discussed above, if this residue is neither involved in catalysis 
nor in a dimer interface. However, although the equivalent region of ERCC1 is well 
conserved as well, R788 is replaced by a threonine residue. It is clear that the 
presence of this arginine is not absolutely essential, as the Hef nuclease domains 
homodimerise in its absence. More information on the nature of the ERCC1-XPF 
dimer is required to completely resolve the question of nuclease/nuclease-like domain 
dimerisation.
Figure 3.10 -  A model suggested for the action of human XPF/ERCC1. (adapted from 
Tsodikov et al., 2005).
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3.4 Investigating the mechanism of ApeXPF action: Model 1
The structure of ApeXPF complexed with 15-mer duplex DNA (Newman et al., 
2005), gave some insights into DNA binding and substrate recognition by ApeXPF. 
The binding of DNA via a minor groove engaged both HhH motifs, each contacting a 
phosphodiester backbone on a different strand. This suggested how the enzyme may 
position a substrate the correct distance away from its double-strand/single-strand 
junction. However, the structure did not contain DNA in the active site and models 
about how DNA extended into the active site were proposed for validation.
The simplest model involved a single-stranded overhang threading its way into the 
active site, as depicted in figure 3.11. In this scheme, the duplex DNA observed in 
the crystal structure would act as the upstream duplex of a substrate. At a double- 
strand/single-strand junction, the single-strand would thread its way into the active 
site. Any downstream DNA would presumably pass around the enzyme. This model 
will be referred to as “Model 1”. There are some obvious caveats to this model. 
Firstly, one of the (HhH)2 domain is not used in substrate recognition for no obvious 
reason. Indeed footprinting experiments on Hef, have showed that both (HhH)2 
domains are thought to bind duplex DNA (Nishino et al., 2005). Also, the model does 
not fit with with kinetic data from Malcolm White’s group in St. Andrews. They 
showed that the preferred substrates for another crenarchael XPF from Sulfolobus 
solfataricus, SsoXPF, were nicked duplexes and 3’-flaps (Roberts and White, 2005). 
3’-overhangs are not considered to be good substrates for crenarchaeal XPF 
homologues. However, it remained the simplest model that fitted with the structure of 
ApeXPF with DNA-bound.
In order to produce a structure to potentially validate this model, various synthetic 
DNA substrates with 3’-overhangs were obtained. Since the ApeXPF: 15-mer DNA 
structure identified only 8 base pairs of the duplex DNA were necessary for 
interaction with the (HhH)2 domain, shorter stems of 8 base pairs and 10 base pairs 
were used. The DNAs for co-crystallisation were composed of single oligonucletide 
strands with hairpins between the complementary regions. The overhangs consisted 
of 2,4, 6 and 8 thymine bases (figure 3.13).
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INACTIVE
ACTIVE
Figure 3.11 -  Model 1. The structure o f ApeXPFANAC complexed with 15-mer DNA is 
shown. The active protomer is coloured red, the inactive protomer, green. The possible path 
o f a single stranded 3’-overhang to the active site is shown as a dashed line. The magenta 
sphere is the Mg2+ in the active site. Adapted from PDB file 2BGW.
3.5 Expression of ApeXPFANAC protein
The pET14b-3C ApeXPFANAC (18-231) construct created by Matthew Newman was 
transformed into rosetta pLysS cells. The protocol used is described in Lally et al. 
(Lally et al., 2004). Bacteria were grown, induced and harvested according to the 
methods outlined in Appendix A. Protein was extracted in a Tris buffer containing 
500 mM NaCl. The high salt concentration was necessary for the extraction of a high 
yield of soluble protein. A dependence on high salt buffers is not uncommon 
amongst DNA-binding proteins (Yang; 2004) and there are examples of proteins such 
as MarA (Jair et al., 1995) that require 1 M NaCl for solubility in the absence of 
DNA. The ApeXPFANAC protein was purified by affinity chromatography on Ni2+- 
NTA and eluted from the resin using imidazole. After overnight dialysis to remove
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the imidazole, 3C protease was used to remove the His6-tag (figure 3.12; previous 
attempts by John Lally to elute the protein from the Ni2+-NTA with 3C protease were 
unsuccessful). The protein was then dialysed again against a low salt buffer (50 mM 
NaCl). This served to eliminate the small peptide with the His6-tag but also to 
prepare the protein for binding to DNA. High concentration of C f ions may have 
otherwise competed against the DNA for access to basic DNA binding residues on 
ApeXPF. The dialysis however resulted in a substantial loss of protein due to 
precipitation (approximately 75 % loss). The remaining 25 % remained soluble and 
was concentrated to 10 mg/ml. This loss, whilst disappointing, had been tolerated in 
the earlier crystal trials and had not prohibited the growth of proteimDNA complex 
crystals.
kDa
97
66 ~  
45 i f
20 -  
14
Figure 3.12 -  ApeXPFANAC protein expression and purification. Purification followed 
published methods (Lally et al., 2004). The figure shows the removal o f the His6-tag by 3C 
protease.
3.6 Co-crystallisation of ApeXPFANAC protein with model 1 substrates
Crystallisation trials were set-up using ApeXPFANAC protein and the new 3’- 
overhang substrates with a protein to DNA ratio of 1:1.2. Vapour diffusion and 
microbatch drops were set-up using commercial sparse matrix and grid screens.
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Figure 3.13 -  Synthetic DNA oligonucleotides with overhangs and crystals produced when
co-crystallised with ApeXPFANAC. [A] 8-2T. [B] 8-4T. [C] 8-6T. Only the crystals with the
8-6T DNA were reproducible.
Crystals were obtained for three of the four substrates. Small crystals were obtained 
in hanging drops with the 8-2T and 8-4T substrates. The precipitant in both these 
cases was 200 mM magnesium chloride, 0.1 M Tris (pH 8.5) and 20 % PEG 8000. 
As figure 3.13 shows these were not single crystals but rather plates grown on top of 
one another. These crystals proved to be difficult to reproduce.
76
Chapter 3: Structural analysis of Aeropyrum pemix XPF domains and complexes with
DNA substrates.
Thin plate crystals originating from the 8-6T trials were grown using the microbatch 
method with a precipitant of 10 % PEG 3350, 100 mM potassium chloride (figure 
3.13 c). These plates took approximately 7 days to grow. It was possible to 
reproduce these crystals.
The crystals were harvested and flash-frozen in 12 % PEG 3350, 100 mM potassium 
chloride with 20 % ethylene glycol as a cryoprotectant. A dataset was collected to
2.2 A at the ESRF ID14-1. A summary of the data collected is displayed in table 3.4. 
The cell constants given in table 3.4 gave a cell volume of 62989 A3. Using the 
monomeric molecular weight of ApeXPFANAC as 25631 Da, a Matthews’ coefficient 
calculation was performed (Matthews, 1968). This indicated that for one 
ApeXPFANAC subunit in the asymmetric unit, the Matthews’ coefficient would be 
2.45 translating into a solvent content of 49.9 %. No other number of ApeANAC 
subunits could give a sensible Matthews’ coefficient and thus a permissible solvent 
content within the crystal. Since the crystals were triclinic, this meant that two 
protomers in a dimer could not be related by a crystallographic two-fold axis, as is 
sometimes the case. This suggested that the ApeXPFANAC dimer had not been 
crystallised; there was simply insufficient room within the unit cell to house such a 
dimer, let alone with DNA bound.
Data collection site ESRF ID 14 EH1
Space group PI
Celia, b, c(A) 33.643,38.683,55.321
Cell ct, p, y (°) 89.073, 102.900, 115.685
Resolution range (A) 34 - 2.2
Wavelength (A) 0.9791
Total number o f reflections 41 926
Unique Reflections 11 581
<I/aI> 4.5 (1.5*)
Completeness (%) 96.4 (97.1 *)
Rsym 0.103 (0.283*)
Mosaic spread (°) 0.7
Table 3.4 -  Data processing statistics for crystals o f ApeXPFANAC co-crystallised with 8-
6T DNA. Figures in parentheses refer to the highest resolution shell.
At this point, a similarity between the cell parameters of this dataset and the ApeXPF 
nuclease domain dataset discussed in section 3.2 became obvious. The equivalent cell 
constants and space group suggested that perhaps these crystals were in fact ApeXPF
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nuclease domain crystals again. After integration, scaling and conversion to structure 
factors using Mosflm, Scala and Truncate respectively (Collaborative Computational 
Project, 1994; Leslie, 1992), molecular replacement using Molrep was attempted 
using the refined structure of the ApeXPF nuclease domain. The molecular 
replacement was successful and the electron density housed the ApeXPF nuclease 
domain. No extra density for DNA was evident.
Figure 3.14 -  ApeXPFANAC co-crystallised with 8-6T DNA. [A] Diffraction from ESRF 
ID 14-1. Circles are at 2.1, 2.8, 4.1 and 8.3 A. [B] Initial electron density showing that the 
molecular replacement solution using the refined ApeXPF nuclease domain appears to be 
correct.
Excess crystals were harvested, washed, dissolved in SDS-PAGE sample buffer and 
ran on a SDS-PAGE gel. From the gel it was clear that proteolysis had occurred in 
the drop, meaning the prevalent protein species was the ApeXPF nuclease domain. 
The exact cause of the proteolysis remains unclear. Slightly puzzling is that fact that 
the preparation of ApeXPFANAC for the solved complex (with 15-mer DNA) was 
essentially identical, yet the protein within those crystals was not degraded. One 
obvious difference is in the crystallisation method. For the ApeXPFANAC: 15-mer 
DNA complex, sitting-drop vapour diffusion was used. Also the precipitant 
conditions are very different. The condition found previously used was 100 mM 
sodium acetate (pH 4.6), 200 mM (NH4)2S04, 20 % PEG MME 2000. The low pH in 
this drop may have prohibited proteolysis in these drops. The neutral pH provided by 
20 % PEG 3350, 0.1 M KC1, is likely to fall within the optimal range of a great 
number of proteases.
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3.7 Investigating the mechanism of ApeXPF action: Model 2
The absence of DNA in these crystals was a setback. However, further refinement of 
the ApeXPFANAC structure by Judith Murray-Rust suggested a new approach should 
be taken. The refinement identified sulphate ions near the DNA-free (HhH)2 domain 
at positions equivalent to the phosphate backbone contacts with the DNA-binding 
(HhH)2 domain (figure 3.15 a). It is possible that these sulphate ions mimic the 
phosphodiester backbone of DNA. Rotation of the observed 15-mer DNA about the 
two-fold axis relating the (HhH)2 domains of both protomers generates a second 15- 
mer DNA with its a 3’ end close to the active site of the enzyme (figure 3.15 b). This 
has led to a second model of how ApeXPF interacts with its substrates, which will be 
referred to as “Model 2”.
Model 2 is attractive as it positions the end of the DNA closer to the active site of the 
enzyme and utilises both (HhH)2 domains. An obvious caveat is that the second 
(HhH)2 domain does not bind DNA in the crystal structure. This can be explained by 
analysis of crystal packing in which it is evident that a second 15-mer DNA would 
have clashed with a crystallographic axis, sterically inhibiting crystal growth. This 
model was also in good agreement with kinetic data from Malcolm White’s group in 
St. Andrews. They showed that the preferred substrates for SsoXPF, were nicked 
duplexes and 3’-flaps both of which contained upstream and downstream duplexes 
(Roberts and White, 2005). Model 2 accounts for binding of both upstream and 
downstream duplexes in a way Model 1 did not. Model 2 is also in agreement with a 
model later proposed by Kosuke Morikawa’s group in Osaka. They also proposed a 
model for P.furiosus Hef action in which both (HhH)2 domains bind duplex DNA 
(backed up by foot-printing data) and although the nuclease domains independently 
dimerise, only one nuclease domain is active (fig 3.14 c). Attempts to crystallise 
ApeXPFANAC with synthetic DNA substrates mimicking 3’-flaps according to 
Model 2 were therefore undertaken.
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Figure 3.15 -  Model 2. [A] Further refinement of the ApeXPFANAC-DNA structure
showed sulphate ions at key positions near the (HhH)2 domain and near the active site. It is 
likely that these sulphate ions mimic a phosphodiester DNA backbone. [B] Model 2. Again 
the active subunit is coloured red, the inactive subunit, green. An upstream duplex is 
generated by rotating the observed duplex 90 ° around the two-fold axis relating the (HhH)2 
domains. Possible path for a continuous strand and the cleaved strand are shown as dashed 
lines. Adapted from PDB file 2BGW. [C] Model for P.furiosus Hef action. Although a 
stalled replication fork is modelled, the basic features are similar. Adapted from Nishino et 
al. 2005b).
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As discussed previously, it is not unusual for DNA-binding proteins to precipitate in 
low salt buffers in the absence of cognate DNA. We took advantage of this property 
to purify the protein by first selective precipitation and then resolublising the 
precipitated protein in a high salt buffer. Most contaminants tend to remain soluble in 
the first step. In this case, ApeXPFANAC was expressed, purified, eluted and de­
tagged as before. The protein was dialysed into a low-salt buffer. The precipitated 
protein was spun down and the pellet retained. These pellets were resolublised in 20 
mM Tris (8), 300 mM NaCl, 1 mM DTT and concentrated to 10 mg ml*1. Dynamic 
light scattering (data not shown) showed the resolublised protein to be monodisperse 
with an apparent molecular mass consistent with a dimeric species (~ 52 kDa).
Different DNA substrates were trialled in crystal screens with ApeXPFANAC at a 
protein to DNA molar ratio of 1:1.2. Trials were set-up using commercial sparse 
matrix and grid screens and both vapour diffusion and microbatch methods. After 
three weeks crystals were found in two drops (figure 3.16). The DNA substrate was a 
3’-flap substrate (figure 3.16) and the conditions were (a) lOOmM MES (pH 6), 
lOOmM NaCl, lOOmM MgCl2 and (b) lOOmM Tris (pH 8), 10% PEG 8000, lOOmM 
MgCl2, 2mM spermidine, 5% glycerol. These crystals were too small for diffraction 
studies. Attempts to reproduce these crystals were only partially successful and 
optimisation proved impossible. No diffraction data was collected.
3.7 Promoting a DNA binding conformation of ApeXPF.
A reason why it has been so difficult to crystallise ApeXPFANAC with synthetic 
substrates could be that a significant conformational change occurs on DNA binding, 
both in the DNA and indeed the protein. This could be why crystals of 
ApeXPFANAC with DNA-bound took over 3 months to grow. Comparisons of the 
apo-ApeXPFANAC structure with the structure of ApeXPFANAC once 15-mer DNA 
was bound showed a large movement (~ 30 A) of the (HhH)2 domains towards the 
nuclease domains on DNA-binding (figure 3.17). Given ApeXPF is optimised for 
working at high temperatures (-95 °C), this conformational change might be easier to 
promote at such temperatures than at room temperature. The role of the sliding clamp 
PCNA in promoting the activation of ApeXPF could promote a conformation 
competent to engage the substrate fully. Malcolm White’s group have suggested that
81
Chapter 3: Structural analysis of Aeropyrum pernix XPF domains and complexes with
DNA substrates.
PCNA affects the kinetic constant kcat rather than Km when stimulating XPF activity 
(Malcolm White, unpublished result). This is consistent with an activation event as 
opposed to enhancement of ApeXPF’s affinity for its substrate. This idea is explored 
further in Chapter 4. However, at this point a way of tethering the nuclease domain 
and (HhH) 2  domain together in a DNA-binding conformation was considered.
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Figure 3.16 -  Synthetic DNA oligonucleotide with upstream and downstream duplex and 
crystals produced when co-crystallised with ApeXPFANAC. [A] The oligonucleotide that 
yielded crystals. Initial crystallisation hits. [B] Precipitant was lOOmM MES (pH 6), 
lOOmM NaCl, lOOmM MgCl2 . [C] Precipitant was lOOmM Tris (pH 8), 10% PEG 8000, 
lOOmM MgCl2, 2 mM spermidine, 5% glycerol.
In the apo structure of ApeXPFANAC, amino acid residues lysine 46 (in the nuclease 
domain) and aspartic acid 165 (in the (HhH) 2  domain) of the “active” protomer are far 
apart (~ 33 A). In the DNA bound form of ApeXPFANAC, lysine 46 and aspartic acid 
165 are close together and form a salt bridge (figure 3.18). Assuming that the 
interdomain contacts seen in the ApeXPFANAC-DNA structure are complete, it was 
hoped that if this salt bridge could turned into a permanent covalent bond such as a 
disulphide bridge, then the ((HhH)2 domain) could be tethered to the nuclease domain 
to mimic an activated conformation.
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a p o  sup erp o sed  DNA-bound
Figure 3.17 -  The conformational change in ApeXPF upon binding DNA. Apo-protomers 
are coloured magenta and yellow. DNA-bound protomers are coloured dark-blue/dark- 
green and light-blue/light-green. [A] apo-ApeXPFANAC. The linker connecting the 
“active” nuclease domain and its (HhH)2 domain is extended. [B] Superposed structures of 
apo and DNA-bound ApeXPFANAC. Note the large (~ 30 A) conformational change of the 
(HhH)2 domains relative to the nuclease domains. The linker connecting the “active” 
nuclease domain and its (HhH)2 domain is now more compact. [C] Structure of DNA-bound 
ApeXPFANAC. Adapted from 2BHN and 2BGW.
Figure 3.18 -  Salt bridge across the nuclease -  (HhH)2 interface in the ApeXPFANAC -  
DNA complex. [A] Nuclease domains are shown in blue and cyan, the (HhH)2 domains in 
dark green and green, DNA in is grey. Residues K46 and D165 are shown in magenta. [B] 
Close-up of residues K46 and D165. Adapted from PDB file 2BGW.
Aspl65
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To test this hypothesis, a double mutant of ApeXPFANAC was generated using the 
Stratagene QuikChange protocol. Lysine 46 and aspartic acid 165 were both mutated 
to cysteine residues. Mutant protein was expressed in Rosetta pLysS cells and 
extracted as for wild-type protein. However, SDS-PAGE analysis after elution with 
imidazole showed that 50 % of the mutant protein had been degraded (figure 3.19). 
The reason for this degradation was not clear. The His6-tag was removed from the 
mutant protein using 3C protease and was concentrated and loaded onto a pre­
equilibrated Superdex 75 column. The protein eluted as a single peak indicating that 
degraded protein was complexed with full-length protein. This made this approach 
unsuitable for further investigation. This approach should have worked, although the 
effects of protein engineering experiments are notoriously difficult to predict.
Mutant ApeXPF 
doublet
Figure 3.19 -  Expression of ApeXPFANAC K46C D165C mutant protein.
3.8 Summary
Solving the structure of ApeXPFANAC with DNA bound provided the first insight 
into how this family of enzymes engage DNA. The solution of this structure was not 
easy and required a combination of phases from heavy atom derivatives and 
molecular replacement using data from ApeXPF nuclease domain solution. Using the 
data for the ApeXPF nuclease domain was a useful “training exercise” in building and
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refinement. It also had the additional benefits of being at higher resolution. The final 
model has acceptable R-factors and geometry.
The overall structure of the ApeXPF nuclease is closely related to that of the 
Pyrococcus furiosus Hef nuclease domain. The overall fold and the dimer interface 
are all closely related. The residues of the GDXnERKX3D motif common to all 
XPF/Mus81 homologues are mostly found in the active site. However, there is a key 
difference at the dimer interface. Residue R126 is not conserved in Hef but it is 
present in eukaryotic XPF orthologues. The equivalent residue in human XPF, R788 
was mutated to tryptophan in a patient with late-onset XP. This suggests that this 
patient’s phenotype was caused by distortions in the dimer interface between XPF and 
ERCCl’s nuclease and nuclease-like domains. However, ERCC1 does not have this 
conserved arginine residue and such an ERCC1-XPF nuclease-nuclease-like domain 
dimer is contrary to the model of Ellenberger’s group at Harvard. More information 
is needed to elucidate the precise role of R788 in XPF’s biology.
The structure of ApeXPFANAC with and without 15-mer DNA bound provided 
information as to the conformational changes that occur when the enzyme binds 
DNA. The actual binding of DNA occurs mostly through one (HhH)2 domain across 
a minor groove. Models for how ApeXPF might engage substrates with double- 
strand/single-strand junctions were formulated. The first of these, model 1, proposed 
that a simple 3’-overhang would extend from the observed 15-mer duplex into the 
nuclease domain to the active site. Attempts to co-crystallise ApeXPFANAC with 
synthetic DNA oligonucleotides with appropriate overhangs were undertaken. 
Crystals grown using the microbatch method with PEG 3350 as a precipitant were 
promising. However, the processing of diffraction data collected at the ESRF showed 
that these crystals were of the ApeXPF nuclease domain with no DNA bound.
A second, more probable model, model 2, was proposed. Sulphate ions near the 
second (free) (HhH)2 domain were thought to mimic a phosphodiester backbone. The 
modelling of an equivalent 15-mer duplex to the second (HhH)2 domain provided a 
means by which XPF engages both upstream and downstream duplexes, generating a
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~ 90 ° kink in the DNA substrate. This is consistent with the preferred substrates of 
SsoXPF (another crenarchaeal XPF), namely 3’-flaps and nicked duplexes.
Attempts to crystallise ApeXPFANAC with more sophisticated DNA substrates 
designed with model 2 in mind have been largely unsuccessful. Despite two 
promising leads it has not been possible to produce crystals suitable for diffraction 
studies. An attempt to tether ApeXPFANAC in a DNA-binding conformation by 
introducing a disulphide bond between nuclease and (HhH)2 domain residues has 
been blighted by proteolysis. Experiments investigating the effect of ApePCNA on 
stimulating ApeXPF are detailed in Chapter 4.
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4 Preparation and characterisation of Aeropyrum pem ix  
XPF-PCNA complexes.
This chapter describes experiments relating to the preparation and characterisation of 
Aeropyrum pemix XPF-PCNA complexes. A flowchart describing these experiments 
can be found below (Figure 4.1).
ApePCNA 
with ApeXPF PIM 
p ep tide
D esign an d  creation 
o f ApeXPF expression
Design m eth o d  for 
co-expression o f  ApePCNA 
com plex
Expression an d  purification 
o f ApePCNA com plex
Expression an d  purification 
o f ApeXPF p ro tein
Crystallisation trials
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o f ApeXPB expression
Expression a n d  purification 
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Figure 4.1 -  Flowchart o f the experiments described in chapter 4.
4.1 General considerations
The models of archaeal XPF action proposed by Newman et al. 2005 and Nishino et 
al. 2005 discussed in chapter 3 are different to that proposed by Tsodikov et al., 2005. 
for eukaryotic XPF action. One of the limitations of such models is that the structural 
evidence that they are based on is only a snapshot of a small part of a more complex 
machine. The effects of the other parts of this machine cannot be “second-guessed”.
With respect to crenarchael XPFs such as the XPF homologues from Aeropyrum 
pemix and Sulfolobus solfataricus, it has been shown that the presence of PCNA is 
essential for efficient XPF activity (Roberts et al., 2003). The presence of XPB and 
XPD homologues in these genomes (Kelman and White, 2005), suggests that a
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unified model of NER/replication fork repair in crenarchaea would need to 
incorporate the roles of all these proteins.
It has been noted from the kinetics of SsoXPF that the heterotrimeric SsoPCNA is not 
just responsible for guiding the XPF to the appropriate site in damaged DNA but 
actually appears to activate the SsoXPF. This manifests itself as a change in the 
kinetic constant kcat, rather than Km (Malcolm White, unpublished observation). The 
structural basis of such an activation event is of some interest and was the question we 
sought to address by these studies.
The proliferating cell nuclear antigen (PCNA) is a ring-shaped sliding clamp protein. 
Such sliding clamps are found in all organisms (Bruck and O'Donnell, 2001). In 
bacteria, they are referred to as P-clamps, which is in reference to their role as the 13- 
subunit of DNA polymerase III. Both PCNA and (3-clamp form a ring structure 
around DNA, composed of six domains. In PCNA the ring is compose of three two- 
domain subunits. In bacterial P-clamps the ring is composed of two three-domain 
subunits. Structures of bacterial p-clamps, eukaryotic and euryarchaeal PCNAs are 
very similar (figure 4.2).
The three PCNA homologues in Aeropyrum pemix had previously been identified and 
characterised by their interaction with DNA polymerases (Daimon et al., 2002). This 
study considered that the three subunits might each form homotrimeric processivity 
factors for the DNA polymerases in Aeropyrum pem ix  cells under different 
conditions. The study by Malcolm White’s group in 2003 (Roberts et al., 2003) 
reporting that the XPF from Sulfolobus solfataricus is dependent on a heterotrimeric 
PCNA means it is likely that when considering NER, the three PCNA homologues 
present in Aeropyrum pemix could also associate into a heterotrimer. In the study of 
Roberts et al., it was found that SsoXPF interacts with two SsoPCNA subunits but not 
the third. It seems reasonable to assume that this would be case for an equivalent 
Aeropyrum pemix complex. However, phylogenetic comparisons of SsoPCNA and 
ApePCNA subunits do not readily identify which PCNA subunits are functional 
orthologues. Instead they show that PCNA subunits from within each genome are 
closely related to one another.
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Proteins that bind PCNA are usually involved in various aspects of DNA replication 
and processing, using PCNA’s sliding-clamp properties. It has become clear that a 
great many PCNA binding proteins contain a conserved PCNA-binding motif (PIM) 
(Warbrick, 2000). The interactions of some of the proteins listed in Table 4.1 have 
been extensively studied and the interaction of PIM and PCNA examined by 
structural methods. These studies have led to the establishment of consensus PIM 
sequences. Perhaps the most essential feature of a PIM is the presence of two 
aromatic amino acid residues adjacent in the polypeptide to one another.
Figure 4.2 -  Structures of sliding clamps. [A] E.coli P-clamp (PDB code 2POL (Kong et al., 
1992)). [B] Pyrococcus furiosus PCNA (PDB code 1GE8 (Matsumiya et al., 2001)). [C] 
Human PCNA (PDB code 1AXC (Gulbis et al., 1996)).
Protein Function PCNA-binding consensus
P-l CDK regulatory protein RQ--MTDFY----- RR------
FEN-1 Structure-specific endonuclease -QGR1D-FF----- S ------
Cdc27 DNA polymerase i> subunit -Q — I-S F F -K
DNA 1 igasc 1 Replication specific DNA ligase - Q - - I - - F F ----- K— K
RFC p!40 Large subunit o f  PCNA-loading complex - I —  FFG----------- K
MSH3 Mismatch repair protein -Q --L S R F F ----------------
MSH6 Mismatch repair protein -Q — L -S F F -K -----------
XPG Nucleotide excision repair endonuclease T Q -R I--F F ---------------
MCMT 5’ cytosine methyltransferase -Q -T I - -H F --------- KRK
UNG2 Nuclear form of UNG uracil DNA glycosylase -Q -T L --F F ----------------
WRN Helicase required for genomic stability DQWKL— DF—KL-------
POGO Type II transposascs -Q — L --F Y
ApeXPF Crenarchaeal NER endonuclease RHASLDDFY
SsoXPF Crenarehaeal NER endonuclease TTSLF-DFL
SsoXPB Crenarchaeal NER helicase MV-RL-RYF
Table 4.1 -  Examples of PCNA Interaction Motifs (PIM). Note the highlighted double 
aromatic motif. Adapted from (Warbrick, 2000).
4.2 Molecular cloning of ApePCNA subunits.
A system for overexpression of SsoPCNA was devised by Stephen Bell’s group at 
Cambridge (Dionne et al., 2003) and was adapted by Malcolm White’s group at St. 
Andrews to study SsoXPF activity. An agreement was made that Malcolm’s White’s 
group would continue to work on SsoXPF-PCNA complexes, whilst our group would
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continue to work on the homologues from Aeropyrum pemix. In order to attempt to 
elucidate the structural basis for XPF activation by PCNA in Aeropyrum pemix, 
several new plasmid constructs were designed and made. Firstly, open reading 
frames for the three ApePCNA subunits were amplified using appropriate PCR 
primers and genomic DNA from Aeropyrum pemix (a gift from Dale Wigley, 
Molecular Enzymology Laboratory, Cancer Research UK). The ApePCNA subunits 
were named ApePCNA 1, ApePCNA2 and ApePCNA3 according to the earlier 
A.pernix PCNA study (Daimon et al., 2002). Within the study of Daimon et al., two 
possible start codons for ApePCNA2 were identified. The authors chose the start that 
encoded the shorter protein and found that endogenous ApePCNA was ran slightly 
bigger on a SDS-PAGE gel than their recombinant protein. In hindsight the first start 
codon was probably the correct one and this is the one chosen for this study. The 
open reading frame for ApePCNA 1 was cloned into the plasmid vector pET30a using 
Ndel and Hind3 restriction sites. The open reading frame for ApePCNA2 was cloned 
into pET3a, using Ndel and BamHl restriction sites. The open reading frame for 
ApePCNA3 was cloned into the plasmid vector pET30a using Ndel and BamHl 
restriction sites (figure 4.3). All three constructs coded for untagged proteins.
4.3 Molecular cloning of new ApeXPF constructs
In addition to the ApePCNA constructs required, two new ApeXPF constructs were 
also required. The major interaction between ApeXPF and ApePCNA is thought to 
utilise a C-terminal PCNA interaction motif (PIM) on XPF. The main ApeXPF 
construct described in Chapter 3 encodes residues 18-231. This construct is truncated 
at both the amino and carboxy termini, and lacks the PIM. Thus two new constructs 
were designed and made. Open reading frames encoding full length ApeXPF (1-254) 
and just the (HhH)2 domain and the C-terminal PIM (164-254) were amplified using 
appropriate primers and Aeropyrum pemix genomic DNA. These open reading 
frames were cloned into pET14b-3C using Ndel and BamHl restriction sites (figure
4.4 (a) and (b)).
4.4 Expression and purification of ApePCNA
Expression trials of the three individual ApePCNA subunits were undertaken using 
the study of Daimon et al. (2002) as a guide. Trials were hindered by the inability to
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transform BL21(DE3) competent cells with plasmids coding for ApePCNA2. The 
inference was that leaky expression of ApePCNA2 in the cells was toxic, possibly due 
to interference in the host cells’ DNA dynamics. The use of minimal media to 
eliminate any p-galactosides in the media causing leaky expression did not 
circumvent the problem. Nor did the use of Rosetta pLysS, an E.coli BL21(DE3) 
strain which expresses T7 lysozyme, a known inhibitor of T7 RNA polymerase. A 
solution was found using BL21-AI cells, in which the expression of T7 RNA 
polymerase is under the control of the arabinose inducible araBAD promoter. Leaky 
expression is not an issue in these cells. Figure 4.5 shows schematically how the 
expression of T7 RNA polymerase is regulated in these cells. To enhance yields, a 
strain of BL21-AI containing a chloramphenicol resistant Codon Plus plasmid 
(extracted from BL21(DE3) Codon Plus cells (Stratagene)) was generated in order to 
supplement tRNAs for rare codons. This strain was named BL21-AI +.
For the sake of simplicity BL21-AI + cells were used for the expression of all three 
ApePCNAs. The transformed strains were grown as described in Appendix A. 
Expression of T7 polymerase within the cells was induced with L-arabinose and IPTG 
was also added to release the lac repressor protein from the lac operator sequence on 
the expression plasmid. Cells were induced at 37 °C for 5 hours before harvesting, 
and storage at -80 °C.
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Figure 4.3 -  Schematic diagram of individual ApePCNA expression plasmids. [A] pET30a 
ApePCNAI. [B] pET30a ApePCNA2 and pET3a ApePCNA2. [3] pET30a ApePCNA3.
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Figure 4.4 -  Schematic diagram of ApeXPF expression plasmids used in this chapter. [A] 
Full length ApeXPF (1-254). [B] ApeXPF HhH2 & PIM (164-254). [C] ApeXPF (18-254).
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Figure 4.5 -  Schemes of protein expression systems. [A] BL21(DE3) cells. [B] BL21-AI 
cells. In the absence of L-arabinose the AraC dimer contacts the O2 and It half sites of the 
araBAD operon, forming a loop. Upon induction, L-arabinose binds to AraC and cause the 
protein to release the 0 2 site and bind the I2 site. This releases the loop and allows 
transcription.
The extraction of these proteins followed the basic strategy described in Appendix A, 
with some additions. The cell pellets were resuspended in 50 mM Tris (pH 8), 100 
mM NaCl, 1 mM DTT. This suspension was sonicated, before centifugation to 
remove cell debris. The crude lysate that remained was incubated at 65 °C for 15 
mins in order to denature most E.coli proteins out of solution. The Aeropyrum pernix 
proteins being thermophilic remained in solution. This denatured lysate was 
centrifuged to remove the denatured proteins and the crude lysates were loaded onto a 
HiTrap heparin-sepharose column. Heparin is a polyanionic glycosaminoglycan and 
is often used in the purification of DNA-binding proteins. Proteins were eluted off 
the heparin column with NaCl and analysed by SDS-PAGE. All three ApePCNA 
subunits appeared to be expressed and those fractions containing proteins of an
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appropriate molecular mass (~30 kDa) were pooled, concentrated and loaded on a 
Superdex 200 gel filtration column. However, all three subunits did not elute from 
the gel filtration column as discrete monodisperse peaks (figure 4.6). An 
interpretation of this result was that the individual subunits together are not stable and 
aggregate. Therefore we hypothesised that all three subunits together are more likely 
to form the sliding clamp ring structure and purify as a monodisperse entity.
To achieve this a method of co-expression was devised. It was decided that a 
dicistronic vector containing two of the ApePCNA subunits would be constructed in a 
kanamycin resistant vector (pET30a) and then this plasmid would be co-transformed 
with an ampicillin resistant plasmid encoding the third ApePCNA subunit.
The method for dicistronic plasmid construction is shown in figure 4.7. The method 
exploits the fact that pET vectors have an unique Xbal site upstream of the ribosome 
binding site. Thus by cutting pET30a ApePCNAI with Xbal and Notl (also unique), 
the coding sequence for ApePCNAI complete with its own ribosome binding site was 
excised. The recipient vector pET30a ApePCNA3 was linearised by digestion with 
Nhel and Notl. Since Nhel (G|CTAGC) and Xbal (T jCTAGA) leave identical 
cohesive ends, the ApePCNAI (with its own ribosome-binding site) sequence can be 
ligated easily into linearised pET30a ApePCNA3. This results in a functional 
ApePCNA3-ApePCNAl dicistronic plasmid with each gene possessing its own 
ribosome binding site.
This newly transformed strain was grown up, induced, harvested and the proteins 
extracted as described for the individual ApePCNAs. Purification of the proteins on 
Hi Trap heparin-sepharose yielded three proteins of the expected molecular mass that 
co-eluted together. These fractions were pooled, concentrated and loaded onto a 
Superdex 200 column. In this case the three ApePCNA subunits were eluted off the 
column together as a monodisperse peak (figure 4.8). The bands on the gel were sent 
for identification by mass spectrometry and peptides for all three ApePCNAs were 
identified. Thus a clean monodisperse ApePCNA 123 sample had been achieved.
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Figure 4.6 -  Expression of ApePCNA subunits. Gel filtration profiles of ApePCNA 
subunits. [A] ApePCNAI. [B] ApePCNA2 [C] ApePCNA3. As all three profiles show, the 
individual ApePCNA subunits are not eluted as single monodisperse peaks.
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Figure 4.7 -  Construction o f ApePCNA3-ApePCNAI dicistronic vector. This strategy 
relies on the presence of a unique Xbal site before the ribosome binding site in pET vectors 
and the fact that Xbal and Nhel sites have identical cohesive overhangs after cleavage. 
Orange circles indicate ribosome-binding sites.
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Figure 4.8 -  Co-expression o f ApePCNA subunits. Mass spectrometry confirmed that all 
three subunits were present in the complex and indicated a heterotrimeric complex had been 
formed. The yield of the complex was ~ 750 pg for 6 litres o f bacterial cultures.
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4.5 ApePCNA-ApeXPF complexes: ApePCNA -  ApeXPF PIM.
The structure of ApePCNA is of modest interest in itself, as structures of other 
PCNAs, have all been homotrimeric, thus far (figure 4.2). The interaction of 
ApePCNA with ApeXPF and how ApePCNA modulates ApeXPF activity is however 
our primary interest. To achieve this, complexes of ApePCNA with various ApeXPF 
constructs were formed.
The minimum part of ApeXPF expected to interact with ApeXPF is the C-terminal 
tail region that contains a canonical PIM. In this case the predicted PIM is back-to- 
back phenylalanine and tyrosine residues. A peptide encompassing this region was 
synthesised by the Peptide Synthesis Laboratory, and a 1 mM stock of the peptide was 
made up in 20 mM Tris (pH 8), 100 mM NaCl, 1 mM DTT buffer. The peptide 
sequence was GGGRRHASLDDFYRGEGEAGSG (residues 233-254). ApePCNA 
was expressed and purified as described earlier and concentrated to 10 mg ml"1. A 
1:1.2 molar excess of ApeXPF PIM peptide was added and crystallisation trials were 
set up. No hits were produced.
4.6 ApePCNA-ApeXPF complexes: ApePCNA -  ApeXPF (HhH)2 & PIM.
The PIM has been shown to be crucial in the interaction of PCNAs with many binding 
partners (Warbrick; 2000). However, if the ApePCNA stimulates ApeXPF activity by 
mechanisms other than enhancement of substrate affinity, (as is suggested by the 
study of SsoXPF), it is likely that there are more extensive contacts between 
ApePCNA and ApeXPF. With this in mind the ApeXPF (HhH)2 & PIM construct 
(164-254) was expressed. pET14b-3C ApeXPF (164-254) was transformed in 
Rosetta pLysS cells and cultures were grown to the basic protocol described in 
Appendix A. The ApeXPF (HhH)2 & PIM protein was extracted in a similar method 
to the ApePCNA incorporating the 65 °C denaturation step. The ApeXPF (HhH)2 & 
PIM protein was purified by affinity chromatography on a nickel-NTA column, and 
after washing, eluted by cleavage with 3C protease.
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Figure 4.9 -  Purification of an ApePCNA-ApeXPF (HhH)2 & PIM complex. [A] Gel 
filtration trace o f ApePCNA- ApeXPF (HhH)2 & PIM complex. The major peak can be 
attributed to the 98 kDa complex. The minor peak is excess ApeXPF (HhH)2 & PIM. The 
SDS-PAGE gel of fractions from the gel filtration shows complex formation. [C] SDS- 
PAGE gel of ApePCNA- ApeXPF (HhH)2 & PIM complex purification using the His6-tag 
on ApeXPF (HhH)2 & PIM.
The eluted ApeXPF (HhFI) 2  & PIM protein was then gel filtered on a Superdex 75 
column. The peak fractions were retained for complex formation with ApePCNA. 
Monodisperse gel filtered ApePCNA was added to a peak fraction of ApeXPF (HhH) 2  
& PIM. The mixture was concentrated and loaded onto a Superdex 200 column. 
Although there was only a modest shift in the position of the ApePCNA peak, SDS- 
PAGE analysis indicated that complex formation had occurred, and that excess 
ApeXPF (HhH) 2  & PIM protein was eluted later (figure 4.9 (a)). The complex was 
concentrated to 10 mg m l'1 and a limited number of crystallisation trials were set up.
The limit as to the number of crystallisation trials set up was the amount of protein 
available. A yield of just 500 jxg at this stage is only enough for three 96 well 
screens, using the Mosquito robot which can dispense 200 nl drops. In a bid to 
increase yields, co-extraction and purification of ApePCNA and ApeXPF (HhH ) 2  &
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PIM was attempted. After bacterial growth, induction and harvesting, pellets 
containing ApePCNA and ApeXPF (HhH)2 & PIM were mixed and the proteins 
extracted together (pellets from 5 litres of ApePCNA culture were mixed with a pellet 
from 1 litre of ApeXPF (HhFTh & PIM culture). The first purification step in this 
case was affinity chromatography on nickel-NTA. It was hoped that ApePCNA 
would be “pulled- down” by the ApeXPF (HhHh & PIM protein, resulting in 
complex formation. Proteins were eluted from the nickel-NTA with recombinant 3C 
protease.
Figure 4.9 (b) shows an SDS-PAGE gel showing the purification of ApeXPF (HhH)2 
& PIM with ApePCNA. Although overloaded, the gel clearly shows proteins at -30 
kDa co-purifying with the 10 kDa ApeXPF (HhH)2 & PIM protein. This eluate was 
concentrated and loaded onto a Superdex 200 gel filtration column, where again a 
complex peak was followed by a peak of excess ApeXPF (HhH)2 & PIM. Crucially 
the yield of complex improved significantly. Crystallisation trials were set-up using 
the vapour diffusion method and the Mosquito robot. A variety of sparse matrix and 
grid screens were set up. Initially no crystal hits were produced but after nine weeks 
crystals were found in a condition from the Hampton Research Index Screen (2.4 M 
sodium malonate, pH 7). Crystals were found in trays set up at 20 °C and 6 °C (figure 
4.10 (a)). Sodium malonate is a cryoprotectant at concentrations greater than 3 M 
(Holyoak et al.; 2003) and thus the crystal was cryoprotected by raising the malonate 
concentration within the drop to 3 M. Only one crystal from the Mosquito drop was 
large enough for diffraction studies and was taken to the ESRF ID 23-2. The crystal 
diffracted well, to better than 2.5 A (figure 4.10 (b)). However, the diffraction pattern 
showed evidence of multiple lattices and a dataset was not collectable. However, 
these test shots remain a promising lead and have been pursued by John Lally 
(Structural Biology Laboratory).
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Figure 4.10 - ApePCNA -  ApeXPF HhH2 & PIM crystals and diffraction. Complex 
crystals grown in sodium malonate at [A] 6 °C and [B] 20 °C. [C] Diffraction from the 
crystal shown in [B]. The data extends to 2.5 A in the comers, although as the close-up 
shows there are multiple lattices. Circles are at 12, 6, 4 and 3 A. Approximate cell 
dimensions are 74, 74, 54 A.
4.7 ApePCNA-ApeXPF complexes: ApePCNA -  ApeXPF .
Ultimately the structure of ApePCNA and full length ApeXPF would provide the 
most information as to how ApeXPF activity is regulated by ApePCNA. As 
discussed in section 4.3, a new construct encoding the entire full length of ApeXPF 
(1-254) was made. Initial expression trials of full length ApeXPF used Rosetta pLysS 
cells and used buffers containing at least 300 mM NaCl (in line with experience 
gained from the work described in Chapter 3). However, after purification of full 
length XPF on nickel-NTA, very little ApeXPF was produced (figure 4.11 (a)). At 
this point the construct design was re-evaluated. The ApeXPF (18-231) construct 
described in Chapter 3 expresses well, but as discussed the carboxy-terminal 
truncation made it unsuitable for this purpose. However, there was no obvious reason
V
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why the full-length ApeXPF could not be truncated at the amino-terminus as before. 
Thus, using appropriate primers and the pET14b-3C ApeXPF (1-254) plasmid as a 
template, cDNA encoding ApeXPF residues 18-254 (ApeXPFAN) was amplified and 
subsequently cloned into pET14b-3C using Ndel and BamFIl restriction sites. In the 
process rare arginine codons present at residues 18, 20, 26 and 29 were changed to 
preferred E.coli arginine codons. An expression trial of this construct used Rosetta 
pLysS cells, a 25 °C overnight induction and buffers containing 300 mM NaCl. 
Figure 4.11 (b) shows a SDS-PAGE gel of the first purification step on nickel-NTA 
and clearly demonstrates the improved yield achieved by this construct. This 
construct represented a viable route to achieve a complex of ApePCNA and a 
“functional” ApeXPF.
Figure 4.11 -  Expression of ApeXPF constructs. [A] Full length ApeXPF (1-254). [B] 
ApeXPFAN (18-254). As the gels show the expression level o f ApeXPF AN is a dramatic 
improvement on full-length XPF.
The ApeXPFAN was then examined for its ability to form a complex with ApePCNA. 
Bacteria expressing ApePCNA and ApeXPFAN were grown, induced and harvested 
as detailed in Appendix A. Cell pellets were then resuspended and mixed in a ratio of 
6  litres of ApePCNA to 1 litre of ApeXPFAN. This suspension was then sonicated 
and heat-treated as before. This lysate was loaded onto a Hi Trap chelating sepharose 
column, which had been pre-charged with nickel ions. The column was eluted using 
an imidazole gradient and the AKTA FPLC. The gradient elution was selected for 
two reasons. Firstly, earlier experiments attempting elution with 3C protease were 
unsuccessful. Secondly, it was critical that the correct concentration of imidazole was
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used to elute the complex. Too little imidazole may not efficiently elute all the 
complex, but too little may have broken the complex. Figure 4.12 (a) shows the 
results of the imidazole elution. As the gel shows the ApePCNA and ApeXPFAN 
complex appears to have formed. Fractions appearing to contain the binary complex 
were pooled and concentrated before gel filtration on a Superdex 200 column. As 
figure 4.12 (b) shows, the complex elutes at an appropriate elution volume.
®
Figure 4.12 -  Purification of ApePCNA-ApeXPF AN. [A] SDS-PAGE profile o f complex 
purification on Ni2+-sepharose. The column was eluted with an imidazole gradient. [B] Gel 
filtration profile of the complex. All three components co-purify together and the elution 
volume is consistent with a 140 kDa complex. (The X-axis indicates the volume in ml and 
the Y-axis the absorbance in mAU).
Although the structure of this complex would be of great interest, this was beyond the 
time limits of this study. The activity of this complex is discussed in section 4.10.
4.8 Expression and purification of ApeXPB
During the formative stages of this study, it became obvious that the binding of a 
homodimeric XPF to a heterotrimeric PCNA would create an asymmetric complex 
leaving one of the PCNA subunits without a binding partner. The study of the
e lu te d  fractions
ApePCNA, ApeXPF
e lu te d  frac tions
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interaction of SsoXPF with SsoPCNA indicates that the SsoXPF dimer interacts 
preferentially to two of the three SsoPCNA subunits. There are clear similarities 
between Sulfolobus solfataricus and Aeropyrum pemix and their enzymes; not least 
highlighted by the fact that SsoPCNA stimulates ApeXPF activity in vitro (Newman 
et al, 2005). Thus, it seems reasonable to assume that two of the ApePCNA subunits 
specifically bind to ApeXPF whilst the other does not. Unpublished data from 
Malcolm White’s laboratory in St. Andrews has suggested that the third SsoPCNA 
subunit binds the Sulfolobus solfataricus homologue of the NER helicase XPB. 
SsoXPB contains a canonical double aromatic PIM at its amino-terminus. A blast 
search of the Aeropyrum pemix genome identifies a clear orthologue. Although 
ApeXPB lacks a canonical double aromatic PIM near either terminus, it does have a 
double tyrosine motif within the polypeptide and aligns well with other XPB 
homologues.
Using appropriate PCR primers and genomic DNA from Aeropyrum pemix as a 
template, an open reading frame encoding full length ApeXPB was amplified and 
subsequently cloned into pET30a using Ndel and EcoRl restriction sites. In the 
process rare arginine codons present at residues 5, 9, 533, 534, 535, 536 and 538 were 
changed to preferred E.coli codons. Expression trials of this protein used Rosetta 
pLysS cells, 25 °C overnight induction and buffers containing 100 mM NaCl. 
Bacteria were grown, induced and harvested as usual and protein was extracted by 
sonication and heat denaturation as before. The first purification step was affinity 
chromatography on a Hi Trap heparin-sepharose column with elution using a NaCl 
gradient. After analysis by SDS-PAGE, fractions containing protein of the 
appropriate molecular mass ( - 6 6  kDa) were pooled, concentrated and loaded onto a 
Superdex 200 gel filtration column. A clean peak was eluted which contains the 
target - 6 6  kDa protein. The protein was identified by mass spectrometry (Protein 
Analysis Laboratory, Cancer Research UK) to be the expected ApeXPB protein.
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ApeXPB
Figure 4.13- Expression and purification of ApeXPB. Gel filtration trace of ApeXPB 
together with the SDS-PAGE gel of peak fractions. (The X-axis indicates the volume in ml 
and the Y-axis the absorbance in mAU).
4.9 ApePCNA-ApeXPF complexes: ApePCNA -  ApeXPF AN - ApeXPB
The ApeXPB was then examined for its ability to form a complex with ApePCNA 
and ApeXPF. Bacteria expressing ApePCNA, ApeXPFAN and ApeXPB were grown, 
induced and harvested as detailed in Appendix A. Cell pellets were then resuspended 
and mixed in a ratio of 6  litres of ApePCNA to 1 litre of ApeXPFAN to 5 litres of 
ApeXPB. The proteins were extracted and purified in an identical manner to the 
ApePCNA-ApeXPF AN complex, with elution from a Ni2+-sepharose column with 
imidazole. Figure 4.14 (a) shows the results of the imidazole elution. As the gel 
shows the ApePCNA, ApeXPFAN, ApeXPB complex appears to have formed. 
Fractions appearing to contain the ternary complex were pooled and concentrated 
before gel filtration on a Superdex 200 column. As figure 4.14 (b) shows, the 
complex elutes at an appropriate elution volume, although the peak does have a slight 
shoulder to it, which may be indicative of heterogeneity.
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ApeXPB
ApePCNA, ApeXPF
Figure 4.14 -  Purification o f ApePCNA-ApeXPFAN-ApeXPB. [A] SDS-PAGE profile of 
complex purification on Ni2+-sepharose. The column was eluted with an imidazole 
gradient. Fractions containing all three components are boxed. [B] Gel filtration profile of 
the complex. All three components co-purify together and the elution volume is consistent 
with a 200 kDa complex. (The X-axis indicates the volume in ml and the Y-axis the 
absorbance in mAU).
The overall yield of ApePCNA/ApeXPFAN/ApeXPB was modest (~ 500 pg from 6  
litres + 1 litre + 5 litres of each culture respectively) and not suitable for a broad 
crystallisation screen. This coupled with the probable heterogeneity meant that the 
few crystallisation trials set up did not produce any hits. However, the theoretical 
mass of the ternary complex is 208 kDa means it could be large enough to study by 
electron microscopy. A collaboration with Dr. Hannes Ponstingl and Prof. Helen 
Saibil at Birkbeck College was initiated and is currently underway.
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Figure 4.15 -  Electron micrograph of ApePCNA- ApeXPFAN- ApeXPB complex. 
Micrograph taken using a complex concentration of 0.025 mg ml-1 and at a magnification of 
52,000 x g. The negative stain means the protein is white in the micrograph.
A sample of the ternary complex was prepared as before. An aliquot of the sample 
was applied to an EM grid and uranyl acetate was used in a negative staining 
experiment. Images were taken using the electron microscope at Birkbeck College. 
Although the electron microgram in figure 4.15 is difficult to decipher, ring structures 
with 6 -fold symmetry with extra protein elements “hanging” off them were identified.
4.10 Activity of ApePCNA -  ApeXPF complexes
The studies of the activity of the SsoXPF-SsoPCNA complex have provided the first 
information on how crenarchaeal XPFs work. Flowever, the activity of ApeXPF- 
ApePCNA has not been characterised to date. Moreover there are no published 
studies on the effect of XPB in such a complex. To investigate the complex,
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ApePCNA-ApeXPF AN-ApeXPB and ApePCNA-ApeXPF AN were prepared as 
discussed before. In order to verify that any perceived activity was due to the 
prepared complexes and not an E.coli contaminant, a catalytically dead form of 
ApeXPFAN was engineered. Amino acid residue 68 of ApeXPF was mutated from 
aspartic acid to asparagine using the Stratagene QuikChange protocol. This mutation 
was functionally equivalent to the hXPF D720N mutation made in chapter 2 and 
originally in the mutagenesis study of Enzlin and Scharer (2002). It is expected that 
the role of D68  is as a general base, activating a water molecule as the nucleophile 
required for phosphodiester bond hydrolysis. Hence this D68N mutation was 
predicted to kill activity but not to affect the protein fold. Protein complexes of 
ApePCNA-ApeXPF AN D68N with and without ApeXPB were expressed and purified 
as for the wild-type protein.
The protein complexes were assayed for endonuclease activity using 32P-labelled 
substrates by Maureen Biggerstaff (Structural Biology Laboratory). Assay conditions 
were adapted from the SsoXPF studies (Roberts et al., 2003). Two synthetic DNA 
substrates were used. The first was a 3’-flap, which is generally regarded as a good 
substrate for SsoXPF. As figure 4.16 details, ApePCNA-ApeXPF cleaves this 
substrate efficiently in the presence and absence of ApeXPB. There is some residual 
activity in the D68N mutant experiments. However, the cleavage pattern is consistent 
with structure-specific activity. The second substrate was a splayed arm. The 
complexes also show activity against this substrate, although the cleavage appears to 
be less efficient and there is a difference in the presence and absence of ApeXPB. In 
this case the D68N mutation eliminates endonuclease activity completely.
These results show that the ApeXPFAN protein expressed is active. However, no 
clear effect of ApeXPB on the activity could be detected.
4.11 Summary
In this chapter, a system for expression of the heterotrimeric PCNA from Aeropyrum 
pemix was established for the first time. After failed attempts at producing individual 
ApePCNA subunits, co-expression of all three ApePCNA subunits together yielded a 
clean, monodisperse complex.
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Complexes consisting of ApePCNA and different ApeXPF constructs were pursued. 
Crystallisation trials of ApePCNA with an ApeXPF PIM peptide were unsuccessful. 
A more successful approach involved crystallisation trials with ApePCNA complexes 
with an ApeXPF (HhH)2 & PIM construct. Initial crystals diffracted well at the ESRF 
and although the diffraction images clearly show multiple lattices, these crystals 
provide a promising start. Complexes of ApePCNA and ApeXPFAN are also 
currently being crystallised.
A ternary complex of ApePCNA-ApeXPFAN-ApeXPB was also formed. The yields 
of this complex were not sufficient for crystallisation. However, a collaboration has 
enabled structural studies by electron microscopy to be initiated. Preliminary results 
have identified intact ApePCNA rings with approximate 6-fold symmetry possibly 
with appropriate staining for ApeXPF and ApeXPB. Low-resolution structure 
determination by this method remains a possibility.
Finally, the endonuclease activity of ApeXPF-PCNA complexes has been examined. 
ApePCNA-ApeXPF AN shows structure-specific activity towards 3’-flap and splayed 
arm substrates similar to that of SsoXPF-PCNA. The presence of ApeXPB does not 
appear to radically alter the activity of this complex.
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Figure 4.16 -  ApeXPF activity. Autoradiograms showing the activity of ApeXPF 
complexes towards 3 ’-flap and splayed arm substrates. (Substrate sequences can be found in 
Appendix A).
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5 Structural and functional analysis of human Mus81 ACE 
domain.
The role of Mus81-Emel as a structure-dependent endonuclease belonging to the 
XPF/Mus81 family of endonucleases is outlined in chapter one. In this chapter a 
novel domain of human Mus81 is identified and characterised using molecular 
biology, biochemistry and structural techniques. A description of the experiments 
carried out is illustrated in the flowchart in Figure 5.1.
D ata no t good  
enough
Verify protein 
is folded by 
circular dichroism
Alter protein 
buffer to  find new  
crystallisation 
conditions
Try yeast ACE 
dom ains
Assay effect of 
ACE deletion 
on Mus81 activity
Data collection on  ACE 
dom ain crystals
Bioinformatics and 
identification 
of th e  ACE dom ain
Crystallisation and 
optim isation 
o f th e  ACE dom ain
Expression and  purification 
o f ACE protein
Design and  creation 
of ACE expression 
constructs
m ethionine 
residues as 
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Figure 5.1 -  Flowchart o f the experiments described in chapter 5.
5.1 Identification of the Mus81 ACE domain.
The reported domain organisation of eukaryotic Mus81 orthologues has mainly been 
based on the presence of equivalent domains in XPF and homologues. These 
analyses have suggested that Mus81 is a multi-domain protein, with an amino- 
terminal HhH domain (Pfam PF00633), followed by a nuclease domain (Pfam 
PF02732) and finally a carboxy-terminal HhH domain.
I l l
Chapter 5 Structural and functional analysis of human Mus81 ACE domain
human(1-96) - M A A P V R  L G lK R  R l  P A C P ||P  L F VRWLT |W R « A T  R 5 R R i§ R  f  V F ® A L R S  i B p ' P  LP L R S G « A | |  l | H  F G§G L C iM L M B L Q S ►.
m oused  96) - MA EPV R L GBKR P LPVCPBP L F VRWLT gW R gilA A S |G R  HfR F V F « A L  R $ l S * * P  LP LR S G |E a | |  L0H F G |R  L C lM L f H L  KGH
i 1 931 MPT OQVC L GBKR P L P SC P IIP L F  LQWLT 1 L r | s  AK E lG  L |T : H I VY QRA I N S L X fc-P  LP LKN GM bABi L<|n F G |G  I C l I  H L D f
x e n u p u s d  9 9  M P-GE I T I g | k  R P I P  A C P » P  1 f  LKWLT | w r |  S A A  E |N  l l i < )  F V I QUA I 3 S L B f P  LP L N J G K a R i  l« N F G |S  I C |h L B « L E K M
drosophilad-81)  M E T |L  EVLLR £ P # P  L FT RWL E RW I # | A  E r I e o U Q  F *  LRftAL E S L ls> iP  LP L A SG W C  S I LR C F 6GT L C 91 I L R H||
celegans d -93) - - -  MS NQS k |v T  VR I E g j K N #  f  f  E KV L K F Q h Ie  - Q |0  r ¥ l  k S V 1 h | a |  E N l M c P F  E I L l  I v | l l N V i |G  I G E N 1A L K t  E |T  VfNVA
pom be(1 -84) ---------------------------------- M DCG*PLFLOW 1QfW M Eg*T R |  1 P |S Y  QIW iJ a IID S M lS  CP l«F>HRP S U L  ALKG I GPT I CAKLEKlW N
cerevisiae (1-89)  M E L IS  N LKD i l l  EW L Q lL V tG  LT p I q eI l K I A H H A K  R N l | n A E G1 FT T PT l l i K V K G  I GNT I l |R L lT |L R N Y
CONSERVATION —— —
> G G D H A P O fi-- - P
; g g o h a p s | - - - p
E N G S D K p V fl--  LA
E CGPN LP I MT VP S
. I ENNflQDPT LR -  - -
J l e n n i p i C t I n - -  E 
|K  I HH I S PVEJ8PSET
S |E » S P A * Q |R  LA EVQOS S$P V P A C (P ................................................ KAftfiS «S
S fi K Kid -  A S K.SPP E G VQ D S S » VPT Q B .......................................    QABSJ S V 8
S S KQME E S Q K E P S 6  M S  E B t  KjjT QK E V R ......................K E K f
APS P L S #P H 8L  EPP EQES QDL SB S KKKKT
human (97-175) 
mouse(97-I7S) 
zebrafish (99-186)
xenopus (100-198) S S ST LR KAQAGPIK  
drosophila (82-109) 
celegans (94-147)
pom be (85-164) (LN D SH V N A NK SSSET SSE K PR SIlK K P................  T
cerevisiae(90-179) QT S ST RPPKRT T T A LR S i VN SC  ENDKN E AP E E----------------- K jT K
p a r h S g a r v i LLVLlR  EHLNPNGHHfLI 
PAQNSGAR E IL L O L lR  EH LNlDGHS F LI 
POKRfGGTAVLLT LlRH M Q M PG SK G FM fjNjKKRE
P .  - s
EO<lVQiVVRK.aQ E)I"
|L Q R  iA Q K S -fcR V A
I l QK 6ACIKT-PRVV
BUT EA<2PLCEK.S F -T  VPD
I q k e « q p l g d k s f - t l t o
V fftE N  EflES o j•0  0 DK..............
i P f l  VTMA QPY (l o s s  Fi s  AT 0
if V A G K i SDHi: mt P N ------F s
CONSERVATION .......................................   8 0 I » » - T T »
human (176-238) 
mouse (176-238) 
zebrafish (187-282) 
xenopus (199-293) pNSKl 
drosophila (110-141)
P 8 S -A P P T tP A l|R K ’C H |N tV K R |H Q P A n B L lP E G L |L  
p g s  - | k p w p a l r s l l h | n l i  l g « h r p a I B a l B p  e g l|1 l
It a w s  s v s | i i < i | e l v v k | h n p a S T S L * d q g l s l a e  T AWT S VS T L I QBE L V 1 KTH S P A BTS LT E KG LfiLAQS LEE......................q J ehB k r q n k c d r p r B -  - iJ k k d l a e l a a l e e M
celegan s(148-184) ........................... Q P S V P iiT |T  K&FQVS K P V f tP S il  » 5 ( « | nMs s | s ST S
avis a m k B l i t  | n l vI q B S h p M B c l§ d d g e" -----------
( TGAWS S I A A L K K H S L V L E E G R P F . l « L t E  EGV
LA E S | .....................................S i s  L L N V filG PK E P P fiE E
l a e a I .................... ................S l s t r h a s f r P e e h h I ed
RH EDVOSQDflQNVVD LT LEEEDEDE EKESWS S E RpAVA LPVN--------- QARGL
OOGRADGFPRQ-VQASSNE EEEQ EEA ESETN PY IH A O PV Q C PO Q Q ----------LNLAT
liiA K V |O S F <lR K H T V SN F SV S K SO O H O S SL C < 2P P N F V T S IN K A iS S S D H fflJ  ELHVT
Ik SSKT a | g i S F PK EN EE PN E TSV T R N E SS EFTANLTD LRBEy BKE E E P C 0IN N T SF M L D 1T
CONSERVATION ...........................
hum an(239-298) T AVPBAAS A E L a | E  A iV a Q Q P fE f lR P lI  E |R  V L L C V j I GjMRGGG- - f l P l t i ' L R  E lQ .........................................................................................................................
m ouse(239-298) SA V P EA LS E P 4 T b EGAV<2<2RP.EE LRPS e | r V L lC V l  1 G l |R G A G - -  I l M L  R E IG ................................................... - .............. - .................................................I L R V P g
zebraflsh (283-344) MS EIDPM DKS QTBET CRT AMGWH L S P G S 1 0  I VLC V lj L CBnT GGS S V rI q U v KEGQ ..................................................... - .................................................... |N S « T B
xenopus (294-355) S HNAKNT S S D P P iV Q T  N H V P E P T L H P 8 d I n tL L C jW  F i H t H a A Hr I q H v T E JR  ..................................................... - .................................................... i N G l p g
drosophila(142-184)..............................................................R VVRMKPGQFQLL L LVfiT OfflBsfiKNKRflL O ^ lR  S Y I E  - ......................................................................................................S LGARB
celegan s(185-239) ...................... S S S S N |S  0 8 L S  F R LBTBR P F E Q P fv H H A D N R  E HR N N P R 'S s  V«EH L «K ...............- ...............................- .................................................................... iE O p R *
pombe (261-360) T CPVDHNEVSDGVETO I D V O Q y o |L * C  I S o l f f l l  I NN EQL I OLT EQ E KjOPN  E S N *S N L K I ET VL F S NCTVF L L I D T R E IR S P L D R N L II OKLTNiFGVNC  
cerevisiae (280-379) FQ O IS T PQR LQM NV F KND R L N f c l N  IS  s | kI e IEYMDQT VflOS A L K /f lS  T |K R RR  Y WBVS Y E LWC SSO F EVF P I I OHR E I KS OS DR E F F S RAF eI kGUk S
CONSERVATION -fflV
human (299-392) 
mouse (299-392) 
zebrafish (345-444) 
xenopus (356-454) 
drosophila (185-272) El 
celegans (240-321) 
pombe (361-446) 
cerevisiae (380-467) Eil]
■iH V G ifV W V A Q E T N P R D P A N P  G,
KLHVGOFVW VAQETRPRDPERP------------ G|
|LN V G ftF LWVAR ERVTPVPGQLRPPVGK  
fCL H I GO F LW IAQEKVQPVPflQLR I PQARI 
|L T  I G0F LWVAQBQE*....................................N
F K s y G M I W lC R K I D f l ....................................T
S L E LG OA LW V AR lM ES$................................ Q
■ l A C o i t  IWVAKNKNT G....................... L
CONSERVATION l i , l  x i h m.
L C G S Il 
LCGS I 
0 0  LAS
LQSSTRGG
DOLVASI
G L E R R V Y L V tflfG - S VHMIiS
G L G H R v iL v M B G - S V H N f is iS P E S r  
G -LR K PI8L V M C G SA A A H LS IPEST
 G LRR P I YL V raflfG - S AQH tS  V.P Et I
^ jH C G tQ H I l E B M H - D N E a i S U P L D I .  _
Il n m a p n k n r v il  I B  a q h .................... kg I v a c e S a v a s U l
I s  Y D EsB T EBI RT AVS HTJS
W- -  S GN I43NMN EALKT ALWV I L
human (393-483) H d H
mouse (393-483) 
zebrafish (445-536) H d H  
xenopus (455-544) M o m
drosophila(273-360) I q t H  
celegans (322-389) I n C M  
pombe (447-543) I D Q L I  
cerevisiae (468-567) ■ t k I
E SA A fL A L L
LT I M
S LL A E M fliQ I N LFjj
^ ■ H I h t v |  s  H H
aGHT L R S R P ..............WGTPONPESGAMT S P N P --------- L C S L |T  | S  D f  N A G A 11
a fiH T U R S R P ............. WCAPGAAES E A K PSTN P--------- LC SllJT  fS D ^ N A E A » |
O N C T L L C R f..............RELEGDGEAE5EKHVAN L- -  - S €S L M A fT  EFN Y G A ll
l ( s  R K S Llji S C l ............. KEEEWKCDRS LR PO A S................ S C I tV E  fcKDftN EGAK
[ Q l lA f iK K i l s V D  R G A lD Q ST C L L T H SD L fi.....................LLKIR A ^Y  E D |
A I e e i  I g v p ............................................................................................. -
E K R K fL A V IP D  LS I EAKTY ES LREQL LKI 0 PS - - - T P Y f T S |H A f S S V L |
fftEVF A|QLMCtVR 
r f * v p  a J q l m q v r  
ICCiT VftCVF A^GLMQ I S
A Q T V K E V F A tQ L M Q I■ . . .__      ^ iA Q L T V M V F V M L L a i .H
lA F fc K E V llR tlN K A i E E lf G V P ..........ASQfiQN L L Q IK |A tT  V * f  AW ViOLM yCP
■ ■ ■ M H f l E K R K f u y f P D L S     I  I O   Y i t S  |H A M  S v O f l s  S t |L t V G |  I F | | k ______
ISQ K D IIV IFPSD LK SK D D Y K K V LL Q FR R E FE R K G G l ECC0NLECFQE LM GlG ftLKTV GiLTIHV LM LV K
LMT I K
CONSERVATION P . . . .  - T o  o o o o o o 0 d o o o o o d -------
human (484-551) H H
mouse (484-551) GLSC
zebrafish (537-604) 
xenopus (545-612)’ 
drosophila(361-426) s i  
celegans (390-445) 
pombe (544-608) < j|
cerevisiae (568-632) f lS
AAV L K H
I E I ■:
P A SLL A |K-«RlQ
PAS LMSAY
H P  R WL L D
PSM V SLL SY FR  ANGDDAP I r l l q
  PT FMHL F E ARE  k RS 8 s Q | R  N L
A V A IQ E IF P f lN K !L M A R k T C S S E eI a k L
L G P A L S 
LGPAL 
LGPAL 
IG P V l
l g d k i
Q ......................... IT R P I
rinraYGPLT
r LY^LTC j H S P L S
• IY Q LY C fR G PLS
• ISQ L Y C IK E P L S
l h e f y s I h f r - -ufkffvq-^^h
■qGygfRt i g p a l S a k v a s VF F P E S - - - 
GOA PGaRkIT K ilR R K lR P A F G K L --------
CONSERVATION
Figure 5.2 -  Sequence conservation in eukaryotic Mus81 orthologues. Sequence numbers 
for each alignment panel are indicated. The blue line demarcates the nuclease domain; and 
the green lines, the HhH domains. The red line demarcates the ACE domain.
Human Mus81 is 551 amino acid residues in length (in fission yeast 572 residues) and 
thus a large proportion of Mus81 has no clearly identifiable domain assignment. 
Subsequent sequence alignment and secondary structure predictions identified an 
extra region of conservation between the amino-terminal HhH domain and the
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nuclease domain (figure 5.2). This patch of conservation is approximately 100 amino 
acid residues in length and is present in all eukaryotic Mus81 orthologues, apart from 
the orthologues from Caenorhabditis elegans and Drosophila melanogaster. We 
have named this putative domain, the Mus81 Absent in Caenorhabditis elegans 
(ACE) domain.
Based on the sequence conservation the boundaries of the human Mus81 ACE 
domain (hACE) were set (residues 128-230). The hACE sequence was submitted to 
the 3D-PSSM/Phyre fold recognition server (http://www.sbg.bio.ic.ac.uk/phyre/). 
The output from this server, (figure 5.3), predicted a mainly helical secondary 
structure. The best fold prediction was that from the winged-helix DNA-binding 
domain family. The estimated precision of this prediction was 60% with an E-value 
of 1.9. These values mean that this prediction can only be considered speculative, 
(c.f. hXPF nuclease domain entered into the same server has a fold prediction 
precision of ApeXPF nuclease domain of 100% and an E-value of 3.2'18).
Secondary Structure Prediction
YW RH RVH.LVLRSHL* N MHL KEEUO gC OK RV Wf LR UHWHLVm HQ R
Cor**rr*u*
Cor* proto
Fotd Rtcogro&on
Figure 5.3 -  Phyre server output for hACE sequence. The secondary structure prediction 
suggests a predominantly a-helical structure, with three (3-strands with the fold recognition 
algorithm consistent with a winged helix domain (ringed).
Winged-helix domains (also known as forkhead domains) are well-characterised 
protein domains normally associated with DNA recognition. Studies of winged-helix 
proteins began with the discovery of HNF-3, a liver specific transcription factor
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Figure 5.4 -  Structure of winged-helix proteins. [A] Transcription factor RFX1 bound to its 
cognate DNA (PDB accession code 1DP7 (Gajiwala et al. 2000)). [B] SCC1 (green) bound 
to SMC1 (blue). Both proteins are involved in sister chromatid cohesion (PDB accession 
code 1W1W (Haering et al. 2004)).
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(Gajiwala and Burley, 2000). Structures of winged-helix motifs, (figure 5.4), have 
shown them to be compact a/p  folds, usually consisting of three a-helices and three 
p-strands. These secondary structure elements combine to form two wings that flank 
an a-helix, inspiring the m otifs name. It is this a-helix that is often involved in the 
recognition of DNA by binding in a major groove.
The theoretical isoelectric point (pi) of the hACE domain is 10.0. Often proteins with 
such a preponderance of basic residues might be expected to bind to a polyanionic 
ligand such as DNA. This coupled with the winged-helix prediction could point to a 
role for the hACE in DNA binding and recognition. However, there are two pieces of 
information to temper this conclusion. Firstly, not all winged-helix domains are 
involved in binding DNA. Others are involved in protein-protein interactions. For 
example, the carboxy-terminal region of SCC1, a protein involved in sister chromatid 
cohesion and segregation is a winged-helix domain that has been shown to mediate an 
interaction with SMC1, another cohesion protein (figure 5.4, (Haering et al., 2004)). 
Secondly, recent literature has suggested residues 125-244 of hMus81 interact with 
the C-terminal domain of the human Bloom’s Syndrome helicase BLM (hACE falls 
within these residue limits; (Zhang et al., 2005)). Thus the questions we sought to 
address were, what fold does hACE adopt and is it involved in Mus81 substrate 
recognition or does it mediate and regulate Mus81 protein-protein interactions.
5.2 Molecular cloning, expression and purification of hACE domain.
Based on the conservation observed from the sequence alignments discussed earlier, 
an open reading frame for hACE was amplified using appropriate PCR primers and a 
DNA template from a dicistronic pET28a hMus81-hEmel plasmid (a gift from 
Alberto Ciccia, Genetic Recombination Laboratory, Cancer Research UK; details for 
cloning methods can be found in the general Materials and Methods in Appendix A). 
The hACE open reading frame was cloned into three different plasmid vectors; the 
first pET41a-3C, the second pGEX-6P2 and the third pET14b-3C. These constructs 
are depicted in Figure 5.5. On first inspection it may appear that that pET41a-3C- 
hACE and the pGEX-6P2-hACE plasmids are essentially the same but they are not. 
The difference is in the RNA polymerase promoter regions. Expression from 
pET41a-3C starts from a T7 RNA polymerase promoter, whilst pGEX-6P2 relies on
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Figure 5.5 - Schematic diagram of hACE expression plasmids. [A] pET41a-3C hACE. [B] 
pGEX6P2-hACE. [C] pET14b-3C hACE.
Chapter 5 Structural and functional analysis of human Mus81 ACE domain
the endogenous Escherichia coli RNA polymerase. There is evidence that sometimes 
protein expression under the control of the T7 promoter can prove to be too high, 
even under mild induction conditions (A.J. Fadden and N.Q. McDonald, unpublished 
observation). This effect increases protein packaging into insoluble inclusion bodies 
and lowers the yield of soluble protein.
Test expressions of all three constructs in Escherichia coli strain FB810 showed that 
hexahistidine-tagged hACE produced from the pET14b-3C-hACE plasmid did not 
express well in a range of induction conditions. However, both glutathione-S- 
transferase (GST) tagged hACE domain constructs expressed well across a range of 
induction conditions and produced GST-hACE fusion proteins (details for protein 
expression and purification can be found in Appendix A). Due to the slightly higher 
expression levels the pET41a-3C-hACE plasmid was chosen for further hACE study. 
After scaling up, hACE domain expression was typically around 5 mg I"1 of bacterial 
culture.
After the selection of the appropriate construct and induction conditions, the 
purification strategy was piloted. The first purification step was predetermined as 
affinity chromatography on glutathione-Sepharose. Elution from the affinity matrix 
was achieved by cleaving the hACE domain from its GST-tag with recombinant 
rhinoviral 3C protease. The purity of this hACE domain eluate was not quite 
sufficient for crystallisation, so a need for a second purification step was thus 
identified. Bearing in mind the potential of the hACE domain for binding polyanions 
such as DNA, a second affinity purification step using a 1ml Hi-Trap Heparin- 
Sepharose column was employed.
Purification of the hACE domain on heparin-sepharose was successful. The eluted 
protein was significantly cleaner and few contaminants could be identified on a 
Coomassie stained SDS-PAGE gel. This protein was concentrated and put forward 
into crystallisation trials, using a mixture of commercial sparse matrix and grid 
screens and utilizing both microbatch and sitting-drop vapour diffusion methods 
(details on crystallisation methods can be found in Appendix B). These crystallisation 
trials were unfortunately unsuccessful.
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The lack of crystallisation hits led to concerns that the hACE protein was either not 
folded properly, or worse was not a discrete domain at all! With this in mind, circular 
dichroism experiments using hACE protein were performed.
Circular dichroism (CD) is a technique in which light is polarised into 2 circularly 
polarised components. Asymmetric molecules, such as proteins, absorb the two
®
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Figure 5.6 -  Purification o f hACE on heparin-sepharose. [A] AKTA-FPLC Trace. X-axis 
indicates the volume in ml and Y-axis is absorbance at 280 nm in mAU. The green line 
indicates the 0.1 -  1 M NaCl gradient employed. [B] SDS-PAGE gel o f eluted fractions.
components differently. When one of these components is selectively absorbed, this 
yields light that is elliptical. This ellipticity can be measured and interpreted in terms 
of protein fold and secondary structure relative to a databse of known structure and 
CD spectra.
CD experiments were performed on hACE, using the apparatus of Dr. John Ladbury’s 
group at UCL. The results of the experiment were merged and corrected for the 
contribution of the protein buffer to the spectrum. Figure 5.7 shows the hACE 
spectrum. Model protein secondary structures show characteristic CD spectra in far 
UV wavelengths, a-helices have strong ellipticity peaks near 192 nm with a broad 
trough between 200 and 240 nm (with minima at 208 and 223 nm). p-sheet spectra 
look similar but the maximum is at about 198 nm and the spectra in general are not as
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intense. From figure 5.7 it is clear that hACE is folded and is largely a-helical in 
nature.
The confirmation that hACE was folded renewed confidence that crystallisation 
should be possible. To this end further characterisation of the protein was undertaken. 
Of particular interest was the oligomeric state of the protein and thus an analytical gel 
filtration experiment was performed to determine this.
The initial gel-filtration profile showed that the majority of the hACE protein ran in 
the void of the Superdex 75 column used (figure 5.8 (a)). This indicated that the 
hACE domain was present in an aggregated state and not a monodisperse, 
homogenous solution desirable for crystallisation.
A solution to these aggregation problems was sought. Initial attempts included a 
small amount of the non-denaturing zwitterionic detergent 3-[(3- 
cholamidopropyl)dimethylammonio]-l-propanesulfonate (CHAPS) to a final 
concentration of 0.1 % CHAPS in all extraction, purification and storage buffers. 
However, its inclusion made no difference to the amount of aggregated hACE protein 
in the preparation. A second approach was to increase the concentration of sodium 
chloride, NaCl in the buffers. The rationale behind this approach is that an increased 
salt concentration provides increased counter-ions to polar side-chains and thus may 
encourage a monodisperse protein solution. The salt concentration was increased 
from 100 mM to 500 mM. hACE domain prepared in these new buffer conditions 
was cleaner after the first affinity chromatography step (higher salt concentrations 
often reduce non-specific interactions with affinity resins), and thus the eluate from 
this first step was concentrated and loaded straight onto a Superdex 75 gel filtration 
column.
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Figure 5.7 -  Circular dichroism spectrum o f hACE. The ellipiticity peak near 192 nm with a 
broad trough between about 200-240 nm is characteristic of a mostly a-helical protein.
As figure 5.8 (b) shows the majority of the hACE domain migrated with an apparent 
molecular weight of 9.3 kDa. This indicates that the hACE domain runs mainly as a 
monomer. Armed with pure, monodisperse protein further attempts were made to 
produce hACE crystals.
5.3 Crystallisation of hACE domain
Crystallisation trials were carried out using the hACE domain (20 mM Tris (8 ), 500 
mM NaCl, 1 mM DTT) at a concentration of 10-12 mg m l 1 and a mixture of 
commercial sparse matrix and grid screens. Both sitting drop vapour diffusion and 
microbatch trials were performed. After 3 days small crystals were found in a sitting- 
drop ammonium sulphate ((NH^SCU) grid screen. The condition was identified as 
45 % saturated (NH4 )2 SC>4 buffered with 100 mM citric acid at pH 4. An optimisation 
tray was set up around this condition and larger hexagonal rods grew overnight in 41 
% saturated (N H ^SC^ buffered with 100 mM citric acid at pH 3.5. Subsequently the 
substitution of citric acid for formic acid was found to improve the morphology of the 
crystals, resulting in fewer crystals growing together and single crystals suitable for 
diffraction studies (figure 5.9).
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Figure 5.8 -  Purification o f hACE. [A] Gel filtration profile o f hACE extracted in 100 mM 
NaCl. The majority of hACE protein elutes in the void fractions. [B] Gel filtration profile 
of hACE extracted in 500 mM NaCl. The majority of hACE protein elutes as a 
monodisperse species. The peak is consistent with the protein being monomeric. (X-axes 
indicate the volume in ml and Y-axes the absorbance at 280 nm in mAU.
To check that the crystals were not inorganic salt crystals, a minute amount of 
Hampton Research’s Izit crystal dye was added to a drop with small crystals. Izit dye 
is a small molecule dye that fills solvent channels within protein crystals, colouring 
the crystals blue. Salt crystals do not possess large solvent channels, and thus the Izit 
dye cannot enter the crystal. In this case the crystals took up the dye and turned blue 
(figure 5.9 (a)). Initial diffraction studies using our in-house rotating anode X-ray 
generator provided further confirmation that the crystals were composed of protein. 
Initial images from the home source showed diffraction extending to 3.7 A, using 
mother liquor and either 30 % glucose or 25 % glycerol as cryoprotectants (figure
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5.10). Other cryoprotectants such as ethylene glycol, 2-methyl-2,4-pentanediol 
(MPD) and N-paratone resulted in poorer diffraction.
Figure 5.9 -  hACE crystals. [A] Small hACE crystals stained with Izit dye. [B] & [C] 
Large hACE crystals grown in 100 mM formic acid (3.5), 41 % saturated (NH4)2S0 4 .
However when the crystals were taken to the synchrotron (ESRF ID 14-1), the 
diffraction did not improve and the diffraction pattern showed high mosaicity. It was 
not possible to collect a processable dataset from these crystals. The use of simple 
chemical additives to improve the diffraction was not successful. The crystal 
morphology was altered by small amounts of the detergents nonaethylene glycol 
monododecyl ether (C 12E9 ), Triton X-100 and hexadecyltrimethylammonium bromide 
(CTAB) (figure 5.11) but the diffraction was not improved and the crystals were very
Figure 5.10 -  hACE diffraction. Two test shots taken in-house using a rotating anode 
generator and a Mar detector. [A] 0 °. [B] 90 °. Data extends to 3.7 A. Circles are at 10.4, 
5.2, 3.5 and 2.6 A. Cell parameters are a=60.6 A, b=61.2 A, c=150.2 A ; a=  90 0 , 0=90 °, 
Y=120°.
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difficult to handle. Various other techniques that have been shown to improve crystal 
diffraction such as crystal dehydration and incorporation of a small amount of 
cryoprotectant, such as glycerol or sucrose, into the precipitant mixture did not 
improve diffraction and often made it worse.
Figure 5.11 -  hACE crystals. hACE was crystallised in the presence o f the following 
detergent additives: [A] C i2E9 (nonaethylene glycol monododecyl ether) [B] Triton X-100 
[C] CTAB
5.4 Molecular cloning, expression and purification of yeast ACE domains.
Whilst attempts to improve the diffraction characteristics of the hACE domain 
crystals were underway, it seemed prudent to approach the problem from a number of 
different angles. One of these was to examine other eukaryotic Mus81 ACE domain 
orthologues. To this end open reading frames encoding the Mus81 ACE domains 
from Saccharomyces cerevisiae (scACE) and Schizosaccharomyces pombe (spACE) 
were amplified using suitable PCR primers and purified genomic DNA 
{Saccharomyces cerevisiae genomic DNA was from Promega, Schizosaccharomyces 
pombe genomic DNA was a gift from Trevor Duhig, Cell Cycle Laboratory, Cancer 
Research UK). The resultant PCR products were cloned into pET41a-3C using the 
BamHl and Xhol restriction sites and the final plasmid sequence confirmed by DNA 
sequencing.
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Figure 5.12 -  Expression and purification of yeast ACE domains. [A] Gel filtration profile 
of scACE. The gel shows that scACE co-purifies with a bacterial contaminant. [B] Gel 
filtration profile of spACE. The gel shows spACE as a doublet, indicating degradation. (X- 
axes indicate the volume in ml and Y-axes the absorbance at 280 nm in mAU.
The domains were expressed and purified as for the hACE domain (figure 5.12). The 
scACE domain expressed well similar to its human counterpart and appeared to gel 
filter as a monomer. However, a bacterial contaminant consistently co-purified with 
the scACE protein, making protein purity an issue. The spACE domain is less well 
behaved, showing a doublet on a SDS-PAGE gel and was prone to precipitation. At 
first these problems were thought to be due to an inappropriate buffer pH (spACE pi 
~ 8.5 and the pH of the Tris buffer used was initially 8.0) but use of a Tris buffer set 
to pH 7.0 did not circumvent these problems
Crystallisation trials using these proteins, a mixture of commercial sparse matrix and 
grid screens and the Mosquito robot did not produce any hits at all. Focussed trials 
around the crystallisation condition found for hACE were also set up. These were 
also unsuccessful. This coupled with the precipitation problems plaguing the spACE
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protein led to the conclusion that the hACE domain was perhaps the most amenable 
domain to pursue structurally after all.
S.5 Molecular cloning, expression and purification of truncated hACE domain.
A second approach to circumvent the poorly diffracting hACE domain crystals 
followed a closer look at the hACE domain boundaries. Although the domain 
boundaries for the initial hACE domain constructs seemed sensible considering both 
the sequence conservation and the secondary structure prediction, there remained 
scope to tighten the hACE domain boundaries. Three new hACE constructs were 
designed; the first (hACEAN) encoding hMus81 residues 136-230 (an amino-terminal 
truncation of eight amino acid residues), the second (hACEAC) encoding hMus81 
residues 128-219 (a carboxy-terminal truncation of 11 residues) and the third (hACE 
AN AC) encoding hMus81 residues 136-219 (both truncations in tandem). 
Accordingly, new reading frames were amplified using appropriate PCR primers and 
the original pET41a-3C hACE plasmid as a template. The resultant PCR products 
were cloned into pGEX-6P2 using the restriction enzymes BamHl and Xhol and the 
final plasmids sequences confirmed by DNA sequencing.
The three new constructs were expressed and purified as for the original ACE domain 
(figure 5.13). All three constructs behave well, as for the original hACE construct 
and gel filter as monomers on a Superdex 75 column in similar high (500 mM) salt 
conditions. Preparations of all three gel filtered proteins were concentrated to 10-15 
mg ml' 1 by ultrafiltration.
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Figure 5.13 -  Expression and purification of truncated hACE proteins. Initial purification of 
SeMet protein on glutathione-sepharose. The gel shows insoluble, unbound and glutathione 
eluted protein for each protein.
Crystallisation trials using these proteins, a mixture of commercial sparse matrix and 
grid screens and the Mosquito robot did not produce any hits in the short term. 
Focussed trials around the crystallisation condition found for the original hACE were 
also set up. These were unsuccessful. After between two and three months small 
crystals were found in a 200 nl sitting drop from the Nextal AmS0 4  suite containing 
hACEANAC protein (figure 5.14). The conditions were slightly different from the 
original hACE domain hit. The conditions all contained 1.6 M (N H ^SC^ with a 
small selection of different buffers (100 mM HEPES pH 7.0, 100 mM Tris pH 8.0, 
100 mM bicine pH 9.0). Small hACEANAC crystals were also found in a 200 nl 
sitting drop from the Nextal pH clear suite. The condition in this case was 30 % PEG 
6000 buffered with 100 mM HEPES pH 7.5. These crystals whilst promising were 
too small for diffraction studies. Attempts to reproduce these crystals have yielded 
similar small crystals unsuitable for diffraction studies.
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Figure 5.14 -  hACEANAC crystals. Crystals grown in 100 mM Tris (8), 1.6M (NH4)2S 0 4.
5.6 Molecular cloning, expression and purification of selenomethionine hACE 
domain.
In parallel to attempts to improve the diffraction of the hACE domain crystals, the 
question of how to overcome the phase problem was raised. Since the possibility that 
the hACE domain is a winged-helix protein can be considered no more than 
speculative, molecular replacement was not considered a suitable way to obtain 
phases. Another common approach to consider was to derivatise hACE domain 
crystals with heavy atoms and then obtain experimental phases by multiple 
isomorphous replacement (MIR). Whilst this technique is conceptually simple, in this 
particular case it was potentially problematic as most of the repertoires of heavy 
atoms are non-reactive in the crystallisation conditions (pH 3.5), although there are a 
few platinum compounds that do react at low pH.
Another common method employed to tackle the phase problem is to analyse the 
anomalous scattering of selenium atoms to provide experimental phases. Most 
chemical elements introduced to within a crystal can provide anomalous scattering at 
an appropriate wavelength, but selenium is particularly attractive. This is because it is 
possible to produce recombinant protein in methionine-autotrophic Escherichia coli 
strains that contain selenomethionine (Se-Met) amino acid residues instead of 
methionine. This Se-Met containing protein can usually be purified and crystallised 
in similar conditions to the native protein, and the presence of Se-Met residues 
usually have little to no effects on the protein structure. The problem with this
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approach in the case of hACE is that the domain does not contain any methionine 
residues apart from one vector-derived methionine at the extreme amino-terminus. 
As this methionine as at one of the polypeptide termini it is reasonable to suspect that 
it may well be disordered in the crystals and thus not useful for obtaining phases. A 
possible advantage to this approach is that in a few cases the introduction of Se-Met 
improves crystal quality and diffraction.
Sequence alignments of Mus81 ACE orthologues show that in some cases conserved 
hydrophobic positions are occupied by methionine (figure 5.15). From this, three 
conserved hydrophobic residues likely to be locked in the hydrophobic core of the 
protein fold were selected for mutation to methionine; leucine 185 (L185M), valine 
194 (V194M) and leucine 212 (L212M). Suitable PCR primers were designed to 
effect these mutations using the Stratagene QuikChange protocol. Seven hACE 
methionine mutants were created in this way; three single mutants, three double 
mutants and one triple mutant. The presence of the mutations was confirmed by DNA 
sequencing. In order to maximise the opportunities for phasing, whilst minimizing 
disruption to the protein, the three double mutants were selected for expression.
The mutant hACE domains were expressed in minimal media supplemented with 
selenomethionine and purified as for the original hACE domain (figure 5.16). All 
three double mutants express well, and gel filtration experiments show that the mutant 
proteins are monodisperse and monomeric. The SeMet-labelled proteins were 
concentrated to 10-15 mg ml*1 by ultrafiltration before crystallisation.
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Figure 5.15 -  Rationale for selection of residues for methionine mutagenesis. Arrows 
indicate sites selected for mutagenesis. Magenta boxes show methionine residues in ACE 
orthologues at these positions.
Crystallisation trials using these mutant proteins, a mixture of commercial sparse 
matrix and grid screens and the Mosquito robot did not produce any hits. Focussed 
trials around the crystallisation condition found for the original hACE were also set 
up. In the cases of hACE L185M L212M and hACE V194M L212M, this mini­
screen produced only slight precipitate. However hACE L185M V194M produced 
tiny clusters of needles (figure 5.17 (a)). Whilst unsuitable for diffraction studies, 
these clusters were a useful start.
The formation of these clusters was very dependent on the concentration of the 
precipitant (N H ^SC^. For example for one batch of protein, drops with 40 and 40.2 
% saturated (NH4 )2 S0 4  did not yield clusters but 40.4 and 40.6 % saturated 
(NH4 )2 S 0 4 did. 40.8 and 41 % saturated (NH4 )2 S0 4 yielded only a slight precipitate.
It was possible in some cases to disturb these clusters so that individual crystals were 
broken away but the resultant crystals remained too small for diffraction studies. To 
improve the size of these crystals, streak seeding and microseeding experiments were 
set up. However, single crystals still did not grow and the clusters remained too small 
(figure 5.17 (b)).
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Figure 5.16 -  Expression of selenomethionine labelled protein. [A] Initial purification of 
SeMet protein on glutathione-sepharose. The gel shows insoluble, unbound and glutathione 
eluted protein for each double mutant. [B] Purification o f SeMet by gel filtration. Gel shows 
the load and the peak eluted fractions after gel filtration on a Superdex 75 column.
Another approach to improve the size and quality of protein crystals is the use of 
additives. The introduction of divalent cations, detergents, chaotropes, alcohols and 
other chemicals has been shown to affect crystallisation in many different ways. 
Screening additives generally involves adding a small amount of each additive to 
identical crystallisation drops based on the best condition identified thus far and 
analysing the effect of each additive. It is difficult to “second guess” which additives, 
if any, will improve crystallisation. In this case, additives made a significant
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difference to the hACE L185M V194M crystals (figure 5.17 (c)). Starting from the 
base 41.4 % saturated (NFL^hSCU, 100 mM formic acid buffer pH 3.5 condition, 
additives of 10 mM sodium bromide, 10 mM calcium chloride, 10 mM cadmium 
chloride and 10 mM manganese chloride, all improved crystal size and quality. These 
single crystals were suitable for diffraction studies.
Figure 5.17 -  SeMet hACE crystals. [A] Small needle cluster. [B] Larger clusters. [C]
Single crystals suitable for diffraction studies. The key additive in this case was NaBr.
These hACE L185M V194M crystals were frozen using mother liquor and 25 % 
glycerol as a cryoprotectant, and shot at the synchrotron (ESRF ID 23-2). Despite 
hopes that the crystals would potentially diffract to sub 3 A resolution, coupled with 
anomalous scattering data to overcome the phase problem, these crystals diffracted 
very poorly to ~ 8 A and the diffraction images showed signs of disorder. It is clear 
that further work is needed to enhance the diffraction properties of these crystals.
5.7 Identification of a novel crystallisation conditions for the hACE domain
Given the difficulties in obtaining sub 3 A resolution diffraction despite the size and 
exterior beauty of the original hACE crystals, a new crystallisation condition was 
sought. Given the amount of screening initially for a condition and the fact that the 
condition that was found was at an extreme of most crystallisation screens, it seemed 
reasonable that a change to the protein buffer may increase the likelihood of finding a 
novel crystallisation condition. Since the original hACE crystals were grown using 
(NH4 )2 S0 4  as a precipitant the protein buffer was modified to contain (NH4 )2 S0 4 . 
Given the potential role for this domain in binding DNA, a polyanionic molecule, one 
could imagine that the sulphate ions present in (NH4 )2 S0 4  might be acting as counter­
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ions to a DNA binding surface on the protein. Thus the hACE domain might be 
stabilised by the presence of sulphate ions in the buffer solution.
The hACE protein expression, extraction and purification was the same as normal, 
except all buffers contained 100 mM (NfL^SCU and 50 mM NaCl (this gave an ionic 
strength equivalent to 250 mM NaCl). The protein expressed and purified as for the 
normal hACE preparations. Gel filtration analysis of these preparations showed more 
aggregated protein but the majority of the protein was retained in a monodisperse and 
monomeric state. The protein was concentrated to 10-15 mg ml"1 by ultrafiltration 
before crystallisation.
Crystallisation trials were set using a mixture of commercial sparse matrix and grid 
screens and the Mosquito robot and a variety of new hits were found. Many of these 
turned out to be salt crystals, since the presence of sulphate ions in the protein buffer 
meant that many conditions containing calcium ions produced crystals of calcium 
sulphate. However, novel protein crystals were obtained in a more neutral pH range 
6.5 -» 7.5 with low molecular weight PEGs as preciptants (30 % PEG 400,25 % PEG 
MME 550).
These new conditions were attractive hits for a number of reasons. Firstly the initial 
crystals despite being in 200  nl drops were large enough for diffraction studies. 
Secondly low molecular weight PEGs make excellent cryoprotectants meaning the 
crystals could be scooped from the drops and flash-frozen for diffraction. Thirdly the 
neutral pH meant that the protein crystals should be more reactive with a wider range 
of heavy atoms for phasing.
A single crystal from a 200 nl drop was mounted and frozen directly in the cryo- 
stream of our home-source X-ray generator. Diffraction up to 3.3 A was observed. 
This was the best diffraction seen for this project thus far, despite a non-optimal 
cryopreparation as shown by the presence of several ice rings (figure 5.18).
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®
Figure 5.18 -  hACE crystals and diffraction. hACE was extracted in a buffer containing 
(NH4)2S0 4 . [A] Crystals grown using the Mosquito robot. Precipitants were either PEG400 
or PEG MME 550. [B] Diffraction data collected at the ESRF ID29. Data extends to 2.9 A. 
Circles are at 12, 6 ,4 , and 3 A.
However, it proved difficult to reproduce these crystallisation hits in larger drops and 
with new batches of protein. Crystals from the original 200 nl drops were frozen and 
taken to the synchrotron (ESRF ID 29). Diffraction data from all the crystals were 
poor (~4-5 A) except that for the crystal that was shot on the home-source initially. A 
dataset from this crystal was collected to 2.9 A, although the data had a high mosaic 
spread. This may have been due in part to a poor freeze. Efforts to reproduce these 
crystals are ongoing.
5.8 Functional analysis of the human Mus81 ACE domain
Whilst efforts to obtain a crystal structure of the hACE domain form the bulk of this 
chapter, the role of hACE domain in the context of full-length hMus81 is also of 
interest. A complex of hMus81-hEmel has been expressed recombinantly in 
Escherichia coli and has been shown to be active against 3’-flap and nicked duplex 
substrates in particular. The sequence of a second putative hMus81 partner, hEme2,
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has been identified previously in the literature (Ciccia et al., 2003). The hMus81- 
hEme2 complex has recently been characterised as having activity towards 3’-flap 
substrates, and possibly a greater specific activity than the hMus81-hEmel complex 
(Alberto Ciccia et al. manuscript in preparation). However, there is no information 
about the role of the hACE domain in these complexes.
To this end, four new plasmid constructs were designed and created. The constructs 
were based on two dicistronic plasmids, pGEX-KG hMus81-hEmel and pGEX-KG 
hMus81-hEme2 (These plasmids were a gift from Alberto Ciccia, Genetic 
Recombination Laboratory, Cancer Research UK. Details about pGEX-KG can be 
found in Appendix A). As a control for subsequent activity assays, catalytically dead 
mutants were designed and made for both complexes using appropriate primers and 
the Stratagene QuikChange protocol. This was achieved by mutating hMus81 residue 
339 from aspartic acid to asparagine (D339N). This mutation was based on the 
mutagenesis study performed by Enzlin and Scharer on human XPF (Enzlin and 
Scharer, 2002). By extension from that study, the D339N mutation is though to affect 
the binding of a water molecule involved in nucleophilic attack on the scissile 
phosphodiester bond, whilst leaving metal binding and the protein fold intact. This 
round of mutagenesis yielded two new dicistronic plasmids, pGEX-KG 
hMus81D339N-hEmel and pGEX-KG hMus81D339N-hEme2. Subsequently, using 
appropriate primers, overlap PCR was employed to synthesize hMus81 open reading 
frames devoid of the hACE domain coding sequence. These hMus81AACE reading 
frames were re-cloned into the original dicistronic vectors using the restriction 
enzymes EcoRl and Xhol. This yielded two new dicistronic plasmids, pGEX-KG 
hMus81AACE-hEmel and pGEX-KG hMus81AACE-hEme2. In combination with 
the original wild-type complexes, this gave six plasmid constructs for expression.
Two groups have documented the expression of hMus81-hEmel in Escherichia coli 
at low levels for functional work and thus this was not expected to be a problem 
(Ciccia et al., 2003; Ogrunc and Sancar, 2003). Expression of the hMus81 D339N 
mutant was not expected to be difficult either. However, a little trepidation preceded 
trials of the hMus81AACE constructs, as the effect of deleting the domain could not 
be foreseen. Expression, extraction and purification conditions were adapted from the
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earlier study by Ciccia et al. (2003), except that Triton X-100 was replaced by 0.1 % 
CHAPS. Purification of these proteins was a three-step process. The first step was 
affinity chromatography on glutathione-sepharose. Proteins were eluted from this 
affinity matrix with excess reduced glutathione. These eluates were purified further 
on heparin-sepharose and Superose 12 columns (figure 5.19). Peak fractions from the 
superose 12 columns were aliquoted and flash frozen in liquid nitrogen.
h M u s8 l-e m e 1  hM us81AACE hM us81D 339N
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Figure 5.19 -  Expression of Mus81 complexes. SDS-PAGE gels o f fractions taken after gel 
filtration on a Superose 12 column. The deletion of the ACE domain has a clear effect on 
hMus81 ’s migration on the gels.
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The protein complexes were assayed for endonuclease activity using P-labelled 
substrates by Maureen Biggerstaff (Structural Biology Laboratory). Assay conditions 
were adapted from Ciccia et al. (2003). Against a 3’-flap substrate, (figure 5.20 (a)), 
the deletion of the ACE domain appeared to have little effect on hMus81 activity in 
the context of either hMus81-hEmel or hMus81-hEme2. The D339N mutation 
efficiently killed the endonuclease activity and provided support that the observed 
activity is due to hMus81 and not a bacterial contaminant. The intriguing result is 
shown in figure 5.20 (b), where the complexes were assayed for activity against a 
splayed arm substrate. As discussed in Chapter 1, splayed arms are generally 
regarded as poor substrates for Mus81-type endonucleases. This has previously been 
shown for both hMus81-hEmel and scMus81-scMms4 complexes. However, these 
experiments suggest that although hMus81-hEmel does not cleave the splayed arm, 
hMus81-hEme2 efficiently cleaves the splayed arm in a structure-specific manner. 
On top of this, this activity is abrogated when the ACE domain is deleted from this 
complex. As well as being the first evidence of differing substrate specificities for 
hMus81-hEmel/hMus81-hEme2 complexes, this result indicates a role for the ACE 
domain in cleaving splayed arm substrates.
5.9 Summary
The identification of the ACE domain means that motifs and domains outside of those 
previously documented exist in Mus81 orthologues. The possibility that Mus81 has a 
winged-helix domain can be considered no more than speculative, although such a 
fold would be consistent with a role in substrate recognition. Roles in binding other 
proteins such as BLM remain possible.
The cloning and expression of hACE proved successful. Milligram quantities of 
hACE were expressed and purified. Initial problems with purity and aggregation 
were circumvented by use of high salt buffers. CD experiments showed that the 
expressed protein was folded and mostly a-helical in secondary structure.
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Figure 5.20 -  Effect o f hACE deletion on hMus81 activity. Autoradiograms showing the 
activity of Mus81 complexes towards 32-P labelled substrates. [A] 3 ’-flap structure. [B] 
Splayed arm. (Substrate sequences can be found in Appendix A).
Crystallisation of hACE protein was achieved. Crystals were grown using 
ammonium sulphate as a precipitant. Large single crystals were grown, although 
diffraction did not improve past 3.7 A.
Whilst trying to improve these crystals by the use of detergents and additives, other 
approaches were taken to achieve an ACE structure. Attempts to express, purify and 
crystallise ACE domains from S. cerevisiae and S.pombe proved more problematic 
than for the human domain. Tightening domain boundaries at the amino and carboxy 
termini was only a qualified success with only small crystals grown for the double 
hACE ANAC protein. The production of mutant selenomethionine-labelled protein 
was a success but the crystals produced diffracted poorly.
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The best diffraction achieved thus far was when a new area of crystallisation space 
was sampled. This was achieved by adding ammonium sulphate to the buffer the 
hACE protein was manipulated in. Crystals were grown in low molecular weight 
PEGs and diffracted to 2.9 A at the ESRF. However, high mosaicity plagued the 
dataset.
Whilst the structure of hACE has proved elusive to this point, interest in the domain 
has increased in the light of the activity assay experiments. The results suggest hACE 
has a role in the recognition and cleavage of splayed arm substrates by the hMus81- 
hEme2 complex. This may point to an important role in the in vivo recognition of 
such substrates.
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6 Discussion and Conclusions
The aim of this thesis was to better define XPF/Mus81 architecture and to understand 
how XPF/Mus81 endonucleases recognise their substrate and the catalytic mechanism 
underlying the cleavage reaction. Progress towards these aims was made on a number 
of fronts as described in this thesis.
I - Enhanced yields of human XPF-ERCC1 were obtained using a modified 
expression vector and an E.coli host. This has had a profound impact on several 
aspects of the human XPF-ERCC1 project even though ultimately we have concluded 
that producing sufficient XPF-ERCC1 complex in E.coli to allow structural analysis 
is not feasible at present. Sufficient quantities of high quality, unaggregated XPF- 
ERCC1 allowed us to establish a functional assay for structure-specific endonuclease 
activity using fluorescently labelled substrates. This in turn allowed us to determine 
that the C-terminal fragment (629-905) of XPF bound to ERCC1 retains no detectable 
endonuclease activity. This implies that the helicase-like domain at the extreme N- 
terminus of XPF may play a role in catalysis or substrate engagement. From this we 
conclude that efforts to trap a full stem-loop substrate bound to a catalytically dead 
mutant of XPF-ERCC1 will require the helicase-like domain. Even with the 
availability of nano-drop dispensing crystallisation robots, a structural analysis of full- 
length hXPF-hERCCl remains a very ambitious aim at this time. Despite 
optimisation, yields are still low and the protein remains susceptible to proteolysis. 
Alternative strategies at this point could involve screening further homologues of 
XPF-ERCC1 from other species. Preliminary efforts to express the S.pombe 
equivalent, the Swi 10-rad 16 complex, did not show any improved yields.
It was possible to produce a truncated form of XPF-ERCC1 with good yields, though 
as stated, the complex was not active. However, domains contributing to DNA- 
binding were present and we therefore undertook experiments to co-crystallise 
ERCC1-XPF (629-905) bound to various oligonucleotides and to XPA. ERCC1-XPF 
(629-905) had a tendency to aggregate suggesting further optimisation of buffer 
conditions is required and perhaps further truncations may be required. For example, 
~ 40 residues before the start of the nuclease domain may be unstructured. Similarly,
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from the crystal structure of the nuclease-like domain of ERCC1 (Tsodikov et al., 
2005), residues 1-96 of ERCC1 are also unstructured and are not necessary for 
activity. A similar XPF-ERCC1 construct reported in the study of Tsodikov et al. 
suggests that XPF(655-905)-ERCCl(96-297) retained modest structure-specific 
activity, though this study required overnight incubations to observe any activity. 
Tsodikov and colleagues were unable to crystallise this truncated form of XPF- 
ERCC1.
Further modifications of full-length XPF-ERCC1 could improve yields further. 
Although with hindsight, changing three basic loops simultaneously in XPF may have 
been too ambitious, more focussed efforts to produce individual basic loop mutations 
could eliminate proteolysis and could conceivably enhance expression levels. The 
functional assay could be used to check whether loss of a given basic loop affected 
catalytic activity. Using the dicistronic vector described in this thesis, milligram 
quantities of recombinant XPF-ERCC1 were stockpiled and were sufficient to allow a 
screening project with Cancer Research Technology to be set up to identify an 
inhibitor of the human enzyme.
It had been hoped that this inhibitor could be co-crystallised with the A.pemix XPF 
nuclease domain. However, such a co-crystallisation experiment is contingent on the 
inhibitor of hXPF-ERCCl not being so specific that it does not inhibit other XPF 
homologues. Indeed, preliminary data from Maureen Biggerstaff (Structural Biology 
Laboratory) has shown that the putative inhibitor does not appear to inhibit ApeXPF- 
ApePCNA nuclease activity or the activity of hMus81-hEmel or hMus81-hEme2 
complexes. If these preliminary results are borne out, it is unlikely that co­
crystallisation trials of the inhibitor with ApeXPF nuclease domain would be 
successful.
Recent data by Tsodikov et al. (2005) described a similar reductionist approach to 
crystallise the ERCC1 nuclease-like domain and the heterodimer of XPF-ERCC1 
(HhH)2 domains. They were unable to crystallise the nuclease domain of XPF thus far 
and this perhaps remains an outstanding objective since, if inhibitors of human XPF- 
ERCC1 can be found that are competitive with substrate, then there will be a need for 
such a structure to contribute to a rational drug design program. Constructs coding for
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the hXPF nuclease domain (residues 671-815) have been cloned to facilitate structure 
studies on a relevant nuclease:inhibitor complex.
II -  During this thesis, our laboratory published results for the apo- and DNA-bound 
conformation of the A.pemix XPF (Newman et al., 2005). This structure contained the 
nuclease and (HhH)2 domains as well as the connecting linker. The determination of 
the structure of ApeXPF complexed with DNA was not straightforward and required 
heavy atom derivatives and molecular replacement phases using a partially refined 
structure of the ApeXPF nuclease domain. Thus the production, crystallisation and 
data collection of selenomethionine-labelled ApeXPF nuclease domain described in 
this thesis made a significant contribution to the eventual structural analysis of an 
essentially intact ApeXPF (residues 18-231). Solving, building and refining the 
nuclease domain at 2.1 A resolution provided an important learning experience and 
provided a structural platform for co-crystallisation with small molecule inhibitors 
that may be used in the future. Future experiments may also address the position of 
the scissile phosphate in the active site, whether the mechanism is truly a single-metal 
reaction centre and where the activated nucleophilic water is positioned in relation to 
other invariant XPF/Mus81 sidechains.
Disappointingly, efforts to co-crystallise ApeXPF with 3’ flap substrates were 
unsuccessful. It is well documented that protein-DNA complexes can be very 
sensitive to the precise length and nature of the DNA fragments used. Whilst several 
crystals were grown in the presence of DNA, no diffraction was obtained suggesting 
further exploration of different DNA substrates may yet be warranted. A similar 
finding was made with ApeXPF in that diffraction quality crystals could be grown 
using oligonucleotides of 15 bases in length, whilst shorter or longer oligos gave 
crystals but no diffraction.
Our own data, combined with recent DNA footprinting data from Kosuke Morikawa’s 
group in Osaka (Nishino et al., 2005b), suggests that model 2, in which DNA 
substrate is bent by roughly 90 degrees to allow it to engage both (HhH)2 domains, 
may be an integral part of structure-specific recognition of double-strand/single-strand 
DNA junctions by XPF/Mus81. The preferred 3’-flap substrates for ApeXPF provides 
an upstream and downstream duplex that can be engaged by XPF. XPF-ERCC1 has a
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different substrate preference, instead targeting stem-loop or splayed arm substrates. 
This provides a single region of duplex DNA that suggests a more elaborate and 
distinctive mode of substrate recognition. Model 2 also implies that ERCC1 may 
mimic the “inactive” subunit of ApeXPF that is proposed to engage the upstream 
duplex of a 3’-flap. If true, this could argue that ERCC1 plays an important role in 
substrate recognition and not just simply to stabilise the XPF subunit as previously 
proposed.
Ill -  In order to produce more physiologically relevant complexes containing XPF, it 
was thought necessary to explore producing and reconstituting the A.pemix PCNA 
heterotrimer. By analogy to other crenarchaeal PCNA complexes, we wished to 
investigate whether the PCNA complex indeed stimulated XPF activity. An 
equivalent PCNA heterotrimer from S. solfataricus had been previously produced 
successfully at high yields by Bell and colleagues in Cambridge (Dionne et al., 2003). 
However, others had little success in crystallising the S. solfataricus XPF homologue. 
Moreover, the SsoPCNA only weakly stimulated ApeXPF catalytic activity, and it 
was felt that many groups had already initiated crystal screens using the SsoPCNA. 
Therefore some effort was made to establish an expression system for ApePCNA in 
E.coli and this proved ultimately to be successful. Since XPF is a homodimer and 
PCNA a heterotrimer, this suggested only two of the three subunits could be engaged 
by XPF. We found that under appropriate conditions, all three subunits co-purified 
with tagged XPF suggesting that the PCNA ring had indeed been reconstituted. More 
evidence that the PCNA complex forming a closed ring has come from preliminary 
negative-stained images measured by electron microscopy (Dr. Hannes Ponstingl and 
Prof. Helen Saibil at Birkbeck College). These clearly show a doughnut shaped object 
with associated additional density, potentially corresponding to XPF or XPB subunits.
Using the strategy established in Chapter 4, John Lally (Structural Biology 
Laboratory) has recently produced crystals of an ApePCNA-ApeXPFAN complex 
(figure 6.1). Although the crystals are currently unsuitable for diffraction studies, 
they provide a promising lead and a structure of this complex would be hugely 
informative with regards to the activation of ApeXPF by ApePCNA. A functional 
assay for ApePCNA-ApeXPF has also been established in the laboratory for the first 
time using protein produced by this thesis work. Activity can be measured at 55 °C
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indicating that it is now possible to conduct structure-function analysis of XPF-PCNA 
complexes for A. pernix for the first time. Future efforts could probe which PCNA 
subunits contribute to XPF stimulation together with structural efforts to trap the 
entire ApePCNA-ApeXPF complex. Forming complexes with DNA remains a major 
obstacle given that a PCNA-DNA complex has so far eluded many groups.
Figure 6.1 -  Crystals of an ApePCNA-ApeXPF complex. Crystals grown in sitting-drop by 
vapour diffusion.
We included XPB in the XPF-PCNA preparations as we reasoned that the third 
PCNA subunit could bind a PIM-containing protein and hypothesised that XPB may 
play such a role. Furthermore, preliminary data from Professor Malcolm White (St. 
Andrew’s University) suggested that S. solfataricus XPB could bind to PCNA (White, 
M.F. unpublished data). This would be in keeping with the notion of a PCNA 
“toolbelf’, whereby multiple enzymes are loaded onto PCNA and each can swing into 
action as required. Future efforts will investigate the effect of PCNA on XPB 
helicase activity and whether the XPB helicase activity in turn affects XPF activity. 
One report has already eluded to XPB regulating XPF activity in human cells since 
XPB phosphorylation by casein kinase at its C-terminus appears to negatively 
regulate the incision carried out by XPF. If and how A. pernix XPB controls XPF 
activity remains to be shown and requires further validation.
IV - Perhaps the most frustrating aspect of this work has been the inability to 
determine the structure of the hMus81 ACE domain within the timeframe of this
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thesis. The bioinformatic identification of the conserved ACE domain, unique to 
Mus81, suggested it was globular and would be a good crystallisation target. It was 
unclear from the sequence alignments whether the ACE domain would be involved in 
protein-protein interaction or whether it contributes towards DNA substrate 
specificity. Thus, there was a need for structural analysis to verify the overall fold of 
the domain and a functional analysis to elucidate the effect of deleting the domain 
from full-length Mus81, as well as characterising the individual domain itself from 
several Mus81 homologues. Initial cloning, expression and purification experiments 
worked very smoothly and early crystallisation hits looked promising. However 
ultimately the best diffraction observed after screening many related crystal 
morphologies and conditions gave at best 2.9A diffraction with a large mosaic spread. 
Further tweaking of crystal harvesting conditions, dehydration and more extensive 
screen for appropriate cryo-preservation conditions may provide a sufficient 
improvement to obtain good sub-3.0 A diffraction. The ACE domain is relatively 
small (103 amino acids) and the limiting diffraction may be a property of the intrinsic 
flexibility within the protein or alternatively poor lattice contacts within the crystal 
form. To identify regions of flexibility, we investigated carrying out NMR 
experiments in collaboration with Dr. Richard Harris at University College. At this 
point it was realised that the sample was of sufficient quality to have its structure 
determined by nuclear magnetic resonance (NMR). hACE protein has been expressed 
in E.coli grown in minimal media with (15NH4)2S0 4  as the only nitrogen source. 
Figure 6.2 shows NMR spectra for the hACE domain. The spectra are good, with the 
2D-15N NOESY spectrum containing an appropriate number of cross-peaks for the 
non-proline main chain amides. The preparation of a double 15N-13C labelled sample 
is also planned to aid structure determination in the near future. The expectation is 
that an NMR structure for the ACE domain would assist in determining the crystal 
structure. This could reveal the location of multiple sulphate ions required for crystal 
growth that may mimic interaction with a DNA phosphodiester backbone. We would 
then be in a position to mutagenise specific sidechains on the Mus81 ACE domain 
and probe the effect of such a mutation in the full-length enzyme.
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Figure 6.2 -  hACE NMR spectra. [A] ID- proton spectrum taken using unlabelled hACE 
protein. [B] 2D -  l5N NOESY spectrum. There are around 90 crosspeaks, an appropriate 
number for the hACE domain.
The availability of a gel-based assay for endonuclease activity allowed Mus81 
complexes to be assayed using radiolabelled substrates. Preliminary work on Mus81- 
Emel, as well as Mus81-Eme2 complexes, either with or without an ACE domain 
deletion, suggested a role in substrate interaction. Future efforts could therefore 
examine whether the ACE domain is able to bind DNA by employing a fluorescence 
polarisation assay to detect binding of single-stranded or double-stranded DNA.
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Similar assays are currently being used in the laboratory. In parallel, we have initiated 
a collaboration with Dr. Tony Carr’s group at the University of Sussex to examine the 
role of the Mus81 ACE domain in vivo in yeast. Towards this goal, Dr. Carr’s group 
have prepared appropriate ACE domain deletion mutants in yeast and are 
investigating phenotypes (if any) that arise from introducing this mutant Mus81 into 
the yeast genome to replace the endogenous wild type allele. It will be interesting to 
see if such a deletion phenocopies the Mus81-null cells which are highly sensitive to 
mitomycin C and cisplatin. Such in vivo experiments will complement our in vitro 
activity assays (detailed in section 5.8) with the human enzyme and the structural 
analysis.
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Appendix A Materials and Methods
A.1 Reagents and enzymes
Reagents were purchased from Sigma-Aldrich or Merck unless otherwise stated and 
were of the highest grade available. Enzymes used in molecular biology protocols 
were purchased from New England Biolabs (NEB).
A.2 Buffers, solutions and media
Common buffers and media used are described here.
Name Composition
SDS-PAGE running buffer (10 X) 15.1 g Tris base, 94 g glycine, 50 ml 10 % SDS, 
up to 1000  ml with water
SDS-PAGE sample buffer 2 % SDS, 80 mM Tris-HCl (pH 6 .8), 10 % 
glycerol, 0.02 % bromophenol blue, 2 mM 2- 
mercaptoethanol before use.
TAE buffer 40 mM Tris-acetate, 2 mM EDTA
TBE buffer 90 mM Tris-borate, 2 mM EDTA
DNA gel sample buffer (6  X) 0.25 % bromophenol blue, 0.25 % xylene cyanol 
FF, 30 % glycerol.
Luria-Bertani (LB) broth media 10 g NaCl, 10 g bacto-tryptone, 5 g bacto-yeast 
extract, made up to 1000 ml with water. 
Autoclaved.
LB-Agar 6 g agar added to 400 ml LB. Autoclaved.
SOC broth media 20 g bacto-tryptone, 5 g bacto-yeast extract, 10 
mM NaCl, 2.5 mM KC1, 10 mM MgCl2, 10 mM 
MgSC>4, 20 mM D-glucose; made up to 1000 ml 
with sterile water and autoclaved.
Table A.1 -  Common buffers and media
A.3 Molecular cloning 
A.3.1 Donated constructs
The following constructs were kindly donated for this work:
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Construct
pET30b XPF-ERCC1 dicistronic 
pET30b XPF 
pET30b ERCC1
pET30b ERCC1-XPF (629-905) 
pET15b XPA
pET14b-3C ApeXPF (18-231) 
pET14b-3C ApeXPF (18-150) 
pET28a hMus81-hEmel dicistronic 
pGEX-KG hMus81-hEmel dicistronic 
pGEX-KG hMus81-hEme2 dicistronic 
Table A.2 -  List of donated constructs
Donated by -
Prof Rick Wood/Dr. Matthew Newman
Prof Rick Wood/Dr. Matthew Newman
Prof Rick Wood/Dr. Matthew Newman
Dr. Matthew Newman
Annabel Borg
Dr. Matthew Newman
Dr. Matthew Newman
Alberto Ciccia
Alberto Ciccia
Alberto Ciccia
A.3.2 Plasmid vectors
The plasmid vectors used for protein expression were either from the pET (Novagen) 
or pGEX (Amersham) family of expression vectors. Figure A.l shows the cloning 
and expression regions of three non-standard vectors used in this thesis; pET14b-3C, 
pET41a-3C and pGEX-KG.
A.3,3 Oligonucleotides
Oligonucleotides were synthesised by the Cancer Research UK Oligonucleotide 
Synthesis Department and purified by ethanol precipitations. Oligonucleotides for 
site-directed mutagenesis, crystallisation or those longer than 45 nucleotides were 
purified by HPLC. After closure of this facility in July 2004, all oligonucleotides 
were purchased from Sigma-Genosys.
A.3.4 Plasmid purification
Plasmid DNA was purified using Qiagen miniprep or maxiprep kits. Plasmid 
concentrations were calculated from absorption measurements at 260 and 280 nm 
using either a Pharmacia Biotech Ultrospec2000 spectrophotometer or a NanoDrop 
ND-1000 spectrophotometer.
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T7 promoter lac opeator _Xba1_ Ndel
AATTAATACCACTCACTATAGGCCAATTGTGAGCCGATAACMTTCCCCTCTACAAATAATTTTGTTTAACTTTMGMCGAGATATACATATCTCCCCT
M e tS e rP ro
__________________ GST-taq______________________________  Ncol
ATACTAGGTTAT. . .6 2 7 b p . . .GACCATCCTCCAAAATCGGATGGTTCAACTAGTGGTGGTGGCGGTCGCCTGGAAGTTCTGTTCCAGGGGCCCACCATG
I l e L e u G l y T y r . . , 2 0 9 a a . . .A sp H isP ro P ro L y sS e rA sp G ly S e rT h rS e rG ly G ly G ly G ly G ly L e u G lu V a lL e u P h e G ln G ly P ro T h rM e t
3C protease I
BamHI EcoRl EcoRV Pstl Sac1 Sail Hind3 Notl Xhol
GGATCCGAATTCTGTACAGGCGATATCCTTGGCGCGCCTGCAGCCGAGCrCCGTCGACAAGCTTGCGCCCGCACTCGAGCACCACCACCACCACCACCACCACTAATTGATTAA
Cl y S e rG lu P h e C y sT h rG ly A sp I le L e u G ly A la P ro A la G l yG luLeuA rgA rgG l nA laC ysG lyA rgT hrA l a P ro P ro P ro P ro P ro P ro P ro P ro L e u Ile A sp E N D
^ v r 2 _  Blpl T7 terminator__________________________
tacctag g ctg cta aa ca a a g cccca a ag g a ag ctg a g ttg g ctg ctg ccaccg ctg a g ca ata a cta ccata a ccccttg gg g cctcta aa cgg g tcttg ag g g gttttttg
®  pET41a-3C c lon ing/expression  regions
Bol2 T7 promoter Xbal rbs
ACATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAACGAGA
Ncol His-tag
TATACCATCGGCAGCAGCCATCATCATCATCATCACACCAGCGCCCTGGTGCCGCGCCGCAGCCATAATGGATCTGAGGTCCTATTCCAGGCA
M etGl y S e rS e r H i  sH i sH i sH i sH i sH i s S e r S e r G ly L eu V alP ro A rg G ly S erH i sAsnGI y S e r GI uV al L euPheG lnG I
thrombin I 3C protease I
Ndel Xhol BamHI Blpl
CCCGGATCTCATATGCTCGAGGATCCGGCTGCTAACAAACCCCGAAACGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAA
P ro G ly S e rH isM e tL e u G lu A sp P ro A la A la A sn L y sA la A rg L y sG l uAl aG luL euA l aAl aAl aT hrA l aGl uGlnEND
_______________ T7 terminator______________________
CCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGI I I I I I G
©  pET14b-3C clon ing /expression  reg ions
EcoRlXbal Ncol Sail XholSacI Hind3
CTGGTTCCGCGTGGATCCCCGGGAATTTCCGGTGGTGGTGGTGGAATTCTAGACTCCATGGGTCGACTCGAGCTCAAGCTTAATTCA
LeuV al P ro A rg G ly S e rP ro G ly lle S e rC ly G ly G ly G ly G ly lle L e u A s p S e rM e tC ly A rg L e u G lu L e u L y s L e u A s n S e r
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Figure A .l -  Cloning and expression regions of non-standard plasmid vectors used in this 
thesis.
A.3.5 DNA sequencing
Plasmid DNA was sequenced using the dideoxynucleotide chain terminating inhibitor 
method (Sanger et al., 1977) and the BigDye Terminator Cycle Sequencing kit (PE 
Applied Biosystems). Sequencing reactions were cleaned up using Qiagen DyeEx 
Sequencing kits and ran on an ABI Prism 3730 Capillary Sequencing Unit (Cancer
149
Appendix A: Materials and Methods
Research UK Equipment Park). Sequence data was analysed using the freeware 
program FinchTV.
A.3.6 Polymerase Chain Reaction (PCR)
PCR amplification of open reading frames was carried out as follows. A typical 
reaction contained 100 ng of plasmid template (or 200 ng of a genomic template), 10 
pmol of each primer, 1 mM of each dNTP and 2 units of NEB Vent DNA polymerase 
in a total volume of 50 pi. The reaction was buffered with NEB Thermopol buffer 
and supplemented with 1 mM MgSCU. If this procedure did not succeed in producing 
a clean PCR product an Optiprime kit (Stratgene) was employed to optimise the 
buffer conditions. A typical thermal cycling program was 95 °C, 5 mins; 58 °C, 4 
mins, 72 °C, 4 mins; followed by 25 cycles of 95 °C, 1 min; 58 °C, 1.5 mins, 72 °C, 
@ 1 min per kb of DNA to be synthesised.
Overlap PCR was used in Chapters 2 and 5. The protocol above was employed to 
generate primary PCR products. After this primary products were annealed together 
in the presence of 1 mM dNTPs, 2 units of Vent polymerase and 1 x NEB Thermopol 
buffer. 15 cycles of 95 °C for 30 secs, 40 °C for 15 secs and 72 °C for 2 mins were 
performed. The reaction mix was purified using a Qiagen Miniprep spin column and 
the overlapped product amplified using a normal PCR protocol and flanking PCR 
primers.
A.3.7 Agarose gel electrophoresis
Analytical gels typically were composed of 1 % agarose in TBE buffer, supplemented 
with 0.5 pg ml'1 of ethidium bromide. Preparative gels were composed of 1 % 
agarose in TAE buffer, again supplemented with ethidium bromide. DNA bands were 
visualised on a UV-transilluminator, cut out with a fresh razor blade and the DNA 
extracted using Ultrafree-DA spin columns (Millipore). Further purification was 
achieved using the Qiagen miniprep kit.
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A.3.8 Restriction digests
Restriction digests were performed using NEB enzymes with the recommended 
buffers for either single or double digests. Typically 1-2 units of enzyme were used 
per pg of DNA.
A.3.9 Ligation
Ligation reactions typically consisted of 50 ng of cut plasmid vector, a 3-5 fold molar 
excess of insert and 20 units of NEB T4 DNA ligase, buffered with T4 DNA ligase 
buffer, in a total volume of 10 pi, The reaction was left to incubate at room 
temperature for 1-3 hours and used to transform either DH5a (Gibco) or NovaBlue 
(Novagen) competent cells. Control transformations with no DNA, cut plasmid 
vector but no insert and uncut plasmid were used to assess the efficiency of ligation 
and transformation.
A.3.10 Transformation of chemically competent Escherichia coli cells 
Frozen competent cells were thawed on ice and the transforming DNA was added to 
the cells and mixed gently. This mixture was incubated on ice for 30 minutes. The 
cells were transformed by heat shock for 1 minute at 42 °C and returned to ice for 2 
minutes. If the plasmid of interest conferred ampicillin resistance, then the cells were 
plated out immediately. If the plasmid of interest conferred kanamycin resistance, 
then 900 pi of SOC media was added and the cells incubated at 37 °C for 1 hour 
before plating out. Selection of transformants was achieved by plating the cells on to 
LB-Agar plates containing the appropriate antibiotic and incubation at 37 °C 
overnight for colony formation.
A.4 Protein Expression 
A.4.1 Escherichia coli host strains
Frozen stocks of electrocompetent cells of the following strains were used for protein 
expression described in this thesis.
A.4.2 Transformation of electrocompetent Escherichia coli cells
Frozen electrocompetent cells were thawed on ice and the transforming DNA was 
added to the cells and mixed gently. This mixture was then transferred to a cooled
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EquiBio 2 mm electroporation cuvette. The cuvette was placed in a BioRad 
GenePulser electroporator and pulsed at 2.5 kV, 25 [i¥ and 200 Q. 1 ml of SOC 
media was added to the cuvette immediately. If the plasmid of interest was ampicillin 
resistant then the cells were plated out immediately. If the plasmid of interest 
conferred kanamycin resistance then the cuvette was incubated at 37 °C for 30 mins. 
Selection of transformants was achieved by plating the cells on to LB-Agar plates 
containing the appropriate antibiotic and incubation at 37 °C overnight for colony 
formation.
Name Antibiotic1* Source
FB810 None Lab stock
(BL21(DE3) recA )
Rosetta Cam Novagen
Rosetta pLysS Cam Novagen
BL21-AI None Invitrogen
BL21-AI codon + Cam Invitrogen
Table A.3 -  E. coli strains used for protein expression. Cam = 
chloramphenicol
A.4.3 Bacterial growth measurement
The growth of Escherichia coli cultures for protein expression was monitored by 
measuring the absorbance of an aliquot of the culture at 600 nm in a 
spectrophotometer, compared to a blank with just LB media.
A.4.4 Expression of recombinant protein in Escherichia coli
This section provides a framework around which expression experiments were built.
A single colony from a fresh transformation plate was used to inoculate 100 ml of LB 
media supplemented with the appropriate antibiotic(s) for the plasmid of interest. 
This starter culture was grown overnight with shaking at 37 °C. In the morning the 
starter culture was harvested by centrifugation and the supernatant discarded (this was 
to minimise transfer of P-lactamase to the large cultures). The pellet was then 
resuspended in 20 ml of fresh LB media and of this 2 ml was used to inoculate 1 1 of
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LB media (in a 2 1 baffled flask) again supplemented with the appropriate 
antibiotic(s). These flasks were generally incubated with shaking at 37 °C until the 
optical density at 600 nm (OD600) of the culture was greater than 0.6.
At this point the induction procedure was initiated. One of four induction protocols 
was used, depending on the protein of interest.
[A] The flasks remained at 37 °C and protein expression was induced by the 
addition of isopropyl p-D-l-thiogalactopyranoside (IPTG) to a final concentration of 
250 pM. The cells were then incubated for a further 3 hours.
[B] The flasks remained at 37 °C and protein expression was induced by the 
addition of IPTG to a final concentration of 250 pM, plus L-arabinose to a final 
concentration of 0.2 %. The cells were then incubated for a further 5 hours.
[C] The flasks were cooled to 25 °C for 30 mins, and protein expression was 
induced by the addition of IPTG to a final concentration of 25 pM. The cells were 
then incubated for a further 3-4 hours at 25 °C.
[D] The flasks were cooled to 18 °C for 30 mins, and protein expression was 
induced by the addition of IPTG to a final concentration of 25 pM. The cells were 
then incubated overnight at 18 °C.
After induction the cells were harvested in a Beckman J-6B centrifuge at 4000 x g at 
4 °C for 20 minutes. The cell pellets were re-suspended in 35 ml of fresh LB and 
harvested by centrifugation in a Beckman GS-6R centrifuge at 4000 x g at 4 °C for 20 
minutes. The supernatant was discarded and the cell pellets stored at -80 °C.
Table A.4 shows the respective induction protocol for each protein or protein complex 
described in this thesis.
A.4.5 Expression of selenomethionine-labelled recombinant protein in 
Escherichia coli
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(This section refers specifically to the production of selenomethionine-labelled (Se- 
Met) hACE domain protein discussed in section 5.6).
Protein expressed Protocol Notes
Full-length XPF-ERCC1 D
ERCC1-XPF (629-905) C
GST-XPA C +10 mM ZnSC>4 in induction
GST-XPF -  ERCC1 D
ERCC1 -XPFAloops D
ApeXPFANAC (18-231) c*
ApeXPF nuclease (18-150) c*
ApePCNA 1 B
ApePCNA 2 B
ApePCNA 3 B
ApePCNA 1,2,3 B
Full-length ApeXPF c*
ApeXPF AN( 18-254) c*
ApeXPF(HhH)2 & PIM (164-254) A
ApeXPB C
hMus81 ACE A
scMus81 ACE A
spMus81 ACE A
hMus81 ACE AN A
hMus81 ACE AC A
hMus81 ACE ANAC A
GST-hMus81 -hEme 1 D
GST-hMus81A ACE-hEme 1 D
GST-hMus81 -hEme2 D
GST-hMus81 AACE-hEme2 D
Table A.4 -  Induction protocol for proteins and protein complexes described in this
thesis. C* - Slow growth of these strains meant sometimes an overnight induction at
25 °C was used.
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In order to express Se-Met labelled hACE protein, it was necessary to use a 
methionine auxotrophic Escherichia coli strain, in this case B834(DE3) cells 
(Novagen). The SelenoMet Media kit from Molecular Dimensions was used to 
provide a minimal methionine-free broth. This kit involved making two solutions; the 
first an autoclaved medium base containing the 19 other amino acids, the second a 
0 .22  pm filtered nutrient mix containing glucose, ferric chloride and other salts. 
Protein expression experiments were conducted as described above in section A.4.4 
with the following changes. Overnight 100 ml starter cultures were grown in the 
minimal media described, supplemented with a small amount of regular methionine 
(50 pg I-1). These starter cultures were harvested and the pellets washed extensively 
with water. The main cultures were grown using the minimal media described 
supplemented with a small amount of Se-Met (50 pg I'1). To improve yields 500 ml 
cultures were grown in 2 1 baffled flasks.
A.5 Protein purification and analysis
A.5.1 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE)
SDS-PAGE was performed accordingly to the method of Laemmli (Laemmli, 1970). 
12 % resolving gels were generally used to visualise all proteins and consisted of 12 
% (w/v) acrylamide, 0.3 % (w/v) bisacrylamide, 300 mM Tris-HCl (pH 8 .8), 0.1 % 
(w/v) SDS, 0.003 % tetramethylethylenediamine (TEMED) and 0.0003 % (w/v) 
ammonium persulphate (APS). The 3.8 % stacking gel used consisted of 3.8 % (w/v) 
acrylamide, 0.1 % (w/v) bisacrylamide, 125 mM Tris-HCl (pH 6 .8), 0.1 % (w/v) SDS, 
0.003 % TEMED and 0.0003 % APS.
The TEMED and APD were added last as they induce the polymerisation of the 
acrylamide. Gels were cast and run using apparatus purchased from Amersham 
Pharmacia Biotech. Samples to be analysed by SDS-PAGE were resuspended in 
SDS-sample buffer and incubated at 95 °C for 5 minutes. Gels were run in 1 x SDS- 
PAGE running buffer at a constant voltage of 100 V whilst the samples permeated the 
stacking gel, and subsequently 200 V as the samples ran through the resolving gel. 
Electrophoresis was continued until the bromophenol blue dye front had just run off 
the bottom of the gel.
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Gels were stained at room temperature with Coomassie Blue stain (0.1 % (w/v) 
Coomassie PhastBlue (Pharmacia), 30 % (v/v) methanol, 10 % (v/v) glacial acetic 
acid). Gels were destained at room temperature in destain solution (45 % (v/v) 
methanol and 10 % (v/v) glacial acetic acid).
A.5.2 Protein concentration
Protein concentrations were determined in one of two ways. The first was by 
Bradford assay (Bradford, 1976) using an appropriate reagent from BioRad and 
bovine serum albumin to construct a standard curve. This assay is inexpensive and 
sensitive, although the results with different proteins can vary widely (especially for 
arginine rich proteins). The second was using absorption measurements at 280 nm 
from a NanoDrop ND-1000 spectrophotometer and theoretical molar extinction 
coefficients calculated from the Expasy ProtParam server 
rhttp://www.expasv.org/tools/protparam.htmlT This method is rapid and uses very 
little protein, although it is susceptible to contamination.
A.5.3 Purification of His6-tagged proteins
The following sections provide a framework around which purification experiments 
were built. Tables A.5, A.6 , A.7 and A .8 detail the buffers that were used in the 
purification of proteins described in this thesis (unless alternative buffers are given 
explicitly in the text).
A.5.3.1 Batch purification
Frozen pellets were thawed at room temperature and resuspended in lysis buffer, 
supplemented with 10 mM benzamidine and 1 mM PMSF (both protease inhibitors). 
The cells were sonicated on ice using a MSE Soniprep 150 sonicator at 12 pm. 6 x 
30 secs bursts were employed with rest periods on ice of at least 60 secs and end- 
over-end mixing. Cell debris was removed by centrifugation in a Beckman Allegra 
64R centrifuge at 29,200 x g, for 30 mins at 4 °C. The supernatant was mixed on a 
roller shaker at 4 °C for 90 mins with Ni2+-NTA affinity resin (Qiagen) pre-washed in 
lysis buffer (typically 1 ml of Ni2+-NTA was used for 10 mg of protein expected). 
The resin was collected from the unbound fraction in a column and washed 
thoroughly prior to elution. Elution was achieved either by the addition of imidazole-
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^  i
containing elution buffer or by addition of 3C protease to a slurry of the Ni -NTA 
resin in lysis buffer.
Depending on the experiment in hand, proteins were dialysed overnight to remove the 
imidazole and then 3C protease was added to cleave the protein at 4 °C overnight. 
SDS-PAGE was used to monitor the efficiency of purification and cleavage.
Protein expressed Lysis buffer Wash buffer Elution buffer
Full length XPF-ERCC1 20 mM HEPES (7.4) 500 mM Lysis + 20 Lysis + 250 mM
NaCl, 2 mM 2-ME, 2mM MgCl2, 
10% glycerol, 0.01% CHAPS, 5 
mM imidazole.
mM imidazole imidazole
ERCC1-XPF (629-905) 50 mM Tris (8), 300 mM NaCl, 2 Lysis + 20 Lysis + 20 mM
mM 2-ME mM imidazole imidazole
ERCC1-XPF Aloops 20 mM HEPES (7.4) 500 mM Lysis + 20 Lysis + 20 mM
NaCl, 2 mM 2-ME, 2mM MgCl2, 
10% glycerol, 0.01% CHAPS, 5 
mM imidazole.
mM imidazole imidazole
ApeXPFANAC (18-231) 20 mM Tris (8), 500 mM NaCl, 2 Lysis + 20 Lysis + 250 mM
mM 2-ME mM imidazole imidazole
ApeXPF nuclease (18-150) 20 mM Tris (8), 500 mM NaCl, 2 Lysis + 20 Lysis + 250 mM
mM 2-ME, 0.5 % CHAPS mM imidazole imidazole
Full length ApeXPF (1-254) 50 mM Tris (8), 300 mM NaCl, 2 Lysis + 20 Lysis + 3C
mM 2-ME mM imidazole protease
ApeXPF AN (18-254) 50 mM Tris (8), 300 mM NaCl, 2 Lysis + 20 Lysis + 3C
mM 2-ME mM imidazole protease
ApeXPF(HhH)2 & PIM 50 mM Tris (8), 100 mM NaCl, 2 Lysis + 20 Lysis + 3C
(164-254) mM 2-ME mM imidazole protease
ApePCNA- ApeXPF(HhH)2 50 mM Tris (8), 100 mM NaCl, 2 Lysis + 20 Lysis + 3C
& PIM (164-254) mM 2-ME mM imidazole protease
ApePCNA- ApeXPF AN 50 mM Tris (8), 300 mM NaCl, 2 Lysis + 20 Lysis + 20 mM
(18-254) mM 2-ME mM imidazole -* 500 mM 
imidazole
ApePCNA- ApeXPFAN 50 mM Tris (8), 300 mM NaCl, 2 Lysis + 20 Lysis + 20 mM
(18-254)-ApeXPB mM 2-ME mM imidazole -* 500 mM 
imidazole
Table A.5 -  Buffers for the purification o f His6-tagged proteins
A.5.3.2 Gradient purification
Imidazole gradients were used to purify His6-tagged Aeropyrum pemix complexes in 
Chapter 4. Cell pellets were resuspended and sonicated as for the batch purification, 
although being thermophilic proteins all manipulations were performed at room 
temperature. After clearing the cell debris by centrifugation, the lysates were heated 
in a water batch at 65 °C to denature the E.coli host proteins. The precipitated E.coli 
proteins were removed by centrifugation at 29,200 x g, for 30 mins at 22 °C. The 
supernatant was loaded onto a 1 ml Hi-Trap chelating sepharose column (Amersham) 
pre-charged with nickel sulphate using a syringe. After loading the column was
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transferred to the room temperature AKTA FPLC. Unbound protein was washed 
from the column with 5 column volumes of loading buffer. An imidazole gradient 
(from 20-500 mM imidazole) over 10 column volumes was generally used to elute the 
protein(s) of interest. Fraction collection was automated and aliquots of these 
fractions were analysed by SDS-PAGE.
A.5.4 Purification of GST-tagged proteins
Protein expressed Lysis buffer Wash buffer Elution buffer
GST-XPA 50 mM Tris (8), 150 mM NaCl, 1 Lysis w/ 20 Wash + 20 mM
mMDTT mM Tris (8) GSH
GST-XPF -  ERCC1 20 mM HEPES (7.4) 500 mM 
NaCl, 2 mM 2-ME, 2mM MgCl2, 
10% glycerol, 0.01% CHAPS.
Lysis Lysis + 20 mM 
GSH
GST- hMus81 ACE domain 50 mM Tris (8), 500 mM NaCl, 1 Lysis w/ 20 Wash + 3C
constructs mMDTT mM Tris (8) protease
GST- scMus81 ACE 50 mM Tris (8), 500 mM NaCl, 1 Lysis w/ 20 Wash + 3C
domain mMDTT mM Tris (8) protease
GST -  spMus81 ACE 50 mM Tris (8), 500 mM NaCl, 1 Lysis w/ 20 Wash + 3C
domain mMDTT mM Tris (8) protease
GST -hM us81- 50 mM phosphate (8), 300 mM Lysis Lysis + 20 mM
hEmel/hEme2 complexes NaCl, 2 mM 2-ME, 10 % GSH
____________________________glycerol, 0.2 % CHAPS________
Table A.6 -  Buffers for the purification o f GST-tagged proteins
Cell pellets were resuspended and sonicated as for His6-tagged proteins. The cleared 
cell lysate was added to 1 ml of glutathione-sepharose affinity resin (Amersham) 
prewashed in lysis buffer (typically 1 ml of resin was used for 10 mg of protein 
expected). The affinity resin was collected from the unbound fractions and was 
washed thoroughly in wash buffer. Proteins were either eluted with wash buffer 
supplemented with 20 mM reduced glutathione (pH 8) or by addition of 3C protease 
(Structural Biology Laboratory stock) to a slurry of the affinity resin in wash buffer.
A.5.5 Heparin-sepharose affinity chromatography
Heparin-sepharose affinity chromatography was performed using the AKTA FPLC 
apparatus. In general 1 ml HiTrap Heparin columns (Pharmacia) were used with the 
suggested flow-rates and pressure limits. Depending on the volume to be bound to 
the column one of two approaches was taken. For volumes of 10 ml and under, the 
column was connected to the AKTA FPLC and washed with 5 column volumes of 
loading buffer. The protein was then injected onto the column. Alternatively for 
large volumes the column was washed with 5 column volumes of loading buffer with 
a syringe, before the sample was loaded with a syringe. After loading the column was
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transferred to the AKTA FPLC. In both cases, unbound protein was washed from the 
column with 2 column volumes of loading buffer. A NaCl gradient elution up to 1 M 
NaCl over 10 column volumes was generally used to elute the protein(s) of interest. 
Fraction collection was automated and aliquots of these fractions were analysed by 
SDS-PAGE.
Protein expressed Lysis buffer Load buffer Elution buffer
Full length XPF-ERCC 1 As from Ni2+NTA, 20 mM As from Ni2+ Gradient: lysis
(2nd purification step) HEPES (7.4), 50 mM NaCl, 2 
mM 2-ME, 10% glycerol, 0.01% 
CHAPS, 0.5 mM EDTA
NTA-resin -» 1 MNaCl
ApePCNA subunits 50 mM Tris (8), 100 mM NaCl, 1 
mMDTT
As lysis Gradient: lysis 
1 MNaCl
ApePCNA 123 complex 50 mM Tris (8), 100 mM NaCl, 1 
mMDTT
As lysis Gradient: lysis 
-*  1 M NaCl
ApeXPB 50 mM Tris (8), 100 mM NaCl, 1 
mMDTT
As lysis Gradient: lysis 
— 1 M NaCl
hMus81 ACE (2nd From GSH-resin, 20 mM Tris (8), As from GSH- Gradient: -*  1 M
purification step) 100 mM NaCl, 1 mM DTT resin NaCl
GST-hM us81- From GSH-resin, 50 mM As from GSH- Gradient: -» 1 M
hEmel/hEme2 complexes 
(2nd purification step)
phosphate (8), 300 mM NaCl, 2 
mM 2-ME, 10 % glycerol, 0.2 % 
CHAPS, 20 mM GSH
resin NaCl
Table A.7 -  Buffers for the purification o f proteins on Heparin-Sepharose
A.5.6 Size exclusion chromatography
Protein expressed Isocratic elution buffer
Full length XPF-ERCC1 20 mM HEPES (7.4), 50 mM NaCl, 0.5 mM
EDTA, 0.5 mM DTT, 2 mM MgCl2 10% glycerol, 
0.01% CHAPS.
ApePCNA subunits 20 mM Tris (8), 100 mM NaCl, 1 mM DTT
ApePCNA 123 complex 20 mM Tris (8), 100 mM NaCl, 1 mM DTT
ApeXPB 20 mM Tris (8), 100 mM NaCl, 1 mM DTT
ApeXPF(HhH)2 & PIM (164-254) 20 mM Tris (8), 100 mM NaCl, 1 mM DTT
ApePCNA- ApeXPF(HhH)2 & PIM (164-254) 20 mM Tris (8), 100 mM NaCl, 1 mM DTT
ApePCNA- ApeXPFAN (18-254) 20 mM Tris (8), 300 mM NaCl, 1 mM DTT
ApePCNA- ApeXPFAN (18-254)-ApeXPB 20 mM Tris (8), 300 mM NaCl, 1 mM DTT
hMus81 ACE (2nd purification step) 20 mM Tris (8), 500 mM NaCl, 1 mM DTT
scMus81 ACE domain (2nd purification step) 20 mM Tris (8), 500 mM NaCl, 1 mM DTT
spMus81 ACE domain (2nd purification step) 20 mM Tris (8), 500 mM NaCl, 1 mM DTT
GST -  hMus81-hEmel/hEme2 complexes 50 mM phosphate (8), 300 mM NaCl, 2 mM 2-ME,
(3rd purification step)_________________________ 10 % glycerol, 0.2 % CHAPS____________________
Table A.8 -  Buffers for purification o f proteins by size exclusion (gel filtration) chromatography
Size exclusion chromatography (also referred to as gel filtration) was performed using 
a AKTA FPLC apparatus (Pharmacia). Columns used in this thesis (Superdex 75, 
superdex 200 and superose 12) were all purchased from Pharmacia and were used 
with the suggested flow-rates and pressure limits, and stored after use in 20  % (v/v)
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ethanol. Columns were generally equilibrated with two column volumes of buffer. 
After this the sample was injected onto the column and another column volume of 
buffer was used for the isocratic elution of the proteins of interest. Fraction collection 
was automated and aliquots of these fractions were analysed by SDS-PAGE. The 
columns were calibrated using proteins of a known mass (n.b. calibration curves of 
these columns are not definitive as gel filtration relies on both the mass and the shape 
of the protein, given by the Stokes’ radius).
A.6 Activity assays
Substrates used for Mus81 and ApePCNA-XPF activity assays were derived from the 
study of Ciccia et al. (2003). Three synthetic DNA strands were used in combination 
to generate the 3’-flap and splayed arm substrates.
XOl-GACGCTGCCGAATTCTACCAGTGCCTTGCTAGGACATCTTTGCCCACCTGCAGGTTCACCC
X03-CATGGAGCTGTCTAGAGGATCCGACTATCGA
X04-ATCGATAGTCGGATCCTCTAGACAGCTCCATGTAGCAAGGCACTGGTAGAATTCGGCAGCGT
Strand XOl was 32P-5’-labelled. For the 3’-flap all three strands were annealed 
together. For the splayed arm just strands XOl and X04 were anneled together. The 
assay conditions used were identical to those of Ciccia et al. for Mus81 and those of 
Roberts et al. (Roberts et al., 2003) for ApePCNA-XPF. The reaction products were 
separated on a 10 % sequencing gel for 2 hours followed by exposure to a 
Phosphoimager screen or autoradiography using Biomax film for 2 hours.
A.7 Circular dichroism
Circular dichroism spectra were measured on a Aviv 202SF spectropolarimeter using 
60 pi samples in a 0.1 mm quartz cuvette at room temperature. Scans were carried 
out from 190 to 260 nm with a bandwidth of 1 nm and a scan rate of 20  nm/min.
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Appendix B Crystallisation and crystallographic theory
B.l Protein Crystals 
B.1.1 Crystallisation
The basic principle in protein crystallisation is bringing a protein solution to a limited 
degree of supersaturation (Ducruix and Griege, 1992). A phase diagram (figure B.l) 
can be used to illustrate how supersaturated protein solutions yield crystals. There are 
three regions of the phase diagram where the solution is supersaturated.
(a) The precipitation zone where excess protein molecules come out of
solution and form amorphous aggregates.
(b) The nucleation zone where excess protein molecules come out of
solution and form crystalline aggregates.
(c) The metastable zone where conditions for large well ordered crystals
growth can be found, provided nucleation has occurred.
Although the aim is bringing a protein solution to a limited degree of supersaturation, 
the method defining conditions appropriate for the crystallisation of any particular 
macromolecule is still very much one of trial and error. In this work, two techniques 
of setting up crystallisation trials were used to find a path via the nucleation zone and 
into the metastable zone (figure B.l). These were vapour diffusion (using either 
hanging or sitting drops) and microbatch (using either paraffin oil or Al’s oil 
(Hampton Research)). A variety of sparse matrix and grid screens were used, most of 
which were purchased from Hampton Research or Nextal.
The setup of vapour diffusion experiments typically involved 1-2 pi of concentrated 
protein sample being mixed with 1-2 pi of a precipitant solution taken from a 500 pi 
precipitant reservoir to form a “drop”. The initial precipitant concentration in the 
drop was therefore lower than that in the reservoir. In order to reach equilibrium the 
reservoir draws water from the drop, thus increasing the concentration of precipitant 
and protein in the drop. It is hoped that this effect drives the drop into the nucleation 
zone. The removal of some protein molecules into crystal nuclei reduces the protein 
concentration, thus moving the drop into the metastable zone in which crystal growth 
may occur.
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Figure B.l -  Phase diagrams for different crystallisation techniques. [A] Vapour diffusion. 
[B] Microbatch with paraffin oil. [C] Microbatch with A l’s oil. Adapted from Hampton 
Research.
Microbatch experiments work in a slightly different way. Typically 1 pi of 
concentrated protein sample was mixed with 1 pi of a precipitant solution to form a 
drop under a layer of oil. In microbatch experiments with paraffin oil, little 
evaporation from the drop is possible and thus in this scenario, the precipitant must 
alter the level of protein supersaturation so that it falls directly into the nucleation 
zone (figure B.l). Microbatch experiments with A l’s oil, allows some evaporation 
from the drop and thus the phase diagram and theory is more akin to that of vapour 
diffusion.
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B.1.2 The unit cell and space groups
A crystal is three-dimensional ordered array of molecules characterised by its 
repeating unit, the unit cell, that can be translated to generate the crystal lattice. The 
crystallographic unit cell is described by the length of the vectors a, b and c and the 
angles between them a , p and y. In addition to the translational symmetry, a unit cell 
can also have additional internal symmetry such as screw rotations, mirror planes, 
centres of symmetry (inversion centres) and rotation inversion axes (Drenth, 1994). 
The lattice symmetry and internal symmetry together define the space group of the 
crystal. However, protein crystals cannot contain inversion or mirror operations 
(since proteins are made of L-amino acids only) and thus only 65 of a possible 320 
possible space groups are feasible. The smallest portion of the crystallographic unit 
cell that can be used to generate the complete unit cell by applying the whole set of 
symmetry operations of the specific space group is called the asymmetric unit (AU).
B.l.3 Solvent content and the Matthews coefficient.
The Matthews coefficient (Vm) (Matthews, 1968) can be calculated using the unit cell 
parameters and knowledge of the space group to estimate the number of molecules of 
protein and the solvent content of the AU. The range for Vm for protein crystals is 
typically found to be between 1.66 and 4.0. This corresponds to solvent content of 25 
to 70 %, assuming the partial specific volume of a given protein is 0.73 mg g"1. If 
solvent contents outside the given range are predicted, then it is unlikely the AU 
contains that number of molecules. The Matthews coefficient is given by:
vEquation B.l Vm = -----
m MZ
Where Vm = Matthews coefficient; V = volume o f the unit cell, M = the molecular mass of 
the protein and Z = the number o f molecules in the asymmetric unit.
B.2 X-ray diffraction by crystals
B.2.1 Bragg’s law
X-rays are scattered by the electrons within the atoms that make up proteins. A 
charged particle that interacts with an electromagnetic wave experiences a force,
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which caused it to oscillate. This causes it to act as a new source of radiation and thus 
“scatter” the incident radiation. In order to observe constructive interference, the X- 
rays must scatter in phase in a relationship given by Bragg’s Law (Equation B.2)
Equation B.2 rik = 'Id sin 6
Where 0 = angle of diffraction, X = wavelength, n = integer value and d = inter-planar 
spacing between atoms.
The unit cells of protein crystals are much larger than the wavelength of the radiation 
used and so in order to measure data for all reflections the crystal is rotated to bring 
successive reflections into a diffracting position. The rotation method was employed 
for all data collection in this thesis and is where the crystal is rotated about a single 
axis through a narrow, defined angle (normally 0.5-1 °) during each exposure to the 
X-rays. All reflections that satisfy Bragg’s law over each angle are recorded as 
diffraction spots on a single image.
Rearrangement of Bragg’s law shows that 0oc(l/d). This means that it is easier to 
represent the diffraction data using a reciprocal lattice based on 1/d that varies as sin0 . 
This reciprocal lattice can be used to describe the unit cell edges as a/h, b/k and c/1 
where h, k and 1 are integers and are called the Miller indices. The notation (hkl) used 
to describe the plane defined by the h, k and 1 Miller indices. The space described by 
the Miller indices is referred to as reciprocal space.
B.2.2 X-ray sources and detectors
Although some of the crystals described in this thesis diffracted weakly on the 
rotating anode X-ray source at Cancer Research UK, the datasets of the ApeXPF 
nuclease domain described were collected at the ESRF, Grenoble. Synchrotron 
radiation sources produce X-rays by forcing electrons travelling a high speed to adopt 
a curved path by the use of dipole magnets. This change of direction emits X-ray 
radiation. Synchrotrons produce polychromatic radiation from which specific 
wavelengths can be chosen using a monochromator.
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The intensities of all the diffracted X-rays need to be measured in order to determine a 
crystal structure. A detecting device is required to measure the position and intensity 
of the diffracted beams. Accurate measurement of the diffracted pattern was 
performed using either a MAR storage phosphor-based image plate or a charge- 
coupled device (CCD). Image plates offer a wider dynamic range and generally 
larger active detector area than CCD detectors, but also require a longer read-out time. 
This can significantly limit the speed of data collection, especially at synchrotrons.
B.2.3 Cryocrystallography
The useful life of a protein crystal exposed to synchrotron radiation is limited by 
radiation damage. In order to minimise damage created by reactive species generated 
by absorption of high-energy photons, data were collected from crystals cooled to 100 
K in a stream of cold nitrogen gas. Under these conditions, water in the solvent 
channels of the crystals and the surrounding liquor would usually (depending on the 
precipitant condition) form ice crystals. Ice crystals disrupt crystal order and give rise 
to diffraction, which may partially obscure protein diffraction. Crystals were 
therefore pre-soaked in a cryoprotectant solution that freezes to form a “glass”. 
Cryoprotectant solutions are typically composed of a slightly increased concentration 
of the components of the crystal mother liquor together with glycerol, ethylene glycol 
or PEG400. It is usual for several cryoprotectants to be tested, for example in Chapter 
5, many cryoprotectants were tried for hACE crystals. Crystals were supported 
during data collection using nylon loops (Hampton Research) held in a steel pin in 
turn attached to a magnetic base.
B.2.4 Data collection
During data collection, two factors govern the strategy to secure a complete dataset. 
The first is the symmetry of the reciprocal lattice. The second is the accuracy of the 
measure reflections. This depends on factors such as the exposure time, how strongly 
the crystal diffracts and the detector. It is useful to record each reflection multiple 
times as this allows its value to be determined with greater accuracy.
All of the considerations for a complete dataset were taken into account by using the 
STRATEGY option of the Mosflm program (Leslie, 1992) to calculate the initial 
oscillation angle, the oscillation range and the number of images needed to obtain a
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complete dataset. These values were determined by the mosaic spread, the unit cell 
parameters and the crystal-to-detector distance. Mosaic spread is a measure of the 
total angle over which a particular diffraction spot satisfies Bragg’s law. Spreading of 
reflections results from micro-heterogeneity in the orientation, size and cell 
parameters of the mosaic blocks that make up the crystal.
B.2.5 Data processing and reduction
From this point on, the experiment becomes a computational affair. The data 
processing program Mosflm (Leslie, 1992) was used for all diffraction data in this 
thesis. The first step in the data analysis is to obtain an accurate estimate of the space 
group and the unit cell parameters by autoindexing based on a one-dimensional Fast 
Fourier Transform (FFT) method. Then Mosflm was used to predict diffraction spot 
positions on the detector, estimate the X-ray background, and integrate the reflection 
intensities by profile fitting. A number of parameters describing the characteristics if 
the detector (geometry, sensitivity, dynamic range, distance for the crystal), the 
crystal (mosaic spread, cell dimensions, absorption) and incident beam (wavelength, 
divergence) are refined during this process.
Raw integrated intensities from each image must be corrected for differences in 
incident beam intensity between frames, crystal decay due to radiation damage, 
orientation dependent absorption by the crystal, and other systematic errors. The 
programs Scala (Evans, 1993) was used to calculate appropriate scale factors for each 
processed image, apply these scale factors, and merge with the corrected intensities. 
The statistical indicator Rsym is used to assess the quality of the data, along with the 
ratio of observed intensity to noise (I/al).
Y l / - < / > l
Equation B.3 Rsym =  ^ ---------------2k/>l
Where I is the intensity o f an individual reflection, and <I> is the mean intensity o f the set o f  
equivalent reflections including I.
The merged intensities were converted to structure factor amplitudes using the 
program Truncate (Collaborative Computational Project, 1994). At this point the full 
set of unique reflections theoretically measurable for the resolution and space group
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of the dataset are generated and a subset of 5 % of the reflections were “flagged” for 
omission from subsequent refinement.
B.3 Molecular replacement
Every reflection has both an amplitude (F) and a phase (a) determined by the 
positions and scattering power of the atoms contributing to that reflection.
Equation B.4 F (hkl) = F(hkl).QXp[ia(hkl)]
Where F(hkl) is the structure factor for the reflection of Miller indices h, k, 1; F(hkl) is the 
structure factor amplitude and a(hkl) is the phase.
The diffraction pattern is the Fourier transform of the diffracting object (in this case 
the electron density for the molecules of the crystal), and thus the electron density, p 
(xyz) can be calculated by the Fourier summation of the structure factors, F(hkl), that 
define the diffraction pattern.
Equation B.5 p(xyz) = “ " ^ 1  Faw I exp[2m(hx + ky + lz) + icthki]
V  hkl
Where |Fhki| is the structure factor amplitude of reflection (hkl) including the temperature 
factor, V is the volume o f the unit cell, p is electron density, a  is phase angle and xyz are the 
co-ordinates o f the atom in the unit cell.
In the absence of a lens capable of focussing the diffracted X-rays to form an image, 
detectors record only the intensity of the diffracted beam and the phase information is 
lost. This is generally referred to as the phase problem. In order to construct the 
electron density of the molecule, it is necessary to provide approximate phases. When 
the structure of a homologous protein is available (as it was in the case of the 
ApeXPF nuclease domain in Chapter 3), the method of molecular replacement can be 
used to solve the phase problem.
Molecular replacement consists of finding the rotation (a matrix [C]) and translation
(d) that relates a molecule of known structure (XI) to the molecule of interest (X2).
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Equation B.6 X2 = [C] Jfl + d
Molecular replacement was carried out using the program Molrep (Vagin and 
Teplyakov, 1997) which splits this process into three parts, a search for the rotation 
function [C], followed by a search for the translation, d, and finally rigid-body 
refinement of the positioned molecule(s). First the Patterson function, Pc, calculated 
from the model is compared with that calculated using the observed data, PQ, for all 
orientations of the model to find a rotation function, R, that best matches the model to 
the observed data. Solutions are ranked according to R-factor and correlation co­
efficient, which describe the agreement between the observed and calculated structure 
factor amplitudes (Fo, Fc) and Patterson functions (Po, Pc) respectively. The 
Patterson function, P(u) is the Fourier transform of the square of the structure factor 
amplitudes, and can therefore be calculated directly from the measured intensities 
without need for prior knowledge of the phases. Peaks in the Patterson function 
indicate interatomic vectors.
Equations B.8 and B.9
2
P(u) = 2) p(x).p(x + u)dV = — ^  F(hkl)2.cos[2Jt{hu + kv + Iw)]
V ^  hkl
Fh2 -  I(hkl)
Where P(u) is the value o f the Patterson function at a point specified by the vector u(u,v,w); 
p(x) and p(x + u) are the electron density at positions x and x + u; F(hkl)2 is the square of  
the structure factor amplitude for reflection hkl (i.e. the intensity I(hkl)) abd V is the unit 
cell volume.
The intermolecular vectors for the best rotation function solutions are then searched 
for a corresponding translation function, which positions the rotated molecule with 
respect to the symmetry axes of the unit cell. Finally, the transformations showing 
the best agreement are applied to the model, and rigid-body refinement is carried out 
to optimise agreement between the calculated and observed structure factor 
amplitudes.
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B.4 Refinement
Models obtained in by molecular replacement were improved by an iterative process 
of interactive model building using the graphics package COOT (Emsley and Cowtan, 
2004) and refinement using REFMAC 5 (Murshudov et al., 1997). The goal of 
refinement is to maximise the correlation between the correct stereochemical model 
and the observed structure factors. This is measured by two statistical factors known 
as Rfact and Rfree (defined in equation B.10). The R^e is calculated from the random 
subset of 5 % of reflections taken after the merged intensities were converted to 
structure factor amplitudes. These reflections are excluded from the refinement and 
this acts as a method of cross-validation.
EquationB.10
^  II Fobs I —k  I Fcalc  II ^  II Fobs  I ~ k  I Fcalc  II
D .  hkl(£T  D . hklCT
K fa c t  = ------------------ --------------------------------------  K f ree  ------------------V S -----------------------
2 J \F o b s \  2 , \ F o b s \
hkl<£T hklC T
Where |F 0bsl and |F ca]c| are the experimental and calculated structure factor amplitudes 
respectively for a reflection hkl either belonging to the working set o f reflections (Rfact) or to 
the test set o f reflections (R free)
Refinement programs use a target function in order to obtain the best possible model. 
REFMAC 5 (Murshudov et al., 1997) employs a maximum likelihood function using 
Bayes’ theorem which suggests that the best model is that most consistent with the
observations. Restrained refinement was performed in this thesis, which means that
the textbook information known about protein structures was used as additional 
information within the refinement. Such information included known bond lengths, 
bond angles and permitted cp and <j> dihedral angles. Refinement is considered 
complete when Rfact and Rfree have converged and the geometry of the model has been 
positively assessed by programs such as PROCHECK (Laskowski et al., 1993).
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